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Abstract 
The emergence of viruses in the family Paramyxoviridae, especially those such as 
Hendra virus and Nipah virus (NiV) that are zoonotic, highlighted the severity of 
disease that could be caused by infection with viruses belonging to this family. In 
addition to causing disease outbreaks, several newly discovered paramyxoviruses 
were found to have unique genetic features, which provoked renewed interest in the 
study of previously unclassified or uncharacterised viruses in this family. 
 
J-virus (JPV) was isolated from wild mice, in Queensland, Australia, in 1972, and 
has been suggested to be a natural respiratory pathogen of mice. Beilong virus 
(BeiPV), another paramyxovirus, was first isolated from human mesangial cells in 
Beijing, China, in 2003, and was subsequently detected in rat mesangial cells. 
Following initial characterisation, the genomes of JPV and BeiPV were found to 
contain two genes, SH and TM, not common to other paramyxoviruses, as well as 
an extended attachment protein gene. BeiPV has the largest genome in the family 
Paramyxoviridae, which is, in fact, larger than that of any other virus within the order 
Mononegavirales.  
 
The genetic material of paramyxoviruses is not amenable to manipulation via 
classical genetics; a reverse genetics approach was therefore employed to study the 
evolution and classification of JPV and BeiPV. Minireplicon systems utilising green 
fluorescent protein as a reporter were established for JPV, BeiPV and NiV, and were 
used to better assess the taxonomic status of JPV and BeiPV, and to determine the 
relationship between these viruses and henipaviruses, which also have 
exceptionally large genomes. These studies indicate that JPV and BeiPV are closely 
related and should be classified in the same genus and their replication and 
transcription machinery is different from that of the henipaviruses. 
 
To gain an understanding of the biology of JPV and BeiPV, viral surface proteins 
from JPV were expressed and evaluated. Chimeric JPV virions containing 
recombinant surface proteins were generated and electron microscopy was used to 
determine the localisation of the proteins encoded by those JPV genes which are 
uncommon in other paramyxoviruses. Analysis of the attachment protein gene of 
JPV indicated that the virus was able to assemble an exceptionally large protein 
(156 kDa) into the virion structure, providing evidence in support of the hypothesis 
 iv
that JPV and BeiPV may represent an ancient lineage of viruses within the family 
Paramyxoviridae. 
 
In order to determine tissue tropism of JPV during experimental infection and to aid 
future work with a full-length JPV infectious clone, a real-time PCR assay for JPV 
was developed and assessed on tissues collected from mice infected with JPV. A 
multiplex microsphere assay for JPV and BeiPV was developed and used to analyse 
the seroprevalence of these viruses in Australian and Malaysian rodents. Although 
there is currently no evidence for disease caused by JPV or BeiPV, this does not 
preclude the emergence of a zoonotic rodent paramyxovirus related to these 
viruses. If this were to occur, the tools for virus detection and serological monitoring 
are now established. 
 
 v
Preface 
 
 
 
 
 
The research embodied in this thesis was conducted at CSIRO Livestock 
Industries, Australian Animal Health Laboratory from 2003-2006. The research was 
supported by a CSIRO CLI PhD scholarship and Professional Development 
Scholarship of the Australian BioSecurity Cooperative Research Center for 
Emerging Infectious Diseases. 
 
All scientific research contained within this thesis was performed by the 
author, except where duly acknowledged within the text. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
Acknowledgements 
I wish to express my sincere gratitude to my principle supervisor Dr Linfa 
Wang, who was the most instrumental influence throughout my PhD. I sincerely 
thank him for his guidance, patience and sharing of invaluable knowledge. His 
statement “If everything worked the first time, you would never learn anything” 
helped me through the challenging times of my scientific research, making me 
believe I have indeed learned a great deal. His continued support through the 
transcription of the research into the translation of a thesis was appreciated and his 
perpetual enthusiasm was inspirational. His sustained encouragement, especially 
with the frequently occurring comment “It’s just one more clone” has allowed me to 
achieve results in a project I am truly proud of. 
I would like to thank my co-supervisor Professor John Mackenzie. I thank 
him for his continual encouragement and support throughout the project. Even with 
an extremely busy and hectic schedule, he always found the time to assist with any 
aspect of the project, for which I am appreciative. 
In addition to my supervisors, I would like to thank Dr David Boyle. For his 
unwavering support, encouragement and guidance I am grateful. I looked toward 
him as a mentor and I appreciate that he always made himself available to discuss 
research, read a manuscript or provide insightful advice.  
I would like to thank Eric Hansson, for providing the induction into Lab 202, 
always being available to answer any question, locate any reagent and share 
valuable knowledge. I would also like to thank Dr Philippa Jack, for passing on her 
knowledge (and reagents) at the beginning of the project, and for her friendship, 
support and advice. 
I wish to thank Dr Katharine Bossart, for her sharing of knowledge and 
providing encouragement to help overcome the nerves of speaking at an 
international conference. Her friendship and advice were greatly appreciated. I 
would also like to thank Meng Yu for her friendship and being available to provide 
advice at any time. 
I wish to extend a thank-you to my fellow PhD students, especially Michelle 
Wilkins, Sharon Egan, Melissa Kowalski, Luke Lambeth, Megan Retallick, Claudia 
Thalmann and Dave Cummins, for their advice and friendship. I would particularly 
like to thank Janine Muller, not only for being a friend and colleague, but for 
understanding the elation and disappointment of PhD research, the nerves 
associated with presentations and tolerating the occasional tantrum which occurred 
after a failed experiment. 
 vii
I wish to also extend a special thank-you to KC Yaiw, whose quest for 
knowledge was inspirational. I valued his advice, friendship and company in the lab, 
not only during his time as a visiting scientist, but also during my visit to the 
University of Malaya. 
I would like to acknowledge a number of AAHL colleagues for their 
assistance. For their advice and critical review of my writing, I would like to thank Dr 
Kim Halpin, Dr Tim Bowden and Dr Alex Hyatt. Tech support from Peter Kavenagh, 
who I regard as CSIRO’s number ‘one IT’ genius, was fantastic and greatly 
appreciated. I would like to thank all the AAHL library staff, in particular, Howard 
Philpott, for their assistance with my research. I greatly appreciate the assistance I 
received from Dr Bruce Mungall, Gary Crameri, Jenn McEachern, Kaylene Selleck, 
Sandy Crameri, Rosey Van Driel, Tony Pye, Adam Foord and Rachel Amos-Ritchie 
on various aspects of my project. 
The support and encouragement from my fiancé Luke Anderson was 
invaluable. I wish to sincerely thank him for his continual love and understanding, 
and accepting “My PCR didn’t work” as a greeting. For accepting that viruses and 
bacteria do not take holidays or weekends, and for his constant reminder that the 
time and effort would pay off in the end, I am grateful. 
I am immensely grateful for the support from family, especially my parents, 
Joe and Isabel Magoffin, who often asked “Did your experiment work?” and were 
always genuinely interested in the answer. I also would like to thank my sister and 
brother, Michelle and James, my Nanna, Hilda Roszyk, and my uncle, Josef Roszyk, 
for their support throughout these intense three years. I would like to also thank my 
friends for their support.  
Finally, I wish to acknowledge CSIRO Livestock Industries for providing my 
PhD scholarship. I also wish to acknowledge the Australian BioSecurity Center for 
Cooperative Research and Curtin University for the funding they provided. 
 viii
Table of Contents 
Declaration ............................................................................................................ii 
Abstract ...........................................................................................................iii 
Preface ............................................................................................................v 
Acknowledgements.................................................................................................vi 
Table of Contents ..................................................................................................viii 
List of Figures.........................................................................................................xv 
List of Tables ........................................................................................................xvii 
General Abbreviations ........................................................................................xviii 
CHAPTER 1 Literature Review ................................................................................1 
1.1 New and Emerging Viral Diseases .................................................................. 1 
1.2 Classification of Paramyxoviruses................................................................... 3 
1.2.1 Order Mononegavirales ....................................................................3 
1.2.2 Family Paramyxoviridae....................................................................3 
1.2.3 Subfamily Paramyxovirinae ..............................................................5 
Genus Morbillivirus ...........................................................................6 
Genus Respirovirus ..........................................................................6 
Genus Rubulavirus ...........................................................................7 
Genus Avulavirus..............................................................................8 
Genus Henipavirus ...........................................................................8 
Proposed genus TuPV-like viruses ...................................................9 
Proposed genus Ferlavirus ...............................................................9 
1.3 Virus Structure............................................................................................... 10 
1.4 Paramyxovirus Genome Characteristics ....................................................... 12 
1.4.1 Genome organisation......................................................................12 
1.4.2 Genome replication and the ‘rule of six’ ..........................................12 
1.4.3 Coding Capacity..............................................................................15 
1.5 Paramyxovirus Genes and Protein Products................................................. 15 
1.5.1 Nucleocapsid (N) protein gene .......................................................15 
1.5.2 Phosphoprotein (P) gene ................................................................16 
P protein..........................................................................................17 
V protein..........................................................................................17 
C protein .........................................................................................21 
1.5.3 Matrix (M) protein gene...................................................................23 
1.5.4 Fusion (F) protein gene...................................................................23 
1.5.5 Small hydrophobic (SH) protein gene .............................................25 
 ix
1.5.6 Attachment (HN/H/G) protein gene.................................................26 
1.5.7 Large (L) protein gene ....................................................................28 
1.6 Gene Expression of Non-Segmented, Negative-Sense, Single-Stranded 
RNA Viruses .................................................................................................. 29 
1.6.1 Transcriptional stop/start mechanism .............................................29 
1.6.2 Intergenic regions ...........................................................................31 
1.6.3 Genome termini ..............................................................................31 
1.6.4 RNA editing.....................................................................................32 
1.6.5 RNA replication ...............................................................................32 
1.7 New and Emerging Paramyxoviruses ........................................................... 34 
Fer-de-Lance virus..........................................................................34 
Tupaia paramyxovirus.....................................................................36 
Hendra virus....................................................................................37 
Menangle virus................................................................................38 
Nipah virus ......................................................................................39 
1.8 Rodent Paramyxoviruses .............................................................................. 41 
1.8.1 Nariva virus .....................................................................................42 
1.8.2 Mossman virus ................................................................................42 
1.8.3 J-virus .............................................................................................43 
Molecular characterisation of JPV ..................................................44 
1.8.4 Beilong virus ...................................................................................48 
Molecular characterisation of BeiPV ...............................................49 
1.9 Genetic Engineering of Non-Segmented, Negative-Sense, Single-Stranded 
RNA Viruses .................................................................................................. 51 
1.9.1 Reverse genetics ............................................................................51 
1.9.2 Minigenome versus full-length genome ..........................................55 
1.10 Research Significance and Objectives .......................................................... 56 
1.10.1 Aims of this study............................................................................56 
1- To characterise JPV and BeiPV using reverse genetics ............56 
2- To explore the localisation and function of the novel SH and 
TM proteins of JPV .........................................................................57 
3- To establish assays for the detection of JPV and BeiPV............57 
1.10.2 Significance.....................................................................................57 
CHAPTER 2 Development of Reverse Genetics Systems for JPV and BeiPV..59 
2.1 Introduction.................................................................................................... 59 
2.2 Materials and Methodology ........................................................................... 60 
2.2.1 Production of viral cDNA.................................................................60 
 x
Virus and cell culture.......................................................................60 
Antibodies and conjugates..............................................................60 
Virus infection .................................................................................60 
Virus purification .............................................................................60 
RNA extraction................................................................................61 
Synthesis of cDNA ..........................................................................61 
2.2.2 Construction of protein expression vectors.....................................61 
Construction of bacterial expression vectors ..................................61 
Construction of mammalian expression vectors .............................62 
2.2.3 Expression of recombinant polymerase proteins in E. coli .............62 
Plasmids and bacterial strains ........................................................62 
Preparation of electrocompetent E. coli cells..................................62 
Recombinant protein expression ....................................................63 
2.2.4 Expression of recombinant polymerase proteins in mammalian 
cells.................................................................................................64 
Transfection of JPV polymerase proteins in Vero cells...................64 
2.2.5 Western blot analysis of recombinant polymerase proteins............64 
Preparation of bacterial cell lysates for SDS-PAGE .......................64 
Preparation of mammalian cell lysates for SDS-PAGE ..................64 
Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) ...................................................................................65 
Western blot....................................................................................65 
Purification of insoluble proteins .....................................................66 
2.2.6 Preparation of monospecific antiserum against the JPV L protein .66 
PCR amplification of a predicted antigenic region of the JPV L 
gene ................................................................................................66 
Recombinant protein expression and purification ...........................67 
Immunisation...................................................................................67 
2.2.7 Construction of a NiV minigenome with a GFP reporter gene ........69 
Design of NiV minigenome .............................................................69 
PCR amplification of the NiV genome termini .................................69 
Construction of NiV GFP minigenome expression plasmid ............69 
2.2.8 Establishment of a JPV minireplicon system ..................................70 
Design of the GFP minigenome......................................................70 
Construction of the JPV GFP minigenome expression plasmid .....70 
PCR amplification and cloning of JPV N, P, PdC, L and C ORFs ..72 
2.2.9 Establishment of a BeiPV minireplicon system...............................72 
 xi
Construction of the BeiPV minigenome expression plasmid ..........72 
PCR amplification and cloning of BeiPV N, P, PdC, L and C 
ORFs...............................................................................................73 
Sequencing .....................................................................................74 
2.2.10 Minigenome functional studies........................................................74 
FWPV-T7 infection of Vero cells .....................................................74 
Transfection of Vero cells with minigenome and support plasmids 74 
Quantitation of GFP expression......................................................74 
2.3 Results........................................................................................................... 75 
2.3.1 Production of the JPV L monospecific antibody..............................75 
Expression of recombinant JPV L protein.......................................75 
Generation of antiserum .................................................................75 
2.3.2 Expression of recombinant JPV polymerase proteins ....................79 
2.3.3 Construction of minireplicon systems .............................................79 
Construction of minigenomes .........................................................79 
Construction of support plasmids....................................................79 
2.3.4 Functional minireplicon assays .......................................................83 
NiV, JPV and BeiPV minireplicon systems .....................................83 
Examination of the ‘rule of six’ for JPV and BeiPV .........................85 
Effect of the C protein on the replication of the JPV and BeiPV 
minireplicon.....................................................................................85 
2.4 Discussion ..................................................................................................... 87 
CHAPTER 3 Use of Minireplicon Systems to Study Virus Evolution and 
Classification...................................................................................91 
3.1 Introduction.................................................................................................... 91 
3.2 Materials and Methodology ........................................................................... 92 
3.2.1 Construction of minireplicon systems .............................................92 
Construction of NiV, JPV and BeiPV minireplicon systems ............92 
Construction of JPV and BeiPV hybrid minigenomes .....................92 
3.2.2 Mutagenesis of the NiV and JPV L genes ......................................94 
Mutagenesis of the NiV L gene.......................................................94 
Mutagenesis of JPV L gene ............................................................94 
3.2.3 Functional studies using JPV, NiV and BeiPV minigenomes..........95 
3.2.4 Detection of the NiV L protein by radioimmunoprecipitation ...........95 
Antibodies .......................................................................................95 
Transfection and infection of Vero cells ..........................................95 
35S labelling of transfected Vero cells .............................................95 
 xii
Lysis of 35S metabolically labelled Vero cells ..................................95 
Autoradiography..............................................................................96 
3.3 Results........................................................................................................... 96 
3.3.1 Exchange of leader and trailer regions of JPV and BeiPV..............96 
3.3.2 Exchange of NiV, JPV and BeiPV minigenomes and polymerase 
proteins ...........................................................................................96 
3.3.3 Exchange of individual JPV and BeiPV polymerase proteins .........97 
3.3.4 Mutagenesis of NiV and JPV L gene ............................................100 
Mutagenesis of the E residue in the conserved GDNE motif of the 
NiV L protein .................................................................................100 
Attempted quantitation of expression of the mutant NiV L  
proteins .........................................................................................104 
Mutagenesis of the Q residue in the conserved GDNQ motif of 
the JPV L protein ..........................................................................104 
3.4 Discussion ................................................................................................... 104 
CHAPTER 4 Characterisation of the Surface Glycoproteins of JPV ...............111 
4.1 Introduction.................................................................................................. 111 
4.2 Materials and Methodology ......................................................................... 112 
4.2.1 Cells and Viruses ..........................................................................112 
4.2.2 Antibodies and conjugates............................................................112 
4.2.3 Cloning of JPV glycoprotein genes ...............................................112 
Construction of bacterial and mammalian expression vectors......112 
Cloning of JPV fusion (F) protein and attachment (G) protein 
genes ............................................................................................112 
Cloning of the novel JPV genes (SH and TM) and ORF-X ...........113 
Cloning of JPV extended attachment gene (JPV-GstopX and 
JPV-GserX)...................................................................................113 
Cloning of JPV fusion genes (JPV-SH-ISPY, JPV-SH-SARS, 
JPV-TM-SARS, JPV-N-SARS and JPV-G-SARS-S3) ..................116 
4.2.4 Detection of JPV glycoproteins by Western blot ...........................116 
4.2.5 Detection of JPV glycoproteins by immunofluorescence ..............119 
Transfection of Vero cells .............................................................119 
Immunofluorescence.....................................................................119 
4.2.6 Detection of JPV glycoproteins by radioimmunoprecipitation .......119 
Transfection and infection of HeLa USU cells ..............................119 
35S labelling of transfected HeLa USU cells..................................120 
Lysis of 35S metabolically labelled HeLa USU cells ......................120 
 xiii
4.2.7 Detection of JPV glycoproteins by electron microscopy ...............120 
JPV infection and production of chimeric virions ..........................120 
Preparation of JPV for electron microscopy..................................120 
Negative contrast electron microscopy (NCEM) ...........................120 
Negative contrast immuno electron microscopy (NCIEM) ............122 
4.3 Results......................................................................................................... 122 
4.3.1 Construction of recombinant proteins ...........................................122 
4.3.2 Expression of JPV glycoproteins ..................................................123 
Expression of JPV novel proteins .................................................123 
Expression of F and G proteins ....................................................123 
Expression of extended attachment protein..................................126 
4.3.3 Expression of epitope tagged JPV SH protein..............................126 
4.3.4 Localisation of JPV glycoproteins .................................................129 
4.3.5 Localisation of SARS-tagged JPV glycoproteins ..........................132 
Localisation of JPV N SARS protein .............................................132 
Localisation of JPV SH-SARS, TM-SARS and G-SARS-S3 
proteins .........................................................................................132 
4.3.6 Incorporation of recombinant glycoproteins into JPV virions ........135 
Observation of JPV virions by negative contrast electron 
microscopy....................................................................................135 
Incorporation of JPV G-X fusion protein into JPV virions..............135 
Incorporation of JPV G-SARS-S3 protein into JPV virions ...........138 
Incorporation of JPV SH-SARS and TM-SARS tagged proteins 
into JPV virions .............................................................................140 
4.4 Discussion ................................................................................................... 140 
CHAPTER 5 Development of Assays for the Detection of Rodent 
Paramyxoviruses ..........................................................................147 
5.1 Introduction.................................................................................................. 147 
5.2 Materials and Methodology ......................................................................... 148 
5.2.1 Rodent tissue samples..................................................................148 
5.2.2 Isolation of total RNA from rodent tissue ......................................148 
5.2.3 Design of TaqMan primers and probe for JPV assay ...................149 
5.2.4 TaqMan real-time PCR assay.......................................................149 
5.2.5 Generation of real-time PCR efficiency curve...............................151 
5.2.6 Normalisation of real-time PCR data by Q-Gene..........................151 
5.2.7 Animal sera ...................................................................................152 
Rodent field sera samples ............................................................152 
 xiv
Control sera ..................................................................................153 
5.2.8 Purification of JPV and MosPV RNP ............................................153 
5.2.9 Purification of recombinant BeiPV P protein .................................154 
5.2.10 Multiplex microsphere assay equipment, software and 
 calibration......................................................................................154 
5.2.11 Coupling of purified JPV and MosPV RNP and BeiPV P protein to 
microspheres ................................................................................154 
5.2.12 Multiplex microsphere assay.........................................................155 
5.3 Results......................................................................................................... 156 
5.3.1 JPV real-time PCR optimisation....................................................156 
JPV Primer optimisation................................................................156 
JPV probe optimisation .................................................................156 
Determination of efficiency curve for JPV real-time PCR assay ...159 
5.3.2 Detection of JPV in rodent tissue by real-time PCR .....................163 
5.3.3 Purification of antigens for multiplex microsphere assay ..............166 
Purification of RNP........................................................................166 
Purification of recombinant BeiPV P protein .................................166 
5.3.4 Detection of JPV, MosPV and BeiPV antibodies using a multiplex 
microsphere assay........................................................................170 
5.4 Discussion ................................................................................................... 173 
CHAPTER 6 General Discussion and Future Directions ..................................181 
References 189 
Appendix I: Primer Sequences............................................................................215 
Minigenome Primer (DM) Sequences...........................................215 
JPV Primer (DJ) Sequences .........................................................216 
JPV Primer (PJ) Sequences .........................................................217 
BeiPV Primer (B) Sequences........................................................219 
Appendix II: Queensland Rodent Sera ...............................................................223 
 
 xv
List of Figures 
Figure 1.1- Classification of Paramyxoviruses ...........................................................4 
Figure 1.2- Schematic Representation of a Paramyxovirus .....................................11 
Figure 1.3- Paramyxovirus Genome Organisation ...................................................13 
Figure 1.4- Paramyxovirinae Genome Organisation ................................................14 
Figure 1.5- RNA Editing Mechanism Used by Paramyxoviruses .............................18 
Figure 1.6- Conserved C-terminal Region of the V Protein ......................................20 
Figure 1.7- Paramyxovirus Transcription and Replication........................................30 
Figure 1.8- Paramyxovirus Infectious Cycle .............................................................35 
Figure 1.9- Schematic Diagram of JPV Genome and Encoded Proteins .................45 
Figure 1.10- Schematic Diagram of BeiPV Genome and Encoded Proteins............50 
Figure 1.11- Generation of Infectious Paramyxoviruses by Reverse Genetics ........54 
Figure 2.1- Kyte & Doolittle Analysis of the JPV L Protein .......................................68 
Figure 2.2- GFP Minigenome Construct...................................................................71 
Figure 2.3- Expression and Purification of Recombinant JPV L Protein ..................76 
Figure 2.4- Evaluation of JPV L Antibody Production by Western Blot ....................77 
Figure 2.5- Evaluation of the Specificity of the JPV L Antiserum by Western Blot ...78 
Figure 2.6- Analysis of JPV N Expression in Mammalian Cells by Western Blot .....80 
Figure 2.7- Analysis of JPV P Expression in Mammalian Cells by Western Blot .....81 
Figure 2.8- Analysis of JPV L Expression in Mammalian Cells by Western Blot......82 
Figure 2.9- GFP Expression in NiV, JPV and BeiPV Minireplicon Systems.............84 
Figure 2.10- Effect of the C Protein on JPV and BeiPV Minireplicon Systems ........86 
Figure 3.1- JPV and BeiPV Hybrid Minigenomes.....................................................93 
Figure 3.2- Exchange of NiV, JPV and BeiPV Minigenomes and Polymerase 
Proteins ............................................................................................................98 
Figure 3.3- Exchange of the E Residue with a Q Residue in the Conserved NiV 
GDNE Motif ....................................................................................................101 
Figure 3.4- Amino Acid Substitutions of the E Residue in the Conserved NiV GDNE 
Motif ................................................................................................................102 
Figure 3.5- Quantitation of GFP in NiV Minireplicon Assays with Modified GDNE 
Motif ................................................................................................................103 
Figure 3.6- Exchange of the Q Residue with an E Residue in the Conserved JPV 
GDNQ Motif ....................................................................................................105 
Figure 4.1- Schematic Diagram of the JPV G Gene...............................................114 
Figure 4.2- Diagrammatic Representation of JPV G Mutagenesis.........................115 
Figure 4.3- I-SPY and SARS Epitope Tagged JPV-SH Constructs........................117 
 xvi
Figure 4.4- The pCIneo-JPV-G-SARS-S3 Construct..............................................118 
Figure 4.5- Syncytia Formation in JPV Infected Vero Cells....................................121 
Figure 4.6- Analysis of JPV TM Expression in Mammalian Cells by Western Blot 124 
Figure 4.7- Detection of JPV F, G and GserX Proteins by Radioimmunoprecipitation
........................................................................................................................125 
Figure 4.8- Analysis of JPV GserX Expression in Mammalian Cells by Western Blot
........................................................................................................................127 
Figure 4.9- Detection of JPV SH-I-SPY and SH-SARS Proteins by 
Radioimmunoprecipitation ..............................................................................128 
Figure 4.10- Analysis of JPV Glycoproteins by Immunofluorescence ....................130 
Figure 4.11- Analysis of JPV Attachment Protein by Immunofluorescence ...........131 
Figure 4.12- Analysis of JPV N-SARS Protein by Immunofluorescence ................133 
Figure 4.13- Analysis of JPV TM-SARS and G-SARS-S3 Proteins by 
Immunofluorescence ......................................................................................134 
Figure 4.14- Analysis of JPV G-SARS-S3 Protein by Immunofluorescence ..........136 
Figure 4.15- Observation of JPV Virions by Negative Contrast Electron Microscopy
........................................................................................................................137 
Figure 4.16- Observation of Chimeric GserX JPV Virions by Negative Contrast 
Immuno-Electron Microscopy .........................................................................139 
Figure 4.17- Observation of Chimeric G-SARS-S3 JPV Virions by Negative Contrast 
Immuno-Electron Microscopy .........................................................................141 
Figure 4.18- Observation of Chimeric SARS Epitope Tagged JPV Virions by 
Negative Contrast Immuno-Electron Microscopy ...........................................142 
Figure 5.1- Primer Optimisation Assay...................................................................158 
Figure 5.2- Probe Optimisation Assay....................................................................161 
Figure 5.3- JPV N and 18S rRNA Efficiency Curve................................................162 
Figure 5.4- JPV N and 18S rRNA Real-Time PCR.................................................165 
Figure 5.5- Graphical Presentation of Mouse Tissue Containing JPV RNA...........167 
Figure 5.6- Analysis of JPV RNP by Western Blot .................................................168 
Figure 5.7- Analysis of Recombinant BeiPV P Protein Expression ........................169 
Figure 5.8- Multiplexed Detection of JPV, MosPV and BeiPV in Rat Serum..........172 
Figure 5.9- Multiplexed Detection of JPV, MosPV and BeiPV in Mouse Serum ....175 
 
 xvii
List of Tables 
Table 3.1- Minireplicon Support Plasmid Combinations...........................................99 
Table 5.1- JPV and 18S rRNA Primer and Probe Sequences ...............................150 
Table 5.2- Average Ct Values from the JPV N Primer Optimisation ......................157 
Table 5.3- Average Ct values from the JPV N Probe Optimisation ........................160 
Table 5.4- Mouse Tissue Samples.........................................................................164 
Table 5.5- Multiplexed Detection of JPV, MosPV and BeiPV in Rat Serum...........171 
Table 5.6- Multiplexed Detection of JPV, MosPV and BeiPV in Mouse Serum......174 
 
 xviii
General Abbreviations 
AAHL Australian Animal Health Laboratory 
AP alkaline phosphatase 
APMV- 2-9 Avian paramyxovirus virus 2-9 
BeiPV * Beilong virus 
bp base pair 
BPIV-3 Bovine parainfluenza virus 2 
BSA bovine serum albumin 
CAT chloramphenicol acetyltransferase 
cDNA complementary DNA 
CDV Canine distemper virus 
CeMV Cetacean morbillivirus virus 
CMV Cytomegalovirus 
CPE cytopathic effect 
DNA deoxyribonucleic acid 
EBOV Ebola virus 
EGFP enhanced green fluorescent protein 
F fusion protein/ gene 
FCS foetal calf serum 
FDLV Fer-de-Lance virus 
FWPV Fowlpox virus 
GFP green fluorescent protein 
H/HN/G attachment protein/gene 
HeV Hendra virus 
HPIV-1-4 Human parainfluenza virus 1-4 
hr hour(s) 
HRSV Human respiratory syncytial virus 
IFN interferon 
JPV * J-virus 
kb kilobase 
kDa kilodalton 
L large protein/gene 
LB Luria-Bertani 
M matrix protein/ gene 
m.o.i. multiplicity of infection 
MAb monoclonal antibody 
MenPV * Menangle virus 
MeV Measles virus 
min minute(s) 
MosPV * Mossman virus 
MPRV Mapuera virus 
mRNA messenger ribonucleic acid 
MuV Mumps virus 
MW molecular weight 
N nucleoprotein/gene 
n/µ/m m/L/g nano/micro/milli metre/litre/gram 
NarPV Nariva virus 
 xix
NCBI National Center for Biotechnology Information 
NDV Newcastle disease virus 
NiV Nipah virus 
NNS non-segmented, negative-sense, single-stranded RNA 
NNSV non-segmented, negative-sense, single-stranded RNA virus 
OD optical density 
ORF open reading frame 
P phosphoprotein/ gene 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDV Phocine distemper virus 
PoRV Porcine rubulavirus 
PPRV Pestes-des-petits ruminants virus 
RABV Rabies virus 
RNA ribonucleic acid 
rpm revolutions per minute 
RPV Rinderpest virus 
RSV Respiratory syncytial virus 
SARS severe acute respiratory syndrome 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sec second(s) 
SeV Sendai virus 
SH small hydrophobic protein/gene 
ss single-stranded 
SSPE subacute sclerosing panencephalitis 
STAT signal transducer and activator of transcription 
SV-5/10/41 Simian virus 5/10/41 
TBS tris buffered saline 
TCID50 tissue culture infectious dose 50 
TioPV * Tioman virus 
TM transmembrane protein/gene 
TuPV Tupaia paramyxovirus 
UTR untranslated region 
VACV Vaccinia virus 
VACV-ANK modified Vaccinia Ankara 
vRdRp viral RNA dependent RNA polymerase 
 
 
* Denotes viruses abbreviated in accordance with the new naming convention used 
for paramyxoviruses in the 8th ICTV report (Pringle 2005). 
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CHAPTER 1 
Literature Review 
1.1 New and Emerging Viral Diseases 
Infectious diseases have played a significant role throughout human 
history. Identification of disease dates back to ancient times and the quest for 
understanding through science has lead to the discovery of viruses and bacteria as 
the causative agents of various types of infection and illness. Epidemics and 
pandemics such as plague in the 1300s and influenza in the 1900s prompted 
investigations into the treatment and prevention of diseases. Pioneering work by 
Edward Jenner in 1796 lead to the advent of vaccination and, as technology 
progresses, basic principles devised to understand and treat disease are being 
replaced with complex strategies involving molecular biology and genetic 
manipulation of targeted organisms. Pathogenicity of viruses and our vulnerability to 
the effects of infectious agents is highlighted through the emergence of new 
diseases, reappearance of pre-existing disease and, unfortunately, bioterrorism. 
Emerging infectious viral diseases are those that have recently appeared in 
a population as a result of a new virus or the recognition of a previously undetected 
virus. Emergence of an infectious viral disease may occur due to the extension of 
the geographic or host range of the virus (Morse 1995). Emerging infectious 
diseases are often zoonotic, hence having the ability to be transmitted between 
humans and animals either directly or via a vector. Acts of bioterrorism may result in 
the release of new or engineered pathogens with increased virulence into the 
population in an unpredictable manner, resulting in cases of emerging or re-
emerging infectious disease (Feldmann et al. 2002). 
Emerging infectious diseases, and the identification of the pathogens 
responsible, are frequently coupled with disease outbreaks. The emergence of 
severe acute respiratory syndrome (SARS) is one such occurrence. Cases of 
severe atypical pneumonia with unknown etiology were first identified in Guangdong 
Province, China late in 2002 in an outbreak of disease later designated as SARS. 
By April 2003 there were 4300 cases of SARS reported to the World Health 
Organisation, along with 250 SARS-related deaths occurring in 25 different 
countries (Rota et al. 2003). A novel coronavirus was isolated in March 2003 and 
determined to be the causative agent of the life-threatening respiratory illness. 
Clinical samples such as blood, serum and tissue were used to inoculate various 
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continuous cell lines, from which the virus was subsequently isolated (Ksiazek et al. 
2003). Experimental infection of macaques (Macaca fascicularis) proved that the 
newly discovered virus was the aetiological agent of SARS (Fouchier et al. 2003). 
The impact re-emerging pathogens can create is adequately demonstrated 
by the rare, but unpredictable outbreaks of haemorrhagic fevers caused by viruses 
belonging to the family Filoviridae. In 1976, Ebola virus (EBOV) emerged in two 
simultaneous outbreaks of disease in different regions of Africa. One outbreak 
occurred in the Democratic Republic of Congo (formally Zaire), resulting in 318 
cases of haemorrhagic fever with a mortality rate of 79% (Report of an International 
Commission 1978). The other outbreak occurred in Sudan, where 284 cases were 
reported with a mortality rate of 53% (WHO/International Study Team 1978). Re-
emergence of EBOV subtype Sudan in Uganda (Okware et al. 2002) and EBOV 
subtype Zaire in Gabon (Geisbert et al. 2002) and several other incidences of 
outbreaks occurring sporadically since the 1976 emergence of the virus in the 
Democratic Republic of Congo, highlight the susceptibility of the human population 
to a virus that was previously geographically restricted.  
In contrast to the punctuated outbreaks of Ebola, the emergence of Human 
immunodeficiency virus (HIV) resulted in an uncontrollable worldwide pandemic. HIV 
was first discovered in 1983 when a new retrovirus was isolated (Barre-Sinoussi et 
al. 1983). The entire 9,193 nucleotide genome sequence of HIV was published in 
1985 (Wain-Hobson et al. 1985), and considerable genetic diversity was 
demonstrated among subtypes of the virus, designated clades A-J. The oldest 
reported HIV sequence dates back to 1959 and phylogenetically placed this isolate 
between clades C and D (Zhu et al. 1998). Although HIV existed in humans as early 
as 1959, there was no detectable disease until 1983, emphasising the differences in 
disease impact resulting from emerging viruses. 
The last two decades have yielded the emergence of several new 
paramyxoviruses, the majority of which were previously unclassified (Wang & Eaton 
2001). The discovery of these viruses occurred not only as a result of disease 
outbreaks but also under circumstances where no disease correlation was evident. 
New paramyxoviruses have emerged from an extensive range of aquatic and 
terrestrial animals, demonstrating the vast host range of this family of viruses. 
Zoonotic viruses were among the emergent species, emphasising the pathogenicity 
of paramyxoviruses. These emergent viruses provide the opportunity to gain an 
insight into the evolution, diversity, epidemiology and pathogenesis of 
paramyxoviruses. Specific examples of new and emerging paramyxoviruses are 
discussed in Section 1.7. 
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1.2 Classification of Paramyxoviruses 
1.2.1 Order Mononegavirales 
The order Mononegavirales is divided taxonomically into four families- 
Filoviridae, Bornaviridae, Rhabdoviridae and Paramyxoviridae (Figure 1.1). All 
members of these viral families contain a linear, non-segmented, negative-sense 
single-stranded RNA (NNS) genome varying from 8.9-19.2 kilobases in length 
(Pringle 2005). The RNA of viruses in the order Mononegavirales is contained in a 
helical nucleocapsid in the enveloped virion and is no longer infectious once 
deproteinised. The genomes of the four Mononegavirale families are organised in a 
similar order beginning with a 3’ non-translated region, followed by core, envelope 
and polymerase protein genes, and ending in a 5’ non-translated region (Pringle 
2005). Viral genomes also contain complementarity of the 3’ and 5’ termini, and 
transcription occurs via a virion-associated RNA dependent RNA polymerase 
(Pringle 2005). Morphology of viruses differs between the families. 
1.2.2 Family Paramyxoviridae 
Viruses within the Paramyxoviridae family consist of a NNS genome 
contained exclusively within a nucleocapsid of 18 nm in diameter, 1 μm in length 
and 5.5 nm in pitch (Lamb & Kolakofsky 2001). The viral RNA has no 5’ cap or 
covalently linked proteins, and the 3’ end of the genome is not polyadenylated. 
Virions are pleomorphic, but usually spherical, range from 150 nm upwards in size 
and possess an envelope that is derived from the host cell plasma membrane 
(Lamb et al. 2000). Projecting from the viral envelope are two or three types of 
transmembrane glycoproteins of 8-12 nm in length with a placement of 7-10 nm 
from each other, depending on the genus. Replication of paramyxoviruses occurs 
entirely within the cytoplasm of the host cell. Due to the unsegmented single-
stranded nature of the viral RNA, and the location of the RNA within a nucleocapsid, 
paramyxoviruses are genetically stable with mutation the only mechanism whereby 
variation can occur (Bellini et al. 1998). Evidence of recombination has recently 
been reported in paramyxoviruses but recombination rate is unlikely to be a trait that 
is set by natural selection to create advantageous or purge deleterious mutations 
(Chare et al. 2003). The family Paramyxoviridae is divided into two subfamilies- 
Paramyxovirinae and Pneumovirinae (Figure 1.1). 
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Figure 1.1- Classification of Paramyxoviruses 
The order Mononegavirales contains four families; Filoviridae, 
Paramyxoviridae, Rhabdoviridae and Bornaviridae. The family Paramyxoviridae is 
divided into two subfamilies, Paramyxovirinae and Pneumovirinae. The five genera 
contained within the Paramyxovirinae are Respirovirus, Morbillivirus, Rubulavirus, 
Henipavirus and Avulavirus. This figure was adapted from Wang et al. (2003). 
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Classification of viruses to determine subfamily is based on morphology, 
genome organisation, biological activity of proteins, and sequence relationship of 
encoded proteins (Lamb & Kolakofsky 2001). Members of the Pneumovirinae are 
morphologically distinctive from members of the Paramyxovirinae in that they 
possess narrower nucleocapsids and O-linked glycosylation of the attachment 
protein. 
1.2.3 Subfamily Paramyxovirinae 
The subfamily Paramyxovirinae contains viruses with genomes of 15-19 kb 
in length. The term ‘gene’, when used in reference to paramyxoviruses, refers to the 
sequence encoding a single mRNA, even if more than one open reading frame 
(ORF) is present or more than one protein is encoded (Lamb & Kolakofsky 2001). 
Members of the subfamily Paramyxovirinae contain 6-8 transcriptional units within a 
highly conserved genome structure. The genome is encapsidated in a nucleocapsid 
of 18 nm in diameter and a pitch of 5.5 nm. Of the proteins produced by these 
viruses, the most conserved between Paramyxovirinae are the nucleoprotein (N), 
matrix (M) and polymerase (L) protein. The fusion (F) and attachment (HN/H/G) 
proteins are less conserved and the phosphoprotein (P) gene is poorly conserved, 
with the exception of a unique region encoding the V protein-specific region that is 
not present in the P protein (Lamb et al. 2000). Conserved 3’ leader and 5’ trailer 
extragenic regions frame the genome termini with 12 nucleotides demonstrating 
complementarity. Intergenic regions (IGRs) are relatively conserved, with the 
trinucleotide sequence 3’-GAA-5’ predominating, but may also contain sequences of 
variable length (Bellini et al. 1998). 
The lipid envelopes of paramyxoviruses contain two surface glycoproteins. 
The F proteins are present on all viruses and attachment proteins may be 
designated HN, H or G, based on the presence or absence of haemagglutinin and 
neuraminidase activity. Surface glycoproteins, in conjunction with the RNA editing 
mechanism used to translate the P gene, aid in further classifying paramyxoviruses 
into different genera (Lamb et al. 2000). The subfamily Paramyxoviridae is currently 
grouped into five genera. Originally the subfamily was divided into three genera- 
Morbillivirus, Respirovirus and Rubulavirus (Lamb et al. 2000), but recently two 
other genera were recognised- Avulavirus and Henipavirus (Mayo 2002). The genus 
TuPV-like viruses has been proposed (Tidona et al. 1999), along with Ferlavirus 
(Kurath et al. 2004). Several other new or emerging paramyxoviruses cannot be 
classified as part of any of the existing genera (Wang et al. 2003). 
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Genus Morbillivirus 
Morbilliviruses are spherical or pleomorphic viruses 150-200 nm in 
diameter and contain a genome 15.6-15.9 kb in size. The morbillivirus genome 
contains six transcriptional units, producing eight ORFs (Barrett & Rima 2002). 
Viruses currently recognised in the Morbillivirus genus are Measles virus (MeV), 
Rinderpest virus (RPV), Canine distemper virus (CDV), Pestes-des-petits ruminants 
virus (PPRV), Phocine distemper virus (PDV) and Cetacean morbillivirus virus 
(CeMV) (Pringle 2005). During infection, morbilliviruses produce intracytoplasmic 
and intranuclear inclusion bodies containing viral nucleocapsids. Sequence 
relatedness between morbilliviruses is low to moderate, depending on protein 
analysed (Lamb et al. 2000). Members of the genus display a greater amino acid 
homology with members within the genus than with members of other genera within 
the Paramyxovirinae. The P gene of morbilliviruses encodes the P, V and C 
proteins. Transcripts faithfully transcribed from the P gene produce the P protein, 
transcripts where one non-templated G residue is inserted at the RNA editing site 
produce V proteins and the C protein is encoded by an alternate ORF (Lamb et al. 
2000). 
MeV infection results in acute respiratory syndrome followed by systemic 
spread producing a generalised rash. In rare cases subacute sclerosing 
panencephalitis (SSPE), a persistent fatal infection of the nervous system, can 
develop 5-10 years after initial infection (Morrison & Portner 1991) if mutated forms 
of MeV persist (Reutter et al. 2001). MeV is the type species of the genus 
Morbillivirus although a proposal has been made based on antigenic comparison of 
conserved epitopes in MeV, CDV and RPV that RPV is the archetype morbillivirus, 
from which CDV and MeV evolved (Norrby et al. 1985).  
Genus Respirovirus 
Respiroviruses are spherical or pleomorphic viruses 150-350 nm in 
diameter and contain a genome of 15.0-15.5 kb in size. The respirovirus genome 
contains six transcriptional elements separated by a trinucleotide IGR (3’-GAA-5’) 
and all members of this genus produce haemagglutinin and neuraminidase proteins 
(Banjeree & De 2002). Viruses currently recognised as part of the genus 
Respirovirus are Sendai virus (SeV), Human parainfluenza virus 1 (HPIV-1), Human 
parainfluenza virus 3 (HPIV-3), Bovine parainfluenza virus 3 (BPIV-3) and Simian 
virus 10 (SV-10) (Pringle 2005). SeV, the type species of the genus, was isolated in 
1953 (Banjeree & De 2002) and has been fully sequenced (Shioda et al. 1986). 
Relatedness, based on amino acid homology, varies from high to low between 
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group members. SeV and HPIV-1 have considerable sequence relatedness, but are 
distinguished by host range, as SeV infects rodents and HPIV-1 infects humans. A 
similar relationship links HPIV-3 and BPIV-3, where HPIV-3 infects humans and 
BPIV-3 infects cattle (Lamb et al. 2000).  
All members of the genus produce C proteins from alternate ORFs within 
the P gene. Two overlapping ORFs upstream of the RNA editing site within the P 
gene are designated P-amino 1 and P-amino 2 (Lamb & Kolakofsky 2001). SeV and 
HPIV-1 utilise the P-amino 2 ORF to produce up to four nested polypeptides, 
formally identified as C, C’, Y1 and Y2 (Curran & Kolakofsky 1989), with the use of 
four ribosomal initiation sites. Faithful transcription of the P gene results in mRNA 
encoding the P protein. Addition of one non-templated G residue via the RNA editing 
site leads to the production of the V protein (Lamb et al. 2000). HPIV-1 is a notable 
exception to the rule as this virus does not edit RNA of the P gene, hence does not 
produce a V protein. HPIV-3 produces a D protein in lieu of a V protein (Matsuoka et 
al. 1991).  
Genus Rubulavirus 
Rubulaviruses are spherical or pleomorphic viruses 150-250 nm in 
diameter and contain a genome of 15.2-15.6 kb in size. Mumps virus (MuV) is the 
type species and other members of the genus are Human parainfluenza virus 2 
(HPIV-2), Human parainfluenza virus 4 (HPIV-4), Porcine rubulavirus (PoRV), 
Mapuera virus (MPRV), Simian virus 5 (SV-5), Simian virus 41 (SV-41), Menangle 
virus (MenPV) and Tioman virus (TioPV) (Pringle 2005). Avian paramyxoviruses 
were previously classed as rubulaviruses before the creation of the genus 
Avulavirus.  
IGRs of variable length separate transcriptional elements of rubulaviruses 
and all viral members of this genus have an attachment protein with haemagglutinin 
and neuraminidase activities. The P gene is smaller than that of other 
paramyxoviruses and is capable of producing a V and W protein in addition to the P 
protein, but there is currently no evidence supporting the expression of a C protein 
in any rubulaviruses (Lamb et al. 2000). The addition of two non-templated G 
residues in the RNA editing site of the P gene leads to the production of the P 
protein, the addition of one non-templated G residue produces the W protein, while 
a non-edited P transcript produces the V protein. This editing strategy differs from 
that seen in other viruses within the subfamily Paramyxovirinae (Lamb et al. 2000). 
An additional gene encoding a small hydrophobic transmembrane surface protein is 
located between the F and HN genes of MuV and SV-5 (Ito & Tsurudome 2002). 
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Genus Avulavirus 
Viruses belonging to the genus Avulavirus, the name derived from avian 
rubulavirus, are pleomorphic and generally rounded but can sometimes be 
filamentous. Virions range from 100-500 nm in diameter and contain a genome of 
15.1-16.2 kb in size. Avian paramyxovirus type 1 (APMV-1) was first recognised as 
a causative agent of disease in 1926 and subsequently identified as a member of 
the genus Rubulavirus. APMV-1 was later termed Newcastle disease virus (NDV) 
(Peeters & Koch 2002). NDV is the type species of Avulavirus, accompanied in the 
genus by eight other avian infecting paramyxoviruses, Avian paramyxovirus 2-9 
(APMV 2-9). All avulaviruses possess haemagglutinin and neuraminidase activity. 
The P gene encodes the P, V and W proteins (Peeters & Koch 2002). 
Complete sequencing of the NDV genome (de Leeuw & Peeters 1999) 
revealed a genome organisation typical of most paramyxoviruses, but sequencing of 
the APMV-6 genome uncovered the existence of an extra gene between the F and 
HN genes (Chang et al. 2001). The small hydrophobic (SH) gene of APMV-6 has no 
homology to any other known proteins in the NCBI database (Chang et al. 2001), 
but the location of the gene between the F and HN genes is the same as the 
placement of the SH gene in SV-5 and MuV (Ito & Tsurudome 2002). Amino acid 
sequence homology is greatest between members within the genus Avulavirus and 
these viruses are closely related to the rubulaviruses. 
Genus Henipavirus 
The genus Henipavirus currently contains two viral species- Hendra virus 
(HeV) and Nipah virus (NiV). Henipaviruses may be spherical, pleomorphic or 
filamentous, are 40-600 nm in diameter and contain a genome of 18.2 kb in length 
(Wang & Eaton 2002). Genome length of paramyxoviruses prior to the sequencing 
of HeV and NiV was described as uniform, varying no more than 5% among all 
members of the family Paramyxoviridae (Lamb et al. 2000). Complete sequencing of 
HeV revealed the viral genome was 15% longer than the genomes of other 
paramyxoviruses, the size difference due to exceptionally long untranslated regions 
at the 3’ end of mRNA produced by 5 of the 6 genes (Chua et al. 2000).  
HeV is the type species of the genus. HeV and NiV both lack 
haemagglutinin and neuraminidase activity, and the genome termini are highly 
conserved. IGRs separating viral genes contain the sequence 3’-GAA-5’ and are 
absolutely conserved. The F gene of henipaviruses contains a unique sequence 
indicating endocytosis (Meulendyke et al. 2005; Vogt et al. 2005) and host cell 
proteases other than furin are utilised by the viruses to cleave the fusion protein 
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(Moll et al. 2004; Pager et al. 2004; Pager & Dutch 2005). The P gene of 
henipaviruses is capable of encoding a P protein when transcribed exactly, a V 
protein when a single non-templated G residue is inserted into the RNA editing site 
or a C protein via an alternate ORF (Wang & Eaton 2002). The conserved QGDNQ 
motif within the L gene of HeV was replaced with the QGDNE motif (Chua et al. 
2000), as was the case in NiV (Harcourt et al. 2001). 
Proposed genus TuPV-like viruses 
Tupaia paramyxovirus (TuPV) was isolated from a tree shrew (Tupaia 
belangeri), in the late 1970s (Tidona et al. 1999) (See Section 1.7). The isolated 
virus was 300-1000 nm in diameter, pleomorphic and possessed and envelope with 
8 nm long surface projections (Tidona & Darai 2002). Sequencing of the 17.9 kb 
TuPV genome, the N and P/V/C genes in particular, established an evolutionary 
relationship between this emergent virus and the morbilliviruses (Tidona et al. 1999). 
TuPV contains haemagglutinin but does not possess neuraminidase activity. The 
IGRs separating genes are conserved, with the trinucleotide sequence 3’-GAA-5’, 
and the 3’ non-transcribed leader region is also conserved with a 55 nucleotide 
sequence. The 5’ non-transcribed region is significantly longer than that of other 
paramyxoviruses, with a length of 590 nucleotides (Tidona & Darai 2002). 
Sequencing of the L gene revealed the conserved QGDNQ region of the 
polymerase was replaced with QGDNE (Tidona et al. 1999), as reported in HeV and 
NiV (Chua et al. 2000). The genus name TuPV-like virus was proposed for 
placement of viruses phylogenetically related to TuPV, with TuPV as the type 
species (Tidona & Darai 2002). The International Committee on Taxonomy of 
Viruses has not approved this genus. 
Proposed genus Ferlavirus 
Fer-de-Lance virus (FDLV) is an emergent reptilian paramyxovirus (see 
Section 1.7) that was isolated from a Fer-de-Lance viper (Bothrops atrox) in 1972 
(Clark et al. 1979). FDLV was classed as a member of the subfamily 
Paramyxovirinae based on gene length, expression of multiple proteins from P 
gene, conserved V carboxyl terminal domain and lack of an M2 protein, the later 
conclusively excluding the virus from the subfamily Pneumovirinae (Kurath et al. 
2004). Comparative analysis of the F gene revealed a highly conserved heptad 
repeat motif and furin cleavage site typical of other members of the subfamily 
Paramyxovirinae (Franke et al. 2001; Franke et al. 2006).  
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The FDLV genome is 15.3 kb in length, obeys the rule of six and contains 
all genes common to paramyxoviruses, along with an extra gene, designated U. 
Presence of a unique gene distinguishes FDLV from other paramyxoviruses and 
based on phylogenetic analysis of the HN and L genes, FDLV is most closely 
related to the respiroviruses (Kurath et al. 2004). A study of 16 paramyxoviruses 
isolated from reptiles demonstrated strong antigenic relationships between viruses, 
irrespective of the virus origin. The novel U gene was also located in viruses isolated 
from two different snakes. Based on these findings the suggestion was made that 
snake paramyxoviruses should comprise a new genus within the subfamily 
Paramyxovirinae (Kurath et al. 2004). The name proposed was Ferlavirus, with 
FDLV the type species. The International Committee on Taxonomy of Viruses has 
not approved this genus. 
1.3 Virus Structure 
Paramyxovirus virions pleomorphic and are composed of two structural 
components; the helical ribonucleoprotein core and the lipoprotein bilayer 
membrane, acquired from the host cell that constitutes the envelope. Virions are 
sensitive to heat, lipid solvents, ionic and non-ionic detergents, formaldehyde and 
oxidising agents and exhibit a buoyant density of 1.18-1.20 g/cm2 in a sucrose 
gradient (Lamb et al. 2000) 
The NNS genomic RNA is always tightly encased by nucleocapsid (N) 
proteins in a left-handed coil with distinct ‘herringbone’ morphology. The 
nucleocapsid, in conjunction with highly phosphorylated P proteins and 
multifunctional L protein that possesses catalytic polymerase activity, forms a 
complex that has RNA-dependent RNA polymerase activity. Nucleocapsids are 18 
nm in diameter, 1 μm in length and 5.5 nm in pitch (Lamb & Kolakofsky 2001), never 
disassemble naturally and are able to withstand high salt and gravity forces of 
caesium chloride density gradient centrifugation.  
Projecting 8-12 nm from the lipid bilayer of the viral envelope are two or 
three glycoproteins, glycosylated by N-linked carbohydrate side chains (Lamb et al. 
2000). All paramyxoviruses possess attachment (HN, H or G) proteins and 
transmembrane F proteins that are activated by proteolytic cleavage (Conzelmann 
1998). In addition, an SH protein is present in some rubulaviruses (Ito & Tsurudome 
2002). The most abundant protein, the matrix (M) protein is basic, slightly 
hydrophobic and is associated with the inner surface of the lipid envelope. A 
paramyxovirus virion is schematically represented in Figure 1.2. 
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Figure 1.2- Schematic Representation of a Paramyxovirus 
The schematic paramyxovirus diagram illustrates the location of the small 
hydrophobic (SH) protein, lipid bilayer, fusion (F) protein, polymerase (L) complex, 
attachment (HN/H/G) protein, nucleoprotein (N), matrix (M) protein, phosphoprotein 
(P) and the single-stranded (ss) RNA genome. This figure was supplied by Dr. Ian 
M. Mackay, Sir Albert Sakzewski Virus Research Centre (July, 2004). 
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1.4 Paramyxovirus Genome Characteristics 
1.4.1 Genome organisation 
The genome organisation of the Paramyxovirinae is conserved, although 
some species within the subfamily possess additional genes, and is as follows- 
3’-N-P/V/C-M-F-HN-L-5, where HN is the attachment protein and may be either HN, 
H or G. Paramyxovirus genes are defined as sequences encoding a single mRNA, 
even if the sequence contains more than one ORF or encodes more that one protein 
(Lamb & Kolakofsky 2001). Genes are separated by non-transcribed IGRs that are 
generally conserved trinucleotide sequences, but are also present in variable in 
length (1-85 nucleotides in rubulaviruses) and nucleotide composition. A schematic 
representation of a paramyxovirus genome is given in Figure 1.3 and the specific 
genome organisations for the type species of each genus are displayed in Figure 
1.4. 
1.4.2 Genome replication and the ‘rule of six’ 
Viral RNA of paramyxoviruses is required to be bound by a helical 
nucleocapsid in order to be infectious. Electron microscopy analysis of SeV 
nucleocapsids revealed helices of left-handed symmetry, which suggested a 
stoichiometric relationship between six nucleotides of RNA and one N protein 
subunit (Egelman et al. 1989). For efficient replication, SeV RNA must contain a 
total number of nucleotides that is a multiple of six, which was dubbed the ‘rule of 
six’ (Calain & Roux 1993).  
The rule of six does not exclude other requirements for efficient replication, 
such as total minimum RNA length and cis-acting sequences. The RNA polymerase 
initiates more efficiently when cis-acting promotor sequences are found in the 
correct context with relation to N subunits, determined by the length of the entire 
genome (Hausmann et al. 1996). Association of N monomers with hexameric 
genomic nucleotide sequences begins with the first nucleotide at the 5’ end of the 
genome and continues until reaching the 3’ end, until the genome is precisely 
covered by N subunits. Most members of the subfamily Paramyxovirinae obey the 
rule of six, but the requirement for N subunit association correlates with whether the 
virus edits the P gene (Kolakofsky et al. 1998).  
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Figure 1.3- Paramyxovirus Genome Organisation 
Paramyxoviruses contain non-segmented, negative-sense, single-stranded RNA 
genomes. The 3’ terminal region contains an untranslated leader sequence and the 
5’ end contains an untranslated trailer region. Genes common to all 
paramyxoviruses are the nucleoprotein (N) gene, phosphoprotein (P) gene, matrix 
(M) gene, fusion (F) gene, attachment (HN/H/G) gene and the large (L) gene. Gene 
junctions consist of the gene end signal of the upstream gene, an intergenic region 
and the gene end signal of a downstream gene. This figure has been adapted from 
Lamb & Kolakofsky (2001). 
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Figure 1.4- Paramyxovirinae Genome Organisation 
The genome organisation of paramyxoviruses within the Paramyxovirinae is 
represented via illustration of the type species for each genus. The genus Ferlavirus 
has been suggested (Kurath et al. 2004), but has not been approved by The 
International Committee on Taxonomy of Viruses. The schematic representation of 
the Fer-de-Lance virus genome displays the location of the novel U (unknown) gene 
not common to other paramyxoviruses. Representative genomes are drawn to 
scale. 
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The requirement for the rule of six may have evolved to maintain genome 
stability, protecting against insertion of nucleotides into RNA editing sites during 
replication (Hausmann et al. 1996). Paramyxoviruses editing P mRNA either obey 
the rule of six or confront selective disadvantage (Conzelmann 1998). 
1.4.3 Coding Capacity  
A distinct feature of RNA replication is high mutation rate leading to 
deleterious mutations. A compact genome organisation and high coding capacity of 
genes offers a selective advantage for an RNA virus as the genome is replicated 
rapidly and frequently (Domingo & Holland 1997). The average coding capacity of 
genomes within the Paramyxoviridae prior to the isolation of the henipaviruses was 
92%. Exceptionally long untranslated regions in the genomes of henipaviruses 
significantly reduced the coding capacity within the subfamily to 82%. As a high 
genome coding capacity appears to be beneficial, the possibility exists that the 
henipaviruses represent an ancient lineage of paramyxoviruses (Wang et al. 2003). 
The coding capacity of paramyxoviruses is extended by the ability of the P gene to 
encode several proteins (see Section 1.5.2 and 1.6.4).  
1.5 Paramyxovirus Genes and Protein Products 
Members of the Paramyxovirinae subfamily contain a conserved genome 
with the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F) attachment 
(HN/H/G) and large (L) genes present in all viruses (see figure 1.3).  
1.5.1 Nucleocapsid (N) protein gene 
The N protein functions in the encapsidation of viral RNA, and associates 
with the P and L proteins during replication and transcription. The N protein also 
interacts with the M protein during assembly. The P protein functions as a 
chaperone to prevent uncontrolled encapsidation of non-viral RNA, allowing the N 
protein to bind selectively to the genome and antigenome (Errington & Emmerson 
1997). Encapsidated RNA is resistant to degradation by RNase. The N protein is not 
a classical RNA binding protein, but levels of the N protein in the cytoplasm function 
in switching between transcription and replication of the viral genome. Binding of 
antibodies to the N protein releases P proteins (Morgan et al. 1984), proving the 
interaction between the two proteins. Regions of the N protein capable of P protein 
interaction are variable between paramyxoviruses. The N protein region of NDV that 
binds the P protein differs from the binding regions in SeV and MeV (Kho et al. 
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2004). Strong hydrophobic forces maintain N-RNA and N-N interactions and the 
domain F-X4-Y-X4-S-Y-A-M-G (where X represents any amino acid residue) is 
found in a strong hydrophobic region near the middle of the N protein (Lamb & 
Kolakofsky 2001). 
The monomeric N protein, NO, consists of two regions. The N-terminal 
domain, NCORE, constitutes 80% of the N protein and is relatively conserved. In 
contrast, the C-terminal domain, NTAIL, which constitutes the remaining 20% of the N 
protein, is hypervariable. Although NTAIL is poorly conserved, this region is always 
highly charged and mostly negative (Lamb & Kolakofsky 2001). The RNA binding 
domains are located in the conserved NCORE domain (Mountcastle et al. 1974), and 
this N-terminal domain is also required for correct folding of the N protein for the 
formation of a ‘herringbone-like’ structure (Kho et al. 2003). The NTAIL domain is 
dispensable for assembly, may be utilised by the N protein in the transition between 
helical states and contains phosphorylation and antigenic sites (Morgan et al. 1984). 
Conservation of long, unstructured regions of N proteins within the Paramyxovirinae 
may be of functional significance (Karlin et al. 2003). 
1.5.2 Phosphoprotein (P) gene  
The P gene of the Paramyxovirinae represents an example of viruses 
compacting as much genetic information into genes as possible. The P gene 
encodes a vast array of gene products ranging from truncated, modified and full 
length proteins, through a variety of mechanisms. Translation via alternate ORF and 
RNA editing (to be discussed in Section 1.5.4) enable the production of P, V, C, C’, 
D, I, W, X, Y1, Y2 and Z protein products, depending on the genus. The P and V 
proteins are produced as a result of either faithful transcription of RNA or RNA 
editing. All viruses in the subfamily Paramyxovirinae, except HPIV-1, contain an 
RNA editing site (Lamb & Kolakofsky 2001). HPIV-3 produces a D protein in lieu of a 
V protein (Matsuoka et al. 1991). C proteins are produced from alternate ORFs in 
most genera. 
There are two major types of P gene coding strategy observed in 
Paramyxovirinae members- Type A and Type B (Wang et al. 2003). The Type A 
coding strategy, used by all paramyxoviruses except rubulaviruses and 
avulaviruses, involves an unedited version of the P gene encoding a P protein. The 
V protein is translated when a single non-templated G reside is inserted into the 
RNA editing site, which has a consensus sequence of 5’-AAAAAGGG-3’.The C 
protein is produced by internal translation initiation (Wang et al. 2003). The Type B 
coding strategy is used by the rubulaviruses, which do not encode a C protein. An 
 17
unedited version of the P gene encodes the V protein, and the addition of two non-
templated G residues in the RNA editing site, which has a consensus sequence of 
5’-TTTAAGAGGGG-3’, results in the production of a P protein (Wang et al. 2003). 
Type A and B coding strategies of paramyxoviruses are represented in Figure 1.5. 
P protein 
The P proteins of viruses within the genus Rubulavirus are the smallest 
within the subfamily Paramyxovirinae, and viruses within the genus Henipavirus 
contain the largest P proteins (Wang et al. 1998). The P protein consists of two 
distinct domains, based on sequence conservation. The P N-terminal (PNT) domain 
contains sites for phosphorylation, is poorly conserved and is involved in 
chaperoning of newly synthesised N proteins during replication. The P C-terminal 
(PCT) domain is highly conserved and has a critical role in positioning of the L 
protein on the transcription template (Blanchard et al. 2004). 
The P protein is a component of the polymerase complex and is natively 
unstructured in MeV and morbilliviruses, but folded in rubulaviruses (Karlin et al. 
2002). Unstructured P proteins undergo ‘induced folding’ upon binding to N and L 
proteins. N protein binding to the P protein of MeV creates a 4-helix bundle, but MuV 
P protein persistently lacks tertiary structure in the N binding domain, indicating the 
rubulaviruses may have evolved a slightly different binding mechanism from other 
paramyxoviruses (Kingston et al. 2004). The PCT domain of the P protein exists as 
a tetramer (Tarbouriech et al. 2000a). Coiled coils can form dimers, trimers and 
tetramers depending on packing of hydrophobic side chains at helix interfaces and 
the coiled coil region of the P protein conserved in the subfamily Paramyxovirinae is 
sufficient for oligomerisation (Curran et al. 1995). Consistent with this observation, 
SeV was found to contain an oligomerisation domain with a homotetrameric coiled 
coil structure (Tarbouriech et al. 2000b). Phosphorylation of the P protein is directed 
by cellular kinases and SeV and HPIV-1 are highly phosphorylated. HPIV-1 also 
requires two separate regions on the P protein to enable efficient interaction with the 
L protein (Bousse et al. 2001), as precise protein interactions are essential for 
polymerase activity. 
V protein 
The V- and P-coding regions upstream of the RNA editing site are identical, 
and the C-terminal domains of the V protein, located downstream of the editing site, 
are highly conserved amongst members of the Paramyxovirinae (Lamb & 
Kolakofsky 2001). 
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Figure 1.5- RNA Editing Mechanism Used by Paramyxoviruses 
Pseudotemplated addition of nucleotides co-transcriptionally into mRNA occurs in all 
members of the Paramyxovirinae, except HPIV-1 and is confined exclusively 
confined to the P gene. Insertions into mRNA occur in the middle of the P gene, 
resulting in a frameshift that allows ribosomal access to a second ORF. The 
morbilliviruses, respiroviruses, henipaviruses and avulaviruses all encode a P 
protein when the P gene is faithfully transcribed. The V protein is encoded when a 
single, non-templated G residue is inserted into the mRNA transcript. The 
rubulaviruses encode a V protein from the faithfully transcribed P gene and a P 
protein is encoded when two non-templated G resides are inserted into the mRNA 
transcript. This illustration was adapted from Wang et al. (2003). 
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The C-terminal domain contains a region where 15 out of 48 amino acids, 
seven of which are cysteine residues, are perfectly conserved between 
paramyxovirus V proteins (Figure 1.6). This highly conserved C-terminal region of 
the V protein resembles a zinc finger domain and is capable of binding two zinc 
atoms. The zinc-binding capability of SeV is involved in viral pathogenesis. This was 
demonstrated experimentally when SeV lacking the V protein was less virulent in 
mice, with virus clearance from the lungs of the mice occurring efficiently (Huang et 
al. 2000). 
The V protein is capable of functioning in interferon (IFN) signalling 
inhibition (Nishio et al. 2005), cell cycle alterations, inhibition of double-stranded 
DNA signalling and prevention of apoptosis (Nanda & Baron 2006). Host organisms 
inhibit and eliminate viral infection by sacrificing virus-infected cells by apoptosis. 
SV-5 is capable of preventing viral induced apoptosis (Wansley & Parks 2002), but 
deletions in the conserved C-terminal region of the SV-5 V protein increased CPE 
and apoptosis in infected HeLa cells, indicating that the full-length V protein is 
required in the prevention of programmed cell death (Sun et al. 2004). The tumour 
suppressor homologue p73 is thought to be an inducer of apoptosis through a 
mitochondrial pathway. The MeV V protein inhibits the transcriptional activity of p73, 
hence, preventing apoptosis (Cruz et al. 2006). Controlled killing of cells has been 
demonstrated with recombinant paramyxoviruses, such as SV-5 with a mutant V 
protein (Parks et al. 2002), eluding to the possibility of therapeutic vaccine vectors to 
target the destruction of cancerous cells. 
Interferons are a family of soluble cytokines mediating cellular resistance to 
viruses. IFN signalling interference is a common method utilised by 
paramyxoviruses to circumvent host anti-viral responses, but the mechanism 
whereby evasion of host cell defences is achieved is virus-specific (Young et al. 
2000). The signal transducer and activator of transcription (STAT) family of proteins 
are critical components of the IFN signalling pathway, involved in constitutive 
expression of certain genes, such as caspases, and are involved in processing of T 
cell antigens.  
The paramyxovirus V protein is able to function as an IFN antagonist 
(Kubota et al. 2005). The V protein of SV-5 targets STAT1 for proteasome-mediated 
degradation in human cells (Didcock et al. 1999), but not mouse cells. The V protein 
of SV-41 and MuV decrease levels of STAT1 and the V protein of HPIV-2 decreases 
levels of STAT2 (Gotoh et al. 2002). 
 20
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6- Conserved C-terminal Region of the V Protein 
The highly conserved C-terminal region of the paramyxovirus V protein resembles a 
zinc finger domain and is capable of binding two zinc atoms. Within this region, 
fifteen out of forty-eight amino acids, seven of which are cysteine residues, are 
perfectly conserved.  Conserved amino acids are indicated by blue arrows and 
cysteine residues are indicated by green arrows. GenBank database accession 
numbers of paramyxoviruses used in this alignment are as follows- CDV 
(AAQ96302), FDLV (NP899657), HeV (NP047108), HPIV2 (P23057), HPIV4 
(P21740), MenPV (AAK62279), MeV (Q9EMA9), MosPV (NP958050), MuV 
(NP054709), NDV (Q06428), NiV (NP112023), PDV (JQ1565), RPV (Q03340), 
SaPV (AAF63742), SeV (BAC79135), SV-5 (P11207), SV-41 (P36315), TioPV 
(NP665866) and TuPV (Q9QM81). 
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In addition to proteasome degradation, inactivation of STAT is achieved by 
ubiquitin ligase destruction by SV-5, HPIV-2 and MuV V proteins, prevention of 
nuclear import of IFN by STAT with MeV V protein and sequestration of STAT by 
HeV and NiV V proteins (Horvath 2004).  
 A co-dependent relationship exists between STAT1 and STAT2. SV-5 and 
MuV require STAT2 to target STAT1 and HPIV-1 requires STAT1 to target STAT2. 
The V protein of henipaviruses is able to form a tripartite complex with STAT1 and 
STAT2, inhibiting IFN signalling through sequestration of STAT (Rodriguez et al. 
2004). Overactivity of STAT3 is associated with diseases such as cancer, arthritis, 
lupus, autoimmunity, cardiac hypertrophy and obesity. MuV V protein targets the 
destruction of STAT3 via ubiquitin ligase resulting in the inhibition of a diverse range 
of cellular responses. MuV is able to invade the immune system and replicate in 
activated T lymphocytes, perhaps indicating that the MuV V protein may be utilised 
as a treatment in disease where overactive STAT3 is implicated (Horvath 2004). 
C protein 
Several paramyxoviruses are capable of expressing a group of non-
structural proteins, the C proteins, from an alternate ORF within the P gene, 
upstream of the RNA editing site (see Section 1.5.4) and are not affected by addition 
of non-templated G residues into mRNA transcripts (Bellini et al. 1998). 
Rubulaviruses do not encode a C protein, morbilliviruses and henipaviruses encode 
one C protein and respiroviruses are capable of encoding a group of several C-like 
proteins. SeV, a respirovirus, encodes four C-like proteins, designated C, C’, Y1 and 
Y2. Transcription of the Y proteins of SeV is initiated by a ribosomal shunt 
mechanism (Latorre et al. 1998b) that enables the ribosome to utilise codons other 
than AUG to begin transcription. Homology of C proteins within a genus is high, but 
insignificant between genera (Lamb & Kolakofsky 2001). C proteins are abundant in 
virus infected cells, distributed evenly in the cytoplasm of SeV infected cells (Cadd 
et al. 1996), and localised with nucleocapsids in MeV infected cells (Reutter et al. 
2001). 
The C protein has been implicated as playing several roles during 
paramyxovirus infection. Research on MeV suggests that the MeV C protein is an 
infectivity factor, supporting the production of infectious virus particles (Devaux & 
Cattaneo 2004) and sustaining long term infection by inhibiting apoptosis (Takeuchi 
et al. 2005). The MeV C protein prevents early cell death and has been 
demonstrated to be necessary for efficient replication of MeV in vitro, and in 
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macaques (Takeuchi et al. 2005). Alternatively, studies have demonstrated that 
truncating the MeV C protein results in optimal virus growth (Miyajima et al. 2004), 
and abrogating the expression of the expression of the C protein increases RNA 
synthesis (Reutter et al. 2001). One of the functions of the C protein is to limit 
genome amplification and mRNA synthesis, and deletion of the C protein restricted 
the replication of MeV in human peripheral blood mononuclear cells (Escoffier et al. 
1999). Binding of the SeV C protein to the L protein has also been suggested as a 
possible means whereby RNA synthesis is decreased (Kato et al. 2004). Synthesis 
of mRNA is inversely proportional to the level of C protein expression (Curran et al. 
1992) and identification of a coiled coil motif presents structural evidence that 
oligomerisation of C proteins may be involved in this inhibition of transcription (Malur 
et al. 2004). The inhibitory effect of replication may be attributed to the C protein 
increasing the selectivity of the polymerase replication complex for promoter cis-
acting elements, hence governing the activity of the polymerase complex (Tapparel 
et al. 1997). The C proteins play a critical role in regulation of virus assembly, where 
they facilitate incorporation of envelope and M proteins into virions, perhaps by 
acting as chaperones to convert newly synthesised M proteins into assembly-
initiating forms (Hasan et al. 2000). Inhibition of RNA synthesis in SeV occurs 
through the C protein affecting promotor strength and is dependent on co-
expression of the N and L proteins (Cadd et al. 1996). The C and C’ proteins of SeV 
are versatile and not functionally equivalent, and are capable of functioning in a 
positive manner early during infection, but later in infection they exert a negative 
influence to inhibit RNA accumulation (Latorre et al. 1998a). 
The C proteins are relatively absent in primary infection and more abundant 
as infection progresses in order to restrain genome synthesis, hence preventing 
CPE and death of host cells. The smallest C protein, Y1, elicits an anti-apoptotic 
effect in SeV (Koyama et al. 2003). The SeV C protein is an IFN antagonist (Kato et 
al. 2004) and antiviral activity through the action of IFN stimulated tyrosine 
phosphorylation of STAT is circumvented as C protein associates with STAT1 
(Garcin et al. 2004; Gotoh et al. 2004). The C protein of HPIV3 inhibits the activation 
of STAT1 by targeting phosphorylation (Malur et al. 2005). STAT1 targeting by C 
proteins can occur after nuclear translocation. The C protein is also capable of 
inhibiting the activity of IFN-α, IFN-β and IFN-γ, independent of STAT association 
(Gotoh et al. 2004). The counteraction of IFN by C proteins may play a role in viral 
pathogenesis during acute phase of infection and also the establishment of 
persistent infection. 
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1.5.3 Matrix (M) protein gene 
The M protein is the most abundant protein of the paramyxovirus virion and 
has the capability to maintain the virion structure even after dissolution of the 
overlying viral envelope. The M protein is basic, not glycosylated, and is somewhat 
hydrophobic, although hydrophobic domains of sufficient length required for 
transversing of the lipid membrane are not present (Lamb & Kolakofsky 2001). As a 
central organiser of morphogenesis, the M protein interacts with integral membrane 
glycoproteins, the lipid bilayer and nucleocapsids. Modification by acetylation and 
phosphorylation produces M proteins capable of differing interactions with 
glycoproteins and nucleocapsids. Dephosphorylation is associated with M protein 
maturity and is correlated with viral budding from the host cell. As M proteins are 
produced at half the level represented in the virion, the proteins may be rate-limiting 
(Morrison & Portner 1991). Communication between viral components on the host 
cell surface and nucleocapsids is mediated by M protein interaction with actin 
filaments (Giuffre et al. 1982). 
Shutdown of M production in preparation for export is a key component of 
viral assembly and budding from a cell, but the M protein alone is not sufficient for 
initiation of this process. Interaction of M proteins with the cytoplasmic tails of the 
fusion and attachment proteins is required during the budding process (Ghildyal et 
al. 2005), as is nucleocapsid interaction. The cytoplasmic tails of the glycoproteins 
have critical, yet redundant roles of association with the M protein as HN and F 
appear to be interchangeable (Schmitt et al. 2002). Viral export in SV-5 is facilitated 
by F and HN, but in SeV, where F also enhances budding, HN plays a suppressive 
role (Sugahara et al. 2004).  
The absence of M protein results in uncontrolled membrane fusion activity, 
and M inactivation or mutation has been implicated in persistent infection where viral 
budding fails to occur (Lamb & Kolakofsky 2001). The M protein is not absolutely 
required for virus spread and is often defective in cases where MeV infection has 
progressed to the fatal disease SSPE (Cattaneo et al. 1988). During MeV infection, 
wild type virus is cleared by the host immune system but assembly-deficient virions 
are tolerated, resulting in persistent infection. Highly fusogenic virions propagate 
deep within the brain parenchyma, initiating SSPE, which ultimately leads to death 
(Cathomen et al. 1998).  
1.5.4 Fusion (F) protein gene 
Amalgamation of paramyxoviruses with host cells is directly mediated by 
the F protein and occurs at the host plasma membrane. Viral fusion involves 
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docking of the membrane to the target membrane, F protein activation, merger of 
membranes, pore formation, pore expansion and is mediated by the F protein along 
with attachment proteins (Morrison 2003). The transmembrane domain of the F 
protein of Respiratory syncytial virus (RSV) has been identified as the region 
important for transport of the protein to the plasma membrane, control of directional 
trafficking and virus budding (Brock et al. 2005). Interaction of the F protein with 
attachment proteins is required to draw cells into the appropriate juxtaposition for 
fusion to occur (Horvath et al. 1992). The requirement for co-expression of 
attachment proteins with the F protein for fusion is not stringent in SV-5 (Bagai & 
Lamb 1995), but is absolutely necessary in virtually all other paramyxoviruses. The 
F protein of CDV is an important determinant of persistent infection (Plattet et al. 
2005). The interaction between the F and HN proteins takes place at the cell surface 
and is triggered by HN recognition of receptors, the F and HN proteins are not 
transported to the membrane as a complex (Li et al. 2004). Cell surface receptor 
recognition by the G protein of HeV plays a pivotal role in the fusion process, as 
destruction of host cell receptors with proteases abolishes fusion capability of the 
henipavirus (Bossart et al. 2001). 
F proteins are type 1 glycoproteins possessing a hydrophobic 
transmembrane domain at the C-terminus that anchors the protein to the lipid 
envelope. Glycosylated side chains are important in F protein folding, as is a 
structural cylindrical cavity, the F pocket, that contains a hydrophobic region, 
creating a flexible domain (Plemper et al. 2003). The F pocket represents a 
conserved region of the paramyxovirus F protein. The F protein is synthesised as an 
inactive precursor, F0, and proteolytic cleavage of this protein results in two 
polypeptides, F1 and F2, linked by a disulfide bond (Lamb & Kolakofsky 2001). The 
F1 protein of CDV and MeV may also be cleaved again, generating F1a and F1b 
fragments (von Messling et al. 2004b). Furin cleavage occurs via recognition of the 
protease of a conserved multibasic site defined as R-X-K/R-R (Hosaka et al. 1991). 
Inactive F0 precursor proteins delivered to the plasma membrane require cleavage 
of a single basic residue and this cleavage is performed by extracellular host 
proteases, often located in the respiratory tract. The crystal structure of SV-5 
revealed that the structural differences between the inactive F0 precursor and post-
fusion conformation of the F protein are profound (Yin et al. 2005; Yin et al. 2006). 
The method of F protein cleavage utilised by paramyxoviruses is correlated with 
tissue tropism. Cleavage of F proteins with extracellular host proteases in NDV 
strains containing multibasic residues confines viral infection to the respiratory tract, 
whereas virulent strains of NDV are capable of producing systemic infection due to 
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the presence of intracellular cleavage by furin (Glickman et al. 1988). The addition of 
N-linked sugars to F proteins occurs only in the F2 subunit of morbilliviruses, but 
other genera contain 3-6 sites of N-linked glycosylation, distributed between both F1 
and F2 subunits. N-linked oligosaccharides are required for biological stability of 
MeV F proteins (Alkhatib et al. 1994). 
The F protein contains two heptad repeats, consistent with an α-helical 
coiled coil conformation (Chambers et al. 1990). HR1 and HR2 interact with one 
another to form a 6-helix bundle (Baker et al. 1999), and the formation of this bundle 
pulls viral and cellular membranes towards each other to facilitate fusion. Heptad 
repeats are conserved, and HR2 of NiV and HeV are interchangeable (Xu et al. 
2004). Glycine residues are important in maintenance of fusion level (Horvath & 
Lamb 1992), but also act as α-helix destabilising resides. Substitution of glycine 
residues for alanine resides leads to an increase in the α-helix nature of a peptide, 
resulting in increased fusogenic properties (Bagai & Lamb 1997). The balance 
between fusion and replication must be maintained as high fusion activity is 
deleterious to cell viability. 
1.5.5 Small hydrophobic (SH) protein gene 
The presence of an additional gene flanked by the F and HN genes was 
discovered in the genome of the avulavirus APMV-6 and the rubulaviruses SV-5 and 
MuV. The SH protein, first identified in SV-5, contains an extensive hydrophobic 
region, allowing the protein to span the lipid membrane of the virus once (Hiebert et 
al. 1985). An analogous SH gene was later discovered in the genome of MuV 
(Elango et al. 1989) and although the SH genes of both MuV and SV-5 are located 
in the same position between the F and HN genes, no sequence homology exist 
between the two viral genes.  
The SH protein of MuV is an integral membrane protein, anchored through 
the lipid bilayer of the virus and into the cytoplasm via a region located in the C-
terminus. The MuV SH protein may have a role in viral pathogenesis, mediated 
through inhibition of TNF-α-induced NF-ĸB activation (Wilson et al. 2006). Only a 
small amount of SH protein is present in MuV infected calls, and in cells infected 
with the Edmondson strain of MuV there is no SH protein detected at all (Takeuchi 
et al. 1996). The Edmondson strain of MuV does not contain the SH protein, 
indicating that the SH gene is not essential for viral replication. Amino acid disparity 
of the putative SH protein in MuV is high, with up to 23% diversity observed during 
the comparison of six strains of the virus (Takeuchi et al. 1991). The SH protein of 
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MuV may function in modifying the permeability of the host cell plasma membrane, 
hence performing the function of a viroporin.  
In contrast to MuV, the SH protein of SV-5 is anchored to the viral 
membrane via an N-terminus hydrophilic region, and the C-terminal portion of the 
protein extends extracellularly. To examine the function of the SH protein, a 
recombinant SV-5 with the SH gene deleted (rSV5USH) was constructed (He et al. 
1998). The recombinant virus did not exhibit altered morphology and did not differ 
phenotypically from SV-5. Infection of cells with either wild-type SV-5 or rSV5USH 
revealed no difference in growth rate, infectivity or plaque size produced in cells, 
leading to the conclusion that the SH protein is not required for viral growth in tissue 
culture cells (He et al. 2001). Although not required for viral replication in cells, the 
SH protein is implicated in the prevention of apoptosis. SV-5 is capable of replicating 
in MDBK cells for up to 40 days, producing little CPE. Infection of MDBK cells with 
rSV5USH increased the level of CPE, leading to apoptosis of the cells and the 
hypothesis that the SH protein prevents programmed cell death, possibly through 
the inactivation of apoptosis inducing caspases 2 and 3, was proposed (He et al. 
2001). Further studies revealed rSV5USH induced cell death by activating a 
pathway involving TNF-α, leading to apoptosis (Lin et al. 2003). Prevention of 
apoptosis by the SH gene results in survival of the infected host cell, and ultimately 
survival of the virus. 
The avulavirus APMV-6 contains a SH gene and the product of this gene is 
an integral membrane protein containing two potential N-linked glycosylation sites 
(Chang et al. 2001). The C-terminal portion of the APMV-6 SH protein extends to 
the outside of the cell membrane, similar to that of SV-5, but the protein does not 
have any homology to other SH proteins. The SH protein of HPMV-6 contains a 
second hydrophobic region 20 amino acids downstream of the hydrophobic region 
located at the protein terminus (Chang et al. 2001). 
1.5.6 Attachment (HN/H/G) protein gene 
The attachment proteins of the Paramyxovirinae are multifunctional type II 
transmembrane glycoproteins that facilitate the binding of virions to host cells and 
promote membrane fusion. Attachment proteins consist of, from N-terminus to C-
terminus, a cytoplasmic domain, a hydrophobic membrane anchoring domain, a 
stalk region, and a globular head that extends to the extracellular region. Attachment 
proteins are classified into three groups based on the presence or absence of 
haemagglutinin and neuraminidase activity (Bellini et al. 1998). The attachment 
proteins of respiroviruses, rubulaviruses and avulaviruses are designated HN, as 
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they exhibit both haemagglutination and neuraminidase activity. The morbillivirus 
and henipavirus attachment proteins are designated H and G, respectively. 
Co-translationally, the attachment proteins are inserted into the membrane 
of the rough endoplasmic reticulum, transported through the Golgi membranes via 
cellular secretory and membrane proteins, and translocated to the cellular 
membrane (Morrison & Portner 1991). During translocation, oligosaccharides may 
be added to, or modified, on the attachment protein. H proteins are only 
glycosylated with N-linked oligosaccharides, whereas G proteins contain 3-6 
available sites for N-linked, or O-linked addition of oligosaccharides. Attachment 
proteins appear to have evolved in two distinct lineages from one common 
progenitor protein, as the HN protein of NDV displays characteristics of the primitive 
progenitor (Morrison & Portner 1991).  
The HN protein mediates attachment of viruses to host cells by binding to 
cellular sialic acid-containing proteins or glycolipids. Enzymatic cleavage of sialic 
acid is mediated by neuraminidase and this catalytic reaction is thought to prevent 
virus particles from undergoing self-aggregation during budding from the host cell 
(Lamb & Kolakofsky 2001). The HN protein contains a single hydrophobic domain 
close to the N-terminus, and amino acid residues encoded by the conserved 
hexapeptide sequence NRKSCS are thought to interact, forming the sialic acid 
binding site (Jorgensen et al. 1987). Receptor binding to one site on the NDV HN 
protein modulates activity of a second binding site to promote continued receptor 
binding (Porotto et al. 2006). The functional HN protein consists of disulfide-linked 
homodimers that interact to form a non-covalently associated tetramer.  
The NDV HN protein can be synthesised as a biologically inactive 
precursor, HNo, where removal of 90 amino acid residues from the C-terminus is 
required to activate the protein. The HN protein is a major antigenic determinant and 
is responsible for influencing the virulence and tropism of NDV. Reduced receptor 
recognition and neuraminidase activity inherent to avirulent HN proteins translate 
into differences in viral virulence and tropism of NDV, and this is independent of F 
cleavability (Panda et al. 2004). N-linked glycoproteins are important in folding, 
transport and biological activities of HN proteins and loss of glycans from NDV 
attachment proteins leads to a reduction in virulence. Loss of glycans from HN 
proteins may expose T cell epitopes that allow virus infected cells to be targeted by 
cytotoxic T lymphocytes, hence facilitating viral recognition and clearance by the 
host. 
Sialic acid is not the primary receptor for H proteins, as is the case for HN 
proteins, although predictions of glycosidic activity for the H protein were proven in 
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RPV and PPRV (Langedijk et al. 1997). MeV, CDV and RPV all share a common 
cellular receptor, SLAM (CD150) (Ono et al. 2001a; Ono et al. 2001b; Baron 2005), 
which is thought to play a role in the generalised immunosuppression of the host 
upon infection. The structure of the H protein was predicted to consist of a globular 
head domain with a six-bladed β-propeller fold set connected to an anchored 
membrane stalk (Langedijk et al. 1997). The HeV G protein contains the amino acid 
sequence TIHHCS as a replacement for the conserved NRKSCS sequence of the 
putative sialic acid binding site (Yu et al. 1998b). The lack of sequence homology in 
this functionally important region is consistent with the fact that no neuraminidase 
activity has been detected for HeV. 
1.5.7 Large (L) protein gene 
The L gene accounts for 40-50% of the coding capacity of a paramyxovirus 
genome, yet produces the least amount of protein (about 50 copies of L protein per 
virion) as the location of the gene is the most promotor distant on the transcriptional 
map (Bellini et al. 1998). The L protein is a multifunctional polypeptide, catalysing 
many steps in RNA synthesis and processing, and is also involved in methylation, 
capping and polyadenylation. Phosphorylation of SeV P proteins has implicated the 
L protein as a kinase associated with the viral core (Einberger et al. 1990), but as 
phosphorylation occurs in the absence of the L protein, evidence of the involvement 
of the L protein is not conclusive. The N-terminal region of the L protein is involved 
in binding of the P protein and contains an active site for RNA polymerisation, 
whereas the C-terminal region of the protein is not required for binding to RNA, but 
is important in interaction with the N protein (Parks 1994). 
The L gene is highly conserved among other non-segmented, negative-
sense, single-stranded RNA viruses (NNSV). Sequence comparisons of SeV, NDV 
and MeV L genes revealed six conserved domains (I-VI) separated by variable 
regions, suggesting the structure of a concatenated functional domain (Poch et al. 
1990). The MeV L protein contains distinct sequence elements that are postulated to 
be from an ancestral polymerase (Blumberg et al. 1988), and as MeV and SeV 
share high sequence homology, there is speculation that the two viruses evolved 
from a putative common ancestor. Domain II of the L protein is essential for RNA 
recognition. Domain III of the L protein contains a pentapeptide motif, QGDNQ, 
thought to contain an active site for phosphodiester bond formation. Morbilliviruses 
contain three conserved regions, A, B and C separated by two hinge regions of low 
identity. The QGDNQ domain is present in the B region and is flanked by 
hydrophobic resides (Poch et al. 1990). Mutational analysis of the conserved 
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QGDNQ motif of RPV revealed that conservation of D and N residues is absolutely 
required to retain polymerase function (Chattopadhyay et al. 2004). The conserved 
QGDNQ motif of paramyxovirus was found to be altered in HeV, NiV, TuPV (Wang 
et al. 2001) and Mossman virus (MosPV) (Miller et al. 2003). These four viruses 
contain the sequence QGDNE. This amino acid change introduces a second 
negative charge into a functionally important area. The possibility exists that the 
henipavirus sequence motif represents an ancient form of catalytic domain. As the Q 
amino acid is highly conserved in all NNSV, but different in HeV, NiV, MosPV and 
TuPV, it may be concluded that this residue is not directly involved in catalytic 
function (Chattopadhyay et al. 2004). 
1.6 Gene Expression of Non-Segmented, Negative-Sense, 
Single-Stranded RNA Viruses 
1.6.1 Transcriptional stop/start mechanism 
All paramyxovirus RNA synthesis begins with a single entry of the viral 
RNA-dependent RNA polymerase (vRdRp) at the 3’ end of the genome, with 
transcription of the 3’ leader beginning before mRNA synthesis. Initiation of RNA 
synthesis is dependent on the distance between the genome 3’ end and gene start 
signal (Cordey & Roux 2006). Gene junctions of paramyxovirus genomes consist of 
a gene termination signal in the upstream gene, an IGR and a gene initiation signal 
in the downstream gene (Lamb & Kolakofsky 2001). The strength of the replication 
promotor is important in determining initiation of mRNA synthesis (Vulliemoz et al. 
2005). A scanning model predicts that ribosomes initiate translation at the first AUG 
codon that is in favourable context according to the “Kozak” sequence 
5’-GCCAorGCCAUGG-3’ (Kozak 1986). Monocistronic mRNA produced by the 
vRdRp contains a 5’ cap (Abraham et al. 1975) and is polyadenylated by a stuttering 
mechanism that reiteratively copies a short run of 4-7 uridines (U tract) leading to 
the termination and release of the mRNA. After termination of release of mRNA, the 
vRdRp remains attached to the template before reinitiating transcription at the 
downstream gene (Lamb & Kolakofsky 2001). This stop/start mechanism of 
transcription is not perfect and failure of vRdRp to reinitiate transcription at a 
downstream site results in a gradient of mRNA production inversely proportional to 
the distance from the 3’ end of the genome (Figure 1.7) (Lamb & Kolakofsky 2001), 
and this transcription gradient is maintained throughout infection (Plumet et al. 
2005). The vRdRp may also read through IGRs, generating polycistronic mRNA.
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Figure 1.7- Paramyxovirus Transcription and Replication 
The stop/start model for transcription is not perfect and failure of viral RNA-
dependent RNA polymerase to reinitiate transcription at a downstream site results in 
a gradient of mRNA production inversely proportional to the distance from the 3’ end 
of the genome. Transcription and replication occurs via promotor sequences for 
polymerase entry, existing on the 3’ end of both genome and antigenome. The 
relative promotor strength is represented by the arrow size and relative amounts of 
polyadenylated mRNA transcripts are shown. This figure has been adapted from 
Conzelmann (1998). 
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The length of IGR sequence plays a role in termination of transcription and 
polyadenylation but is not a determining factor alone (He & Lamb 1999). 
Mutagenesis studies on the L gene on Human respiratory syncytial virus (HRSV) 
indicate that cis-acting gene end signals and the trans-acting polymerase function 
together, determining the efficiency of transcript termination (Cartee et al. 2003). 
The U tract might serve as a genomic spacer to ensure minimum distance between 
gene stop and start signals are maintained at junctions with short IGRs (Rassa et al. 
2000). Regulation of viral gene expression is possible through the distance of the 
gene from 3’ end of genome, as transcription of downstream genes cannot be more 
abundant that that of upstream genes. 
1.6.2 Intergenic regions 
Morbilliviruses, respiroviruses and henipaviruses contain IGRs exactly 
three nucleotides in length with a highly conserved sequence (usually 3’-GAA-5’). 
Avulaviruses and rubulaviruses, in contrast, contain IGRs variable in length and 
sequence. Sequencing of MenPV revealed an IGR of 85 nucleotides separating the 
F and HN gene (Bowden et al. 2001), expanding the extent of variability in length of 
IGRs, previously believed to range from 1-47 nucleotides (Lamb & Kolakofsky 
2001).  
TioPV, in addition to MenPV, contains IGRs significantly exceeding the 
previous upper limit of 47 nucleotides for the genus Rubulavirus. All IGRs of TioPV 
begin with a C residue, an identical residue as observed in the beginning of the 
trinucleotide IGRs of non-rubulaviruses. TioPV and MenPV are the only 
rubulaviruses lacking haemagglutination and neuraminidase activities, which, when 
taken into consideration with IGR sequence information, may indicate TioPV 
represents an evolutionary intermediate between the rubulaviruses and non-
rubulaviruses (Wang et al. 2003). The sequence variability of IGRs may provide an 
additional level of transcriptional control beyond that resulting from the distance of 
genes from the 3’ end promotor (Rassa & Parks 1999). 
1.6.3 Genome termini 
The coding region of the paramyxovirus genome is flanked by a 3’ leader 
region and a 5’ trailer region. The 3’ leader region of the genome contains cis-acting 
signals for encapsidation, replication and transcription, and is bipartite in nature, with 
the terminal twelve nucleotides almost identical in the genome and antigenome 
(Lamb & Kolakofsky 2001). These two hexameric elements function as replication 
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promotors, and spacing between promotors in genome termini is crucial due to 
hexamer phasing patterns (Egelman et al. 1989). Synthesis of leader RNA differs 
from that of downstream mRNA transcripts in that the leader is not capped and does 
not contain a poly (A) tail. The leader and N gene junction plays a vital role in the 
switch between transcription and replication (Conzelmann 1998), and expression of 
the 3’ leader has been reported to control the induction of apoptosis in SeV (Garcin 
et al. 1998). The trailer region of the SeV genome has been implicated in the 
inhibition of apoptosis, resulting in optimal virus replication (Wiegand et al. 2005). 
1.6.4 RNA editing 
RNA editing, the pseudotemplated addition of nucleotides co-
transcriptionally into mRNA, occurs in all members of the Paramyxovirinae 
subfamily, except HPIV-1 and is confined exclusively to the P gene. The expression 
of two proteins from the P gene of SV-5, that differed by only two G resides, verified 
for the first time the insertion of two non-templated G resides into the transcribed 
mRNA (Thomas et al. 1988). Insertions into mRNA occur in the middle of the P 
gene, resulting in a frameshift that allows ribosomal access to a second ORF. The 
mechanism responsible for RNA editing, known as “stuttering”, was elucidated in 
SeV when RNA editing was predicted to occur as the viral polymerase reiteratively 
copied one of three C residues on the genome template, then slipped backward 
before the next nucleotide was added (Vidal et al. 1990). The stuttering mechanism 
of RNA editing is reliant on the viral polymerase temporarily pausing during 
transcription at a stretch of pyrimidine residues (5’-AnGn-3’). Cis-acting sequences 
located upstream from the editing site, in particular two nucleotides immediately 
upstream, modulate the pattern of G insertion into the mRNA (Hausmann et al. 
1999b), which differs between paramyxovirus P genes. During RNA editing, 
realignment of the stuttering polymerase downstream, rather than upstream, leads 
to nucleotide deletions, as opposed to insertions (Jacques et al. 1994). The 
stuttering mechanism of RNA editing utilised by the polymerase in the P gene is 
similar to the mechanism used for mRNA polyadenylation, suggesting an 
evolutionary relationship between the two (Hausmann et al. 1999a).  
1.6.5 RNA replication 
Propagation of paramyxoviruses involves virus adsorption and entry into a 
host cell, protein production, genome replication, assembly and release of progeny 
virions, with aspects of viral replication taking place in the cytoplasm. Virus 
adsorption into a host cell resulting from attachment (HN/H/G) proteins binding to 
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cellular receptors, is mediated by the F protein, and occurs at the neutral pH of the 
cell membrane. Fusion of the virus with a host cell releases helical nucleocapsids 
into the cytoplasm (Lamb & Kolakofsky 2001). 
The Kingsbury-Kolakofsky model of transcription and replication (Blumberg 
et al. 1991) dictates that a promotor sequence for polymerase entry exists on the 3’ 
end of both genome and antigenome, mRNA is produced via a polarity gradient of 
transcription, and relative amount of mRNA versus genomic RNA is modulated by a 
virus-encoded protein. All viral RNA synthesis begins at the 3’ end of the genome, 
but cannot be initiated until primary transcription and translation provides critical 
levels of N and P proteins. The switch from transcription to replication may be 
delayed until the N protein has accumulated to threshold levels (Plumet et al. 2005). 
The vRdRp replicates the genome via a complementary RNA antigenome, which is 
always encapsidated by N proteins. Synthesis of antigenome from genome and, 
conversely, genome from antigenome, results when the vRdRp ignores junction 
signals and editing sites within RNA. N proteins bind to the nascent strand of RNA, 
preventing recognition of termination signals by vRdRp, a process that is self-
regulatory and is governed by the availability of N subunits (Lamb & Kolakofsky 
2001).  
The 3’ terminal regions of the genome and antigenome contain cis-acting 
promotor sequences recognised by the vRdRp via a scanning mechanism 
(Kolakofsky et al. 2004) as the polymerase does not dissociate from the RNA 
template. Two discontinuous regions essential in promotor function, conserved 
region 1 and 2 (CRI and CRII), identified in SV-5 (Murphy et al. 1998), were not 
confined to the leader region of the genome as CRII is in the coding region of the L 
gene. Genome length is significant (Calain & Roux 1993) and promotor sequences 
in hexamer positions 14, 15 and 16 have been demonstrated to be conserved, with 
the sequence 5’-CGNNNN-3’ in SV-5 (Murphy & Parks 1999), 5’-(GNNNN)3-3’ in 
SeV (Tapparel et al. 1998) and 5’-(GNNNAN)2GNNNCN-3’ in MeV (Walpita 2004), 
indicating the importance of promotor alignment along the same face of the helical 
nucleocapsid. The 3’ end of the antigenome contains a stronger promotor than that 
of the genome, the genome also contains negatively-acting signals (Keller & Parks 
2003) accounting for the higher ratio of genomic molecules to antigenomic 
molecules during replication. The MeV M protein has been shown to be a negative 
regulator of viral polymerase activity, having an equally repressive effect on mRNA 
transcription and genome replication (Reuter et al. 2006). 
Genome synthesis and viral assembly occur concurrently (Gubbay et al. 
2001). Free N subunits associate with template RNA, forming nucleocapsids, and 
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integral membrane proteins are synthesised in the endoplasmic reticulum of the host 
cell. Host cell enzymes and molecular chaperones assist in folding and 
conformational maturation of glycoproteins, and carbohydrate chains are modified in 
the Golgi apparatus. Viral glycoproteins are transported to the plasma membrane, 
which is devoid of host cell proteins, and progeny virus are released by budding 
(Lamb & Kolakofsky 2001). A schematic diagram of viral replication is given in 
Figure 1.8. 
1.7 New and Emerging Paramyxoviruses 
Fer-de-Lance virus 
The extensive host range of paramyxoviruses, previously considered being 
restricted to mammals and birds, became apparent following the emergence of a 
virus capable of infecting reptiles. A disease outbreak occurred in 1972 in a Swiss 
serpentarium where a new virus was isolated from a Fer-de-Lance viper (Bothrops 
atrox) and subsequently termed FDLV, named after the infected reptilian host (Clark 
et al. 1979). FDLV was isolated from embryonic snake eggs seven days after 
inoculation with lung tissue obtained from diseased vipers. CPE was observed in the 
form of syncytia after reptilian cells lines were inoculated with FDLV (Clark et al. 
1979). The optimum temperature for viral replication was determined to be 28-30°C 
(Mayr et al. 2000). Preliminary analysis of FDLV revealed a single-stranded, non-
segmented RNA genome, while electron microscopy displayed pleomorphic virions. 
Structural properties of FDLV, in combination with evidence demonstrating the virus 
was antigenically distinct from other mammalian and bird paramyxoviruses, placed 
the first reptilian virus isolated in the family Paramyxoviridae, intermediately between 
the subfamilies Paramyxovirinae and Pneumovirinae (Clark et al. 1979).  
Molecular analysis of 16 paramyxoviruses isolated between 1972 and 1998 
from 14 different reptilian host species was undertaken in an attempt to clarify 
genetic relatedness and taxonomic position of the new viruses (Ahne et al. 1999). 
Classification of the viruses was dependant on electron microscopy and 
physiochemical studies, such as sensitivity to chloroform, haemagglutination 
properties and syncytia formation. Phylogenetic relationships were established 
based on the comparison of a 518 nucleotide segment of the L gene along with a 
352 nucleotide segment of the HN gene (Ahne et al. 1999).  
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Figure 1.8- Paramyxovirus Infectious Cycle 
Paramyxoviruses attach to host cells through the binding of attachment proteins to 
cellular receptors, a process mediated by the fusion protein. Upon entry, 
transcription and translation of viral RNA occurs in the cytoplasm. The polymerase 
proteins associate with the viral RNA and integral membrane proteins are 
synthesised in the endoplasmic reticulum (ER). Carbohydrate chains of 
glycoproteins are modified in the Golgi apparatus, and then the glycoproteins are 
transported to the plasma membrane. Genome synthesis and viral assembly occur 
concurrently, and progeny virions are released by budding. This figure has been 
adapted from Lamb & Kolakofsky (2001). 
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The study revealed the existence of two distinct subgroups of viruses likely 
to represent divergent viral species. Reptilian paramyxoviruses share strong 
antigenic relationships, regardless of origin, although a correlation between 
subgroup and geographical location was observed (Ahne et al. 1999). Viruses 
isolated from 18 different snake species displaying respiratory symptoms and 
neuronal disease were determined to be paramyxoviruses based on electron 
microscopy, CPE and haemagglutination inhibition (Franke et al. 2001). 
The FDLV genome is 15,378 nucleotides in length and is consistent with 
other paramyxoviruses in that the common N, P, M, F, HN and L genes were 
present, along with conserved CCT or CTT IGRs observed in members of the 
henipavirus, morbillivirus and respirovirus genera. A unique feature observed in 
FDLV was the presence of an extra gene, designated ‘U’ for ‘Unknown’, between 
the N and P genes (Kurath et al. 2004). This new U gene codes for a protein with a 
molecular mass of either 19.4 or 16.6 kDa, depending on the translation initiation 
codon utilised. The protein has no similarity to any protein sequences in the National 
Center for Biotechnology Information (NCBI) database and could possibly function 
as a small transmembrane protein (Kurath et al. 2004). Two other FDLV isolates, 
Biti-CA98 and Gono-GER85, isolated from snakes (Bitis atropos and Gonosoma 
oxycephala, respectively), were found to also contain the U gene (Kurath et al. 
2004). 
Tupaia paramyxovirus 
TuPV was isolated from primary kidney cells of an apparently healthy tree 
shrew (Tupaia belangeri) captured near Bangkok, Thailand in the late 1970s (Tidona 
et al. 1999). Primary kidney cells from the tree shrew were cultured and 
spontaneously degenerated after seven days, producing a cytopathic effect (CPE) 
that manifested as syncytia formation and cell lysis. CPE was also observed when 
clarified supernatant from primary kidney cells was transferred to continuous tupaia 
fibroblast or kidney cell lines, indicative of the presence of an infectious agent 
contaminating the culture (Tidona et al. 1999). Tupaia fibroblast and kidney cells 
were the only cell types capable of supporting growth of TuPV. Pleomorphic 
enveloped particles and helical nucleocapsids distinctive of paramyxoviruses were 
observed by electron microscopy. No cross-reactivity was observed between TuPV 
and other paramyxoviruses such as HPIV-1, SeV, MeV and MuV (Tidona et al. 
1999). Sequencing of the exceptionally large 17,904 nucleotide TuPV genome 
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revealed that the organisation of the P/V/C gene was most similar to that of HeV, 
morbilliviruses and respiroviruses. The TuPV 5’ trailer sequence, at 590 nucleotides, 
is significantly longer in comparison to other members of the subfamily 
Paramyxovirinae, whose trailer sequences range from 25-114 nucleotides (Tidona 
et al. 1999). 
Hendra virus 
In September 1994, HeV caused an outbreak of severe respiratory disease 
resulting in the death of 14 horses and a horse trainer at a stable near Brisbane, 
Australia. The index case was a pregnant mare that died of acute respiratory 
disease (Murray et al. 1995). After the death of the mare, 14 out of 21 sick horses 
died or were euthanased. Clinical signs of illness were fever up to 41°C, depression, 
respiratory distress and frothy nasal discharge. At the stable, a 49-year-old male 
trainer and a 40-year-old male stablehand developed an influenza-like illness with 
symptoms of lethargy, headache and vertigo. The stablehand gradually recovered 
over a period of six weeks but the condition of the trainer rapidly deteriorated and 
proved fatal. Both the trainer and stablehand had been in close contact with the 
index case of the outbreak (Murray et al. 1995). Isolation HeV, which was initially 
named Equine morbillivirus, was achieved when Vero cells were inoculated with 
spleen and lung tissue from two affected horses. These Vero cells experienced 
CPE, with the formation of syncytia. Analysis of the virus by electron microscopy 
revealed a pleomorphic, enveloped structure with virions ranging in size from 38-600 
nm (Murray et al. 1995). Serological surveying of 1600 horses and 90 humans 
(Murray et al. 1995) did not identify neutralising antibodies to HeV. Later findings 
demonstrated that the natural reservoir for the virus are pteropid bats in the genus 
Pteropus (Halpin et al. 2000). 
HeV was determined to be the cause of a second human fatality, when a 
35-year-old male farmer from MacKay, Australia, died as a result of severe 
encephalitis preceded by epileptic activity (O'sullivan et al. 1997). Closer inspection 
into circumstances surrounding the case uncovered prior illness in the man 
corresponding with the time two horses had died on his property. The farmer had 
cared for the horses and had assisted in necropsies before developing a brief 
aseptic meningitic disorder with sore throat, vomiting, headache, drowsiness and 
stiff neck. The initial illness and death of the two horses occurred in August 1994, 13 
months before the reoccurrence of illness and death in the farmer, and also before 
the Hendra stable outbreak of HeV (Murray et al. 1995). Retrospective findings from 
serology, electron microscopy, PCR and immunohistochemistry implicated HeV as 
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the cause of disease in the horses. Another fatal equine case of HeV infection 
occurred in 1999, in Cairns, Australia, in a 9-year-old thoroughbred mare (Field et al. 
2000). Clinical signs of disease prior to euthanasia of the horse were depression 
and oedema of the face, lips and neck (Field et al. 2000). Histological analysis of 
lung tissue obtained from the horse displayed haemorrhage with 
erythrophagocytosis, oedema, emphysema and syncytia formation in endothelial 
cells (Murray et al. 1995). Two more incidences of HeV were reported in 
Queensland, Australia, in 2004 and each resulted in the death of one horse. A 
veterinarian involved in the autopsy of one of the horses was infected with HeV and 
developed a flu-like illness but later recovered (Field et al. ). 
HeV was originally classified as a member of the genus Morbillivirus based 
on partial sequencing of the M gene (Murray et al. 1995). The P gene of HeV was 
deduced to have the potential to encode the proteins P, V and C. This data in 
combination with serological evidence demonstrating the lack of cross-reactivity 
between HeV and morbilliviruses indicated that the virus was not a morbillivirus 
(Wang et al. 1998). Sequencing of the N gene (Yu et al. 1998a) consolidated the 
exclusion of HeV from the genus Morbillivirus, as did sequencing of the G gene (Yu 
et al. 1998b) determining that the HeV attachment protein did not possess 
haemagglutination or neuraminidase activity. Sequencing of the entire 18,234 
nucleotide HeV genome revealed a sequence variation in a highly conserved region 
of the L protein (Chua et al. 2000). Paramyxovirus L proteins contain the sequence 
motif QGDNQ, which is absolutely conserved in all NNSV. The sequence of this 
motif in HeV was determined to be QGDNE (Chua et al. 2000). The QGDNQ motif is 
important for polymerase function and sequencing results have subsequently 
determined that TuPV, NiV and MosPV also contain the QGDNE sequence change. 
HeV has been designated as the type species of the genus Henipavirus. 
Menangle virus 
In 1997, Menangle virus (MenPV) was isolated during an outbreak of 
reproductive disease in pigs at a piggery in New South Wales, Australia. The 
piggery experienced a decrease in farrowing rate from 82% to 62% and there were 
27% less piglets born alive during the outbreak. Mummified piglets were born and 
stillborn piglets were frequently deformed, having severe degeneration of the brain 
and spinal cord (Philbey et al. 1998). No symptoms of disease were observed in 
postnatal pigs. The outbreak began in April of 1997 and lasted for 21 weeks (Love et 
al. 2001). 
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Virus isolation was achieved by inoculation of BHK21 cells with heart, lung 
and brain tissue from affected piglets, where CPE was observed in the form of 
vacuolation of cells and syncytia formation. MenPV was classed as a paramyxovirus 
based on electron microscopic visualisation of pleomorphic particles and 
‘herringbone’ nucleocapsids. Serum samples collected from cattle, sheep, birds, 
rodents, cats and a dog were all negative for MenPV antibodies (Kirkland et al. 
2001). Two piggery workers became ill during the outbreak with an influenza-like 
illness in conjunction with a red, spotty rash. Other symptoms included malaise, 
chills, fever, sweating, headache, with weight loss observed after disease 
progression. Both of these workers had intense occupational exposure to infected 
pigs and serological analysis revealed the presence of MenPV antibodies in both 
cases (Chant et al. 1998). Serum samples were obtained from 250 humans and the 
only MenPV positive samples were those corresponding to the two piggery workers 
(Kirkland et al. 2001). The likelihood of MenPV infection of humans appears to be 
low without the prior amplification of the virus in pigs (Hooper 2001). 
A colony of fruit bats (Pteropus poliocephalus) were found to be roosting 
within 150 m of the piggery and these animals were speculated to be the potential 
source of MenPV infection in the pigs (Kirkland et al. 2001). Serum was collected 
from bats and determined to be positive for MenPV antibodies. Control of the 
MenPV outbreak and eradication of the virus from the piggery resulted following the 
administration of a serological testing and segregation program. Development of 
protective immunity against MenPV by sows also aided in reducing development of 
disease (Kirkland et al. 2001). 
MenPV was reported to lack haemagglutinin and neuraminidase activity 
(Philbey et al. 1998). The neuraminidase encoding region of the attachment protein 
of paramyxoviruses contains seven conserved residues, but only two or three of 
these residues are present in MenPV, suggesting that MenPV does not possess the 
same degree of neuraminidase activity as detected in other rubulaviruses and 
respiroviruses (Bowden et al. 2001). MenPV is closely related to Tioman virus 
(TioPV), a novel virus isolated from the urine of fruit bats (Pteropus hypomelanus) 
(Chua et al. 2001), and both MenPV and TioPV have been tentatively classified in 
the genus Rubulavirus (Pringle 2005). 
Nipah virus 
In 1998, a severe disease outbreak affecting humans and pigs occurred 
just outside the town of Ipoh in peninsular Malaysia. The causative agent of the 
outbreak was initially thought to be Japanese encephalitis virus (JEV), a mosquito-
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borne viral disease enzootic to the region, but aspects of the outbreak did not fit with 
the characteristics of JEV. JEV does not cause death in pigs, and furthermore, 
humans that had been previously immunised against JEV were shown to succumb 
to the new disease. The NiV outbreak claimed the lives of 105 people of the 265 that 
presented with infection, attributing a 40% mortality rate to the virus. The majority of 
cases were males who had direct contact with pigs or pig products indicating NiV 
was a zoonotic agent capable of crossing the species barrier between pig and 
human (Wong et al. 2002). Symptoms of disease in infected humans ranged from 
mild headache, fever, dizziness and reduced level of consciousness. Symptoms in 
pigs were those of porcine ‘respiratory and encephalitis syndrome’ consisting of a 
distinct loud barking cough, paralysis, abnormal movement and fever. Meningitis 
may also occur in pigs with oedema and infiltration of white blood cells (Wong et al. 
2002). 
NiV was isolated five days after inoculation of Vero cells with cerebrospinal 
fluid taken from two of the first three patients that died at the University of Malaya 
Medical Centre (Chua et al. 1999). The emergent virus was ultimately termed 
“Nipah” after Kampung Sungai Nipah (Nipah river village) where specimens were 
obtained that yielded the first viral isolates (Wong et al. 2002). The first of the three 
patients was a 51-year-old male that presented with acute confusion and pain 
associated with myoclonus of the left arm. The condition of the patient deteriorated 
after development of hypotension and bradycardia and he died six days after 
admission to hospital. The second patient was a 34-year-old male that presented 
with fever, drowsiness and lethargy and was comatose two days after hospital 
admission. He died five days after onset of coma after development of hypotension. 
The third patient was a 52-year-old male who was admitted to hospital with 
headache, nausea, fever and chills and died within five days (Chua et al. 1999). The 
brain was the most severely affected tissue and vasculitic vessels displayed vessel 
wall necrosis and thrombosis. Endothelial ulceration with varying degrees of 
inflammation and fibrinoid necrosis was detected in infected blood vessels along 
with extravascular parenchyma (Wong et al. 2002). More than one million pigs were 
culled over the course of the outbreak (Ahmad 2000) as authorities saw this as the 
only means possible to control the spread of disease. 
In March 1999, an outbreak of pneumonia occurred in eleven abattoir 
workers in Singapore. These eleven patients, who all worked at the same abattoir, 
presented with fever, headache and drowsiness, with one case resulting in fatality 
after disease progression lead to cardiac arrest (Paton et al. 1999). Serum was 
obtained from all patients diagnosis was made after detection of IgM antibodies to 
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NiV (Paton et al. 1999). Pigs from NiV affected areas of Malaysia had been imported 
to the abattoir in Singapore and the outbreak was controlled when the abattoir was 
closed and importation of pigs ceased. NiV was also found to be the causative agent 
responsible for outbreaks of fatal febrile encephalitis in Bangladesh in 2001, 2003, 
2004 and 2005 (Hsu et al. 2004; Epstein et al. 2006; Harcourt et al. 2005) and in 
India in 2001 (Chadha et al. 2006). Fruit bats in the genus Pteropus have been 
identified as the natural reservoir host for both NiV and HeV (Hsu et al. 2004; 
Sendow et al. 2006). Serological, virological and molecular studies have revealed 
the presence of NiV or NiV-like viruses in fruit bat populations in Malaysia, 
Cambodia and Thailand (Reynes et al. 2005; Olson et al. 2002; Wacharapluesadee 
et al. 2005; Chua et al. 2002). 
Sequencing of the 18,246 nucleotide genome (Chua et al. 2000) revealed 
the presence of N, P, M, F and G genes (Harcourt et al. 2000), and cross-
neutralisation experiments of NiV revealed that the novel virus was closely related to 
HeV (Chua et al. 2000). Characterisation of the genome revealed a P gene structure 
similar to that of HeV, and the expression of a V protein was determined to occur by 
the RNA editing mechanism utilised by the respiroviruses and morbilliviruses (Chua 
et al. 2000). Cleavage of the F protein precursor into active subunits is usually 
mediated by furin in members of the subfamily Paramyxovirinae, but the conserved 
sequence recognised by this protease is not present in NiV, or HeV, indicating that 
these viruses may possibly utilise different host cells proteases for the activation of 
the F protein (Harcourt et al. 2000). The functionally important conserved amino acid 
sequence, QGDNQ, in the polymerase gene of NiV is replaced with QGDNE, as is 
also the case in HeV (Harcourt et al. 2001). 
Both NiV and HeV have been classified as a Category C critical biological 
agent for public health preparedness, along with other emerging biological threat 
agents that present a possible bioterrorism risk (Rotz et al. 2002). The NiV 
outbreaks in Malaysia caused widespread panic before the etiological agent was 
determined and controlled, leading to suggestions that NiV may be a potential agent 
of bioterrorism (Lam 2003). 
1.8 Rodent Paramyxoviruses 
SeV, an extremely contagious respiratory virus, is one of the most 
important pathogens of rodents, and this member of the genus Respirovirus has 
been indispensable in paramyxovirus research since isolation from laboratory 
rodents in the 1950s (Baker 1998). At least four novel paramyxoviruses, Nariva virus 
(NarPV) (Tikasingh et al. 1966), MosPV (Campbell et al. 1977), J-virus (JPV) (Jun et 
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al. 1977) and Beilong virus (BeiPV) (Li et al. 2006), have been isolated from rodents 
since the 1960s. 
1.8.1 Nariva virus 
NarPV was isolated from forest rodents (Zygodontomys b. brevicauda), 
trapped on Bush Bush Island in the Nariva swamp, Eastern Trinidad, in 1962 and 
1963 (Tikasingh et al. 1966). NarPV was isolated from mouse brains and when the 
virus infected Vero and BHK-21 cells, formation of syncytia was observed. 
Haemagglutination and cell binding studies indicate NarPV may not use sialic acid 
as a receptor for attachment (Karabatsos et al. 1969). NarPV virus particles were 
visualised as 130-250 nm pleomorphic structures capable of haemagglutination of 
red blood cells (Walder 1971). Intracytoplasmic inclusion bodies containing helical 
nucleocapsids engulfed within the matrix of lysosomes of brain cells were observed, 
and brain lesions were comparable to those of MeV infection (Walder et al. 1971). 
Electron microscopic analysis of NarPV enabled categorisation of this virus as a 
member of the family Paramyxoviridae. 
The pathogenesis of NarPV was studied in hamsters, an animal closely 
related to the natural rodent host of the virus. Infection of suckling hamsters with 
NarPV resulted in acute necrotising encephalitis with multinucleated cells observed 
in ependyma and neutrophils (Roos & Wollmann 1979). Weanling hamsters infected 
with NarPV exhibited less cerebral parenchymal necrosis than suckling hamsters. 
NarPV produced non-productive infection in the weanlings, but despite the lack of 
infectious virus particles, the animals developed fatal encephalitis. The maturity of 
the host immune system appears to be important in NarPV pathogenesis, and age-
related changes in susceptible neural cells, such as changes in cell surface 
receptors and cellular enzymes, may be critical in disease progression (Roos & 
Wollmann 1979). 
1.8.2 Mossman virus 
MosPV was isolated in northern Queensland, Australia, on three occasions 
from 1970-1971. The virus was isolated from pooled organs of a female rat (Rattus 
leucopus), trapped near Mossman, Queensland, a pool of mites (Laelaps 
echidninus) and pooled organs from a male rat (Rattus fuscipes) (Campbell et al. 
1977). Infection of BHK-21 cells with MosPV produced CPE with syncytia formation, 
a hallmark of paramyxovirus infection. Electron microscopic analysis of MosPV 
displayed viral particles and free nucleocapsids, which when taken into account with 
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cellular based experiments, lead to the conclusion that MosPV was a paramyxovirus 
(Campbell et al. 1977). 
Sequencing of MosPV revealed a genome of 16,650 nucleotides in length, 
with arrangement of genes consistent with that of the henipaviruses (Miller et al. 
2003). Characterisation of the genome uncovered several features that may assist 
in classification MosPV. The MosPV 3’ leader region of the genome was found to 
contain 55 nucleotides, consistent with all other members of the Paramyxovirinae 
and the IGRs that separate the viral genes were conserved, although not invariant, 
trinucleotide sequences. 
The coding strategy determined for the P gene was similar to that of the 
henipaviruses, morbilliviruses and respiroviruses (Miller et al. 2003). The F gene of 
many paramyxoviruses contain the conserved sequence R-X-K/R-R (Hosaka et al. 
1991) that directs cleavage of the F protein by furin, but the MosPV sequence 
deviates from the conserved sequence and instead contains AGNKK as the 
cleavage sequence. The conserved sequence of respiroviruses and rubulaviruses, 
NRKSCS, in the attachment protein is thought to form part of the sialic acid binding 
site (Jorgensen et al. 1987). Similar to henipaviruses and morbilliviruses, MosPV 
lacks conservation of this site. The lack of conservation of the hexapeptide motif in 
the attachment protein, along with the failure to detect any neuraminidase activity, 
resulted in the attachment gene of MosPV to be designed G (Miller et al. 2003). The 
conserved QGDNQ motif in the L gene was replaced with QGDNE, an observation 
also made in the henipaviruses and TuPV (Wang et al. 2001). MosPV is yet to be 
classified into a genus within the subfamily Paramyxovirinae, but phylogenetically 
appears to be positioned between the morbillivirus and henipavirus genera, along 
with Salem virus and TuPV (Miller et al. 2003). 
1.8.3 J-virus 
The trapping of wild mice (Mus musculus) during a study investigating the 
pathology of feral rodents in northern Queensland, Australia, in 1972 (Mesina et al. 
1974) lead to the isolation of JPV on four separate occasions, via kidney autoculture 
(Jun et al. 1977). The four moribund mice from which kidneys were obtained, all 
displayed extensive haemorrhagic lung lesions. Passaging of JPV in mouse kidney 
and lung primary cell lines, and continuous cell lines from mouse kidney (CSL217), 
human (MRC5 and Hep2), pig kidney (PS), baby hamster kidney (BHK-21) and 
monkey kidney (Vero) resulted in CPE characterised by destruction of the cell 
monolayer and vacuolated syncytia formation (Jun et al. 1977). Cell lines where 
CPE was not observed were bovine kidney (MDBK), human (HeLa and Chang liver) 
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and rat fibroblast (RT). CPE was associated with eosinophilic cytoplasmic 
inclusions, but no involvement of the nucleus was detected. 
Electron microscopy exposed a viral nucleocapsid of 15 nm diameter, with 
‘herringbone’ morphology, typical of paramyxoviruses. Evidence of soluble or virus-
associated haemagglutinin was not detected and haemadsorption using standard 
techniques and erythrocytes from a variety of species was not observed (Jun et al. 
1977). Complement fixation assays were used in an attempt to detect a serological 
relationship between JPV and a range of paramyxoviruses, such as HPIV-1-4, NDV, 
MeV, MuV, NarPV and MosPV, but all produced negative results. 
Intranasal or subcutaneous inoculation of mice, pigs and rats with JPV did 
not produce clinical signs of disease in these animals, although neutralising 
antibodies against the virus were detected. Viraemia, in conjunction with mild 
lethargy was observed in rats and mice inoculated with JPV, and varying degrees of 
haemorrhagic interstitial pneumonia was discovered in the animals upon autopsy, 
three weeks post-infection (Jun et al. 1977). Serological surveillance by serum 
neutralisation tests among Australian mammals detected JPV antibodies in 27/96 
wild mice, 17/123 wild rats, 13/107 pigs, 1/157 cattle and 2/91 humans, but a similar 
survey using complement fixation experiments on American mammals failed to 
detect JPV reactive antibodies in any of 55 laboratory mice, 45 humans and 5 
hamsters (Jun et al. 1977). Serum neutralisation experiments, when taken into 
account with viral characterisation and animal experiments, suggest JPV is a natural 
respiratory pathogen of feral Mus musculus in Queensland, Australia. 
Molecular characterisation of JPV  
The entire genome of JPV has been sequenced and is 18,954 nucleotides 
in length (Jack et al. 2005). The increase in genome size of JPV over that of other 
paramyxoviruses is due to the presence of two additional genes between the fusion 
and attachment genes, and an extensive second ORF within the attachment protein 
gene. The genome organisation of JPV is 3’-N-P/V/C-M-F-SH-TM-G-L-5’ and is 
shown schematically in Figure 1.9. JPV has been classed as member of the family 
Paramyxoviridae. 
At 18,954 nucleotides, the genome of the JPV is compatible with the ‘rule of 
six’ (Calain & Roux 1993). The terminal end sequences of paramyxoviruses 
customarily display complementarity of 11-13 nucleotides (Lamb & Kolakofsky 
2001). Complementarity between the genome termini of JPV is imperfect, differing 
by two nucleotides, but this feature is not extremely unusual, as MeV and MosPV 
also display imperfect complementarity, also differing by two nucleotides.  
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Figure 1.9- Schematic Diagram of JPV Genome and Encoded Proteins 
The genome of JPV contains eight genes and is 18,954 nucleotides in length. The 
increase in genome size of JPV over that of other paramyxoviruses is due to the 
presence of two additional genes between the fusion and attachment genes, and a 
second ORF within the attachment protein gene. The genome organisation is shown 
and arrows represent encoded proteins. The putative ‘X’ protein produced from 
ORF-X is also shown. 
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The 3’ leader sequence of JPV is 55 nucleotides, matching the length of 
that of other paramyxovirus leader sequences, and the 5’ trailer sequence is 36 
nucleotides, similar to the 33 nucleotide trailer region of the henipaviruses. JPV 
genes are separated by trinucleotide IGRs, with the bases CTT making up the 
nucleotide sequence in all gene junctions but that between the 3’ leader and N gene 
where the sequence is TTT (Jack et al. 2005). The genome of JPV consists of eight 
genes and may produce up to twelve proteins. 
The JPV N protein contains 522 amino acids and has a predicted molecular 
mass of 58.37 kDa (Jack et al. 2005). The P gene of JPV has the capacity to 
encode four putative proteins. The highly acidic P protein contains 499 amino acids, 
has a predicted molecular mass of 53.68 kDa, and is translated after faithful 
transcription of the P gene. There are a large number of potential sites for 
phosphorylation on the P protein. The C protein contains 152 amino acids, with a 
predicted molecular mass of 17.72 kDa, and is translated via an alternate ORF 
within the P gene. The V protein is produced as a result of the addition of one non-
templated G residue into the RNA editing site of the P gene and contains 292 amino 
acids, with predicted molecular mass of 31.27 kDa (Jack et al. 2005). The W protein 
contains 310 amino acids, has a predicted molecular mass of 33.74 kDa, and is 
produced as a result of the addition of two non-templated G residues into the RNA 
editing site of the P gene (Jack et al. 2005). 
The M protein of JPV contains 340 amino acids, has a predicted molecular 
mass of 37.69 kDa, and is structurally similar to M proteins of other known 
paramyxoviruses. The F protein is a type I glycoprotein containing 544 amino acids, 
with a predicted molecular mass of 59.74 kDa (Jack et al. 2005). The cleavage site 
of the F protein of JPV is monobasic, with the sequence GVPGVR. Alteration of this 
sequence is consistent with experimental evidence that the JPV F protein is unable 
to be cleaved by furin (Miller 2004). 
The SH protein, consisting of 69 amino acids, with a predicted molecular 
mass of 7.66 kDa, is translated from the novel SH gene of JPV (Miller 2004). SH 
proteins have been identified in SV-5 (Hiebert et al. 1985), MuV (Elango et al. 1989), 
and APMV-6 (Chang et al. 2001), with hydrophobic regions present in these proteins 
functioning as transmembrane anchors. Although the positioning of the JPV SH 
gene is analogous to that of the SH gene of SV-5 and MuV, no sequence homology 
is observed between the JPV SH protein and any other paramyxovirus protein. 
Structurally, the JPVP SH protein is similar to other SH proteins, having a predicted 
transmembrane domain at the N-terminus. Identification of the JPV SH protein in 
infected cells has been achieved by radio-immunoprecipitation, but the location of 
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the protein is yet to be determined. Dicistronic forms of SH mRNA, F-SH and SH-TM 
were detected (Miller 2004). 
The other novel gene within the JPV genome, TM, produces a type II 
transmembrane glycoprotein of 258 amino acids in length, with a predicted 
molecular mass of 29.09 kDa, and this protein lacks homology with any other 
proteins listed in the NCBI database. The TM protein, which is basic in nature, 
contains two potential sites for O-linked glycosylation and has a putative 
transmembrane domain. The TM protein was identified by western blot in JPV 
infected cells, and indirect immunofluorescence experiments supported the 
prediction that the TM protein is an integral membrane protein with the C-terminal 
region exposed at the cell surface (Miller 2004). 
The attachment gene produces a protein containing 709 amino acids, with 
a predicted molecular mass of 78.13 kDa, and also contains an extraordinarily long 
untranslated region of 2,218 nucleotides after the stop codon (Jack et al. 2005). The 
untranslated region of the attachment gene consists of a 2,115 nucleotide second 
ORF, which has been designated ORF-X, beginning directly after the stop codon. 
Paramyxoviruses with HN attachment proteins contain six of the seven conserved 
residues believed to be neuraminidase actives sites (Langedijk et al. 1997). This 
conservation pattern is also present in the JPV G protein. The conserved 
hexapeptide sequence NRKSCS, thought to be the sialic acid binding site 
(Jorgensen et al. 1987), is changed to NRRSCS in the JPV G protein. The 
conservation of the sialic acid binding site, along with the conservation of six out of 
seven resides of the neuraminidase active site suggests the attachment protein of 
JPV would have haemagglutination and neuraminidase activities. In contrast to 
predictions, experimental evidence suggested the absence of either 
haemagglutination or neuraminidase activities, and the JPV attachment protein was 
hence designated as a G protein (Miller 2004). The JPV G protein contains a 
putative hydrophobic transmembrane domain and five potential sites for the addition 
of N-linked carbohydrates. Analysis of mRNA transcripts by northern blot revealed 
monocistronic G mRNA transcripts. JPV may utilise an unconventional mechanism 
to translate a protein from ORF-X, either individually, or as part of a G-X fusion 
product of 1,414 amino acids in length. No evidence of X synthesis or translation 
was detected by western blot, indirect immunofluorescence and 
radioimmunoprecipitation in JPV infected cells (Miller 2004).  
The L gene of JPV produces a protein containing 2,204 amino acids, with a 
predicted molecular mass of 254.46 kDa. The six conserved domains essential for 
polymerase activity are all present in JPV. JPV contains the conserved QGDNQ 
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sequence (Jack et al. 2005), not the altered QGDNE sequence observed in the 
other four paramyxoviruses with large genomes. 
Experiments to determine the pathological effect of JPV were repeated in 
BALB/c mice. Intranasal and aerosol routes of inoculation were used to infect mice 
with JPV in two separate studies. Mice infected with JPV did not display any clinical 
signs of disease, consistent with observations in the original JPV pathogenicity 
experiments (Jun et al. 1977). JPV was isolated from the lungs of infected mice and 
moderate serum neutralising antibody titres were evoked, but in contrast to previous 
experiments, virus was not able to be isolated from any tissue apart from lung, 
viraemia did not occur, and there was no evidence of extensive haemorrhagic lung 
lesions (Miller 2004). Conflicting results between the two animal experiments may 
have resulted from attenuation of JPV due to adaptation of the virus to growth in cell 
culture or that BALB/c mice may be less susceptible to JPV infection than Mus 
musculus, the mouse species that is believed to be a natural host of the virus. 
1.8.4 Beilong virus 
A routine search for sequences related to JPV using BLASTx on the NCBI 
server revealed two putative novel cDNAs, termed Angrem 104 (AF367870) and 
Angrem 52 (AY040225) (Liang et al. 2003), from human mesangial cells with 
significant homology to JPV P, M and F genes (Jack et al. 2005). The relationship 
between the Angrem cDNA sequences to other paramyxoviruses was reported 
(Schomacker et al. 2004; Basler et al. 2005), but the close relationship to JPV was 
not ascertained by these groups as the JPV genome sequence had not yet been 
deposited in the NCBI database. Although non-retroviral RNA integration into a 
eukaryotic genome has been reported (Crochu et al. 2004), contaminating viral RNA 
in the mesangial cells was believed to be the more likely source of the homologous 
paramyxovirus sequence. 
A virus was later isolated from the human mesangial cell line from which 
the cDNA sequences Angrem 104 and Angrem 52 were originally obtained. The 
isolated virus produced syncytia in Vero cells, and upon examination of cell cultures 
and supernatant by electron microscopy, pleomorphic virions were observed (Li et 
al. 2006). The virions observed by negative contrast electron microscopy were 
enveloped, possessed surface projections, and contained ‘herringbone-like’ RNP, 
features characteristic of paramyxoviruses. The new paramyxovirus was named 
BeiPV to represent the joint collaboration between the Beijing and Geelong 
researchers that lead to the isolation and characterization of the virus. Concurrently, 
isolation of this paramyxovirus from human mesangial cells, obtained from the 
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American Type Culture Collection, was unsuccessfully attempted (Basler et al. 
2005). Later, it was discovered that a rat mesangial cell line, from the same 
laboratory in which the human mesangial cells were cultured, carried BeiPV, which 
is believed to be the original source of the virus (Li et al. 2006).  
Molecular characterisation of BeiPV 
The genome of BeiPV has been completely sequenced and at 19,212 
nucleotides in length, the genome is the largest in the family Paramyxoviridae 
sequenced to date, which also is the largest in the order Mononegavirales. The 
genome organisation of BeiPV is similar to that of JPV and is schematically 
presented in Figure 1.10. BeiPV, like JPV, contains the two novel genes, SH and 
TM, and an extended G gene. The BeiPV genome length is compatible with the ‘rule 
of six’ (Calain & Roux 1993). Complementarity between the genome termini of 
BeiPV is imperfect, with differences at three nucleotides. The 3’ leader sequence of 
BeiPV is 55 nucleotides, matching the length of that of other paramyxovirus leader 
sequences, and the 5’ trailer sequence is 25 nucleotides, similar to the trailer region 
of the rubulaviruses. BeiPV genes are separated by conserved trinucleotide IGRs, 
with the bases CTT making up the nucleotide sequence in all gene junctions (Li et 
al. 2006). 
The BeiPV N protein contains 522 amino acids, and has a predicted 
molecular mass of 58.09 kDa (Li et al. 2006). The P gene of BeiPV has the capacity 
to encode four putative proteins, P, C, V and W. The P protein contains 496 amino 
acids, has a predicted molecular mass of 53.60 kDa, and is translated after faithful 
transcription of the P gene. The V protein is produced as a result of the addition of 
one non-templated G residue into the RNA editing site of the P gene and contains 
292 amino acids, with predicted molecular mass of 31.90 kDa. The W protein 
contains 313 amino acids, has a predicted molecular mass of 34.46 kDa, and is 
produced as a result of the addition of two non-templated G residues into the RNA 
editing site of the P gene. The C protein contains 160 amino acids, with a predicted 
molecular mass of 18.44 kDa (Li et al. 2006). The M protein of BeiPV contains 340 
amino acids, and has a predicted molecular mass of 37.43 kDa, and the F protein is 
a type I glycoprotein containing 544 amino acids, with a predicted molecular mass of 
58.98 kDa. The cleavage site of the F protein of BeiPV is monobasic, with the 
sequence KLGNVK (Li et al. 2006). The BeiPV F gene cleavage site is most similar 
to that of HeV and is not expected to be cleaved by furin. 
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Figure 1.10- Schematic Diagram of BeiPV Genome and Encoded 
Proteins 
The genome of BeiPV contains eight genes and is 19,212 nucleotides in 
length. The increase in genome size of BeiPV over that of other paramyxoviruses is 
due to the presence of two additional genes between the fusion and attachment 
genes, and an untranslated region within the attachment protein gene. The genome 
organisation is shown and arrows represent encoded proteins. The putative ‘X’ 
proteins produced from ORF-X1 and ORF-X2 are also shown 
 51
 
 The L gene of BeiPV produces a protein containing 2,172 amino acids with 
a predicted molar mass of 249.97 kDa. BeiPV, like JPV, contains the conserved 
QGDNQ sequence, not the altered QGDNE sequence observed in the other four 
paramyxoviruses with large genomes (Li et al. 2006). 
The gene encoding the attachment protein of BeiPV is the largest of all 
paramyxovirus attachment protein genes identified to date. The attachment gene 
produces a protein containing 734 amino acids, with a predicted molecular mass of 
81.43 kDa, and also contains an extraordinarily long untranslated region of 2,284 
nucleotides after the stop codon (Li et al. 2006). The untranslated region of the 
attachment gene consists of two additional ORFs, which have been designated 
ORF-X1 and ORF-X2. ORF-X1 is present in the same reading frame as the G ORF 
and may encode a protein of 299 amino acids. ORF-X2, overlapping ORF-X1 by 31 
nucleotides, is present in an alternate reading frame and may encode a protein of 
394 amino acids. Currently, there is no evidence to suggest that proteins are 
encoded by ORF-X1 and ORF-X2 (Li et al. 2006). 
The BeiPV SH and TM genes are similar in size and location to those of 
JPV. The SH protein, consisting of 76 amino acids, encodes a protein with a 
predicted molecular mass of 9.05 kDa, and the TM protein, consisting of 254 amino 
acids, encodes a protein with a predicted molecular mass of 28.73 kDa (Li et al. 
2006). The function of these proteins is unknown. 
1.9 Genetic Engineering of Non-Segmented, Negative-
Sense, Single-Stranded RNA Viruses 
1.9.1 Reverse genetics 
Viral research by classical genetics associates a particular phenotype with 
a corresponding gene, and can be accomplished relatively easily, whereas the use 
of reverse genetics to genetically manipulate the viral genome and rescue infectious 
virus particles from entirely engineered clones, while not as straightforward, is 
extremely propitious. Viruses can be generated that have never before existed in 
nature, and desired mutations can be introduced to enable phenotypic studies, 
provided the mutations are not lethal. Reverse genetics permits the study of roles of 
viral components in replication and their contribution to pathogenicity, attributes 
difficult to determine via conventional virology. The unique gene expression strategy 
utilised by NNSV involves replication of the ribonucleoprotein complex and 
sequential synthesis of mRNA and neither the genomic, nor antigenomic RNA 
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genome is capable of initiating an infectious cycle. Development of reverse genetics 
systems for RNA viruses within this replication category has provided a powerful tool 
for genetic manipulation and study of those viruses. 
The establishment of a technique to introduce recombinant RNA into the 
genome of a segmented negative-sense, single-stranded RNA virus was achieved 
through the manipulation of influenza virus (Luytjes et al. 1989). Production of the 
genetically manipulated influenza virus was dependent on co-transfection with 
influenza virus polymerase proteins and support virus. The chimeric influenza virus 
could be passaged in cell culture (Luytjes et al. 1989). The first reverse genetics 
system to be established for a NNSV resulted from the manipulation of Rabies virus 
(RABV), a member of the family Rhabdoviridae, in 1994 (Schnell et al. 1994). A 
reverse genetics system was developed with the supposition that engineering the 
RABV genome would provide an insight into virus-host interactions, viral 
neurotropism, latency and pathogenesis. The deduction was made that RABV 
genome and antigenome transcripts would both be capable of initiating productive 
infection, when supplied in conjunction with N, P and L polymerase proteins. 
Construction of the RABV plasmid using the antigenome was favoured in order to 
prevent interference with encapsidation of RNA and translation of proteins, resulting 
from hybridisation of negative-sense genomic RNA and positive-sense RNA from 
protein-encoding plasmids, produced simultaneously during transcription (Schnell et 
al. 1994). Hence, the antigenome of RABV was cloned in the opposite direction to 
the T7 terminator and hepatitis delta virus (HDV) ribozyme sequence. The HDV 
ribozyme sequence provides a template for autocatalytic cleavage, generating a 
precise and predictable cleavage site in the plasmid (Perrotta & Been 1990). 
Transfection of the RABV plasmid, in addition to N, P and L support plasmids, 
resulted in the formation of transcriptionally active nucleocapsids, and subsequent 
assembly and budding of infectious RABV. Only extremely low levels of infectious 
RABV particles were produced during reverse genetics experiments, although the 
presence of one virally infected cell in a 3.2 cm tissue culture dish was deemed 
sufficient for re-isolation of the engineered virus (Schnell et al. 1994). Recovery of 
infectious virus was enhanced by implementing a freeze/thaw cycle to release 
virions from infected cells. 
The first member of the family Paramyxoviridae for which a reverse 
genetics system was developed was MeV (Radecke et al. 1995). The construction 
of the MeV reverse genetics system was similar to that of the RABV system, and 
recovery of infectious MeV was successful. Viral production in transfected cells was 
monitored via formation of syncytia, a hallmark of paramyxovirus infection. MeV 
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rescue from plasmids encoding the genomic RNA opposed to antigenomic RNA was 
low, this result in accordance with the theory that hybridisation of positive and 
negative RNA transcripts interferes with viral production. The expression of genes 
inserted into the MeV genome was determined not to be detrimental, as the 
expression of the firefly luciferase reporter gene did not reduce MeV infectivity 
(Radecke et al. 1995). Although the efficiency of viral rescue using the MeV reverse 
system displayed a strong inverse correlation to the size of the replicon engineered, 
the recovery of a full-length infectious virus with a long genome is possible. The 
EBOV genome was engineered to express the enhanced green fluorescent protein 
(EGFP) gene between the viral NP and VP35 genes, generating a replicon of 
19,773 nucleotides, and was successfully recovered (Towner et al. 2005). The GFP 
protein expressed from the recombinant EBOV genome was used to visualise virus 
infection, a technique also used for the visualisation of CDV infection in ferrets (von 
Messling et al. 2004a). 
In general, reverse genetics of paramyxoviruses implies the ability to 
recover infectious virus from a cDNA copy of the NNS genome. Establishment of a 
reverse genetics system involves the construction of a plasmid containing the viral 
antigenome, and support plasmids containing the N, P and L genes. Transfection of 
cells with protein expression plasmids occurs in conjunction with transfection of the 
plasmid containing the full-length viral genome, all plasmids being under the control 
of a T7 promotor (Neumann et al. 2002). Supply of T7 polymerase enables 
synthesis of viral RNA and the virus replication cycle is initiated. Generation of 
infectious viral particles from cloned cDNA is schematically presented in Figure 
1.11. Recently, the recovery of infectious MeV from a reverse genetics system was 
achieved through transfection of the MeV genome in two or three segments (Takeda 
et al. 2006). Up to six foreign genes were successfully incorporated into the MeV 
infectious clone containing three segments, and five of the foreign proteins were 
expressed by the recombinant MeV (Takeda et al. 2006). 
The T7 bacteriophage polymerase initiates transcription at a specific base, 
possessing stringent specificity for the T7 promotor sequence, hence is highly 
selective. The natural T7 transcription terminator sequence functions efficiently in 
artificial plasmids. The T7 promotor and terminator sequences are easily engineered 
into expression vectors, and all these vectors require to enable expression of foreign 
genes is the T7 RNA polymerase. Vaccinia virus (VACV) has been used to supply 
the T7 RNA polymerase to cells transfected with plasmids under the control of T7 
promotors. 
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Figure 1.11- Generation of Infectious Paramyxoviruses by Reverse 
Genetics 
Cells are transfected with a plasmid containing the full-length viral genome and 
support plasmids encoding the N, P and L polymerase genes. Plasmids contain a 
T7 promotor and the T7 polymerase is supplied through infection with a recombinant 
virus, such as Vaccinia virus or Fowlpox virus. The T7 polymerase enables 
synthesis of viral RNA. The viral genome is transcribed and polymerase proteins are 
translated. Replication and transcription of the newly synthesised viral RNA is then 
initiated and infectious virions are produced. This figure was adapted from Neumann 
et al. (2002). 
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 DNA encoding the bacteriophage T7 RNA polymerase gene was ligated to 
the VACV transcriptional promotor and integrated into the VACV genome (Fuerst et 
al. 1986). The recombinant VACV retained infectivity and stably expressed T7 RNA 
polymerase in mammalian cells. As T7 localises in the cytoplasm, transfected 
plasmids do not have to enter the nucleus for transcription, and mRNA produced 
does not have to be transported back to the cytoplasm for translation (Fuerst et al. 
1986). 
VACV, although highly effective in delivering T7 RNA polymerase to 
susceptible cells, is highly cytotoxic. Modifications to VACV were implemented to 
reduce the cytotoxic effect on cells, such as creating modified Vaccinia Ankara 
(VACV-ANK), a highly attenuated VACV with a restricted host range (Sutter et al. 
1995). The T7 RNA polymerase gene was also integrated into the Fowlpox virus 
(FWPV) genome, under the control of the VACV early/late promotor (Britton et al. 
1996). This virus, fpEFLT7pol, is able to stably express T7 RNA polymerase in avian 
and mammalian cells, but as FWPV undergoes abortive replication in mammalian 
cells, no infectious virus is produced in these cells. FWPV has a longer replication 
cycle than VACV, allowing increased time for synthesis of foreign gene products and 
CPE is only observed at high multiplicity of infection (m.o.i.) of virus (Britton et al. 
1996). The effects of FWPV-T7 and VACV-ANK-T7 on cells were compared, and 
FWPV-T7 was found to be non-cytopathic, in contrast to VACV-ANK-T7, which was 
highly cytopathic, multiplied rapidly and produced CPE in 3-5 days, even when used 
at a low m.o.i. (Das et al. 2000).  
An alternate method to viral infection for providing T7 RNA polymerase for 
expression of genes under the control of T7 promotors is the utilisation a stably 
transfected cell line. A BHK cell line stably expressing T7 RNA polymerase, 
BHK/T7-9, was created to eliminate detrimental effects of viral infection on cells 
used in reverse genetics experiments (Ito et al. 2003). Homologous recombination 
between the transfected full-length genome and support plasmids mediated by DNA 
polymerase of VACV frequently occurs, but this adverse feature of VACV infection is 
eliminated in the BHK system. 
1.9.2 Minigenome versus full-length genome 
A minireplicon system may be created as the first step towards the 
engineering of a full-length infectious clone by replacing the entire coding region of a 
viral genome with a reporter gene. Optimisation of conditions for rescue of infectious 
virus from cloned cDNA is achieved by first rescuing a reporter gene. Rescue of a 
synthetic genome was first achieved with a SeV construct (Park et al. 1991). 
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Minireplicon systems allow the function of cis and trans-acting sequences at the 
terminal ends of the viral genome to be determined, and also the functionality of the 
support plasmids can be tested. Through analysis of components of viral 
polymerase in a minigenome, the N protein, previously hypothesised to alter the 
dynamic balance between replication and transcription, was found to have limited 
effect on viral RNA synthesis (Fearns et al. 1997). The function of accessory 
proteins, such as V or C, may be analysed. The V protein of SeV was determined 
completely dispensable for viral replication in a model where the protein was 
knocked out (Nagai 1999), and, in a minireplicon system, the MeV (Parks et al. 
2006) and SV-5 (Lin et al. 2005) V proteins were found to repress genome 
replication. Both V and C proteins have been implicated in CDV pathogenesis (von 
Messling et al. 2006). A definite advantage of a minireplicon system over a reverse 
genetics system is that no infectious viral particles are generated, allowing functional 
studies of viruses classified as biosafety level (BSL)-4 to be undertaken without 
biocontainment restrictions (Halpin et al. 2000). 
The development of a reverse genetics system containing a full-length 
infectious clone has obvious advantages over that of a system containing a 
minigenome. Attributes uncovered through the study of individual viral genes and 
proteins may not necessarily correspond to those observed in the natural viral life 
cycle. Functions of viral proteins required early in the natural life cycle are bypassed 
in a minireplicon system, as transfected plasmids are not under the control of viral 
specific promotors and polymerases (Nagai 1999). Viral models where genes are 
knocked out, or substituted with alternate genes, are able to be created with the use 
of reverse genetics. The generation of attenuated viruses for use as vaccines or 
vectors is also possible, as is ascertaining the role genes play in viral virulence (Ito 
et al. 2003).  
1.10 Research Significance and Objectives 
1.10.1 Aims of this study 
 1- To characterise JPV and BeiPV using reverse genetics 
Pursuing characterisation of JPV and BeiPV in relation to viral 
pathogenesis or functions of accessory proteins may only be possible by observing 
the authentic viral life cycle. In contrast, determination of evolutionary relatedness of 
JPV, BeiPV and NiV was possible through the establishment of a minireplicon 
system. Expression of the GFP reporter gene in the minigenome was reliant upon 
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co-expression of N, P and L genes, which were supplied in the form of support 
plasmids. Creation of minireplicon systems for JPV and BeiPV also functioned as 
the initial stage in establishment of complete reverse genetics systems for the 
viruses. 
 2- To explore the localisation and function of the novel SH and TM 
proteins of JPV 
The two novel genes identified, SH and TM, in addition to the untranslated 
region located within the G gene, contributed to the exceptionally long genome of 
JPV. The function of these encoded gene products has yet to be determined. 
Cloning and transfection of the JPV SH and TM genes aimed to facilitate analysis of 
protein expression and localisation. Fusion of the two sequential ORFs of the G 
gene, via mutation and cloning, created an extended G gene encoding a 
significantly larger attachment protein. The functionality of the extended JPV G 
attachment protein was analysed using an electron microscopy technique. 
 3- To establish assays for the detection of JPV and BeiPV 
A JPV specific real-time PCR assay was developed to assist in monitoring 
the tissue tropism of JPV in experimentally infected animals. The real-time PCR 
assay was also developed with the goal of monitoring infectious virus production 
from engineered clones in a reverse genetics system, and to be used as a potential 
diagnostic tool for future applications in disease investigation. The multiplex 
microsphere assay assessed the seroprevalence of JPV and BeiPV in sera samples 
taken from the Australian and southern Asian rodent population. 
1.10.2 Significance 
JPV was isolated from wild mice in Queensland, Australia, in 1972 and has 
been suggested to be a natural respiratory pathogen of mice. BeiPV was isolated 
from human mesangial cells, and subsequently detected in rat mesangial cells. The 
emergence of several other paramyxoviruses, especially those such as HeV and 
NiV, which are zoonotic and have caused fatalities in humans, provoked renewed 
interest in the characterisation of previously unclassified viruses. The potential of 
paramyxoviruses to cause lethal infection in a variety of host organisms should not 
be underestimated, nor should the possibility that uncharacterised viruses may 
possess zoonotic capability.  
JPV and BeiPV have been classified within the family Paramyxoviridae. 
These viruses are unique in that both contain two additional genes, TM and SH, 
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along with an extensive untranslated region within the G gene. With a genome 
consisting of 19.2 kb, BeiPV is the largest known virus within the family 
Paramyxoviridae. Characterisation of JPV and BeiPV and their novel genes may 
facilitate an understanding of disease pathogenesis of the viruses and assist in 
ascertaining the evolutionary relationship between these viruses and other 
paramyxoviruses. 
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CHAPTER 2 
Development of Reverse Genetics Systems for JPV 
and BeiPV 
2.1 Introduction 
The emergence of several paramyxoviruses, especially those such as HeV 
and NiV which are zoonotic and have caused fatalities in humans, have provoked 
renewed interest in the characterisation of paramyxoviruses previously unclassified 
or not associated with known diseases (Wang & Eaton 2001). JPV and BeiPV are 
two recently characterised paramyxoviruses of rodent origin. Complete sequencing 
of the JPV (Jack et al. 2005) and BeiPV (Li et al. 2006) genomes revealed a unique 
genome organisation never before observed in the Paramyxovirinae. Further 
characterisation of JPV and BeiPV may provide a better understanding of the viral 
evolution of the Paramyxovirinae and also aid in the classification of these viruses. 
In this study reverse genetics systems were established for NiV, JPV and 
BeiPV. For each virus a minigenome was generated where all protein coding 
regions were replaced with a negative-sense copy of the EGFP gene. The viral 
leader, trailer, N gene 3’ UTR and L gene 5’ UTR all remained intact in the 
minigenome. The vRdRp complex is sufficient for transcription of a minigenome, and 
each of the N, P and L proteins that constitute the polymerase complex are 
absolutely required. The N, P and L genes of JPV and BeiPV were cloned and in 
conjunction with the minigenomes form the GFP minireplicon system. Minigenomes 
of JPV and BeiPV of differing lengths were constructed to determine if these viruses 
obey the ‘rule of six’ in an in vitro replication assay. To analyse the effect of the C 
protein on the JPV and BeiPV minireplicon systems, both JPV and BeiPV P genes 
were constructed with the start site of the C ORF silenced. The effect of the C 
protein on replication of the minigenome was determined when JPV and BeiPV 
minireplicon systems were supplemented, on separate plasmids, with the C protein 
in a dose dependant manner. 
 60
2.2 Materials and Methodology 
2.2.1 Production of viral cDNA 
Virus and cell culture 
Vero cells were maintained in Eagle’s Minimum Essential Medium (EMEM) 
(Invitrogen, USA), supplemented with 10% (v/v) foetal calf serum (FCS) (Thermo 
Trace, Australia), 2 mM glutamine (Invitrogen), 10 mM HEPES (MP Biomedicals, 
USA) and penicillin (JRH Biosciences, USA) and streptomycin (Sigma, Australia) 
antibiotics. Media supplemented with 10% FCS, glutamine and HEPES will be 
referred to as EMEM-10 from herein. 
JPV was supplied to the AAHL in RK13 cells by the Queensland 
Department of Primary Industries. BeiPV was isolated at AAHL (Li et al. 2006). 
Antibodies and conjugates 
The JPV rabbit antiserum, supplied by Gary Crameri, was obtained from 
rabbits immunised at AAHL. The monoclonal antibodies (MAbs) anti-RGS-His6 
(Qiagen, Germany) and anti-GST (Amersham Biosciences, Australia) were used for 
the detection of the RGS-His6 and GST tags, respectively. The goat anti-mouse 
(Chemicon, USA) and goat anti-rabbit (Silenus, Australia) alkaline phosphatase (AP) 
conjugates were used for the detection of MAbs and rabbit sera, respectively. 
Virus infection 
Vero cell monolayers were propagated in 150 cm2 flasks. Media was 
removed from flasks and 100 μL of JPV or BeiPV (1 x 106 TCID50/mL) in 1 mL of 
PBS-A (Ca++/Mg++ free PBS) was used to inoculate cells. Cells were incubated at 
37°C, with rocking, for 1 hr. After incubation, inoculum was replaced with 30 mL of 
pre-warmed EMEM-10. Cells were incubated at 37°C, until the formation of syncytia 
was evident. Upon observation of syncytia, virus culture supernatant was purified 
and the Vero cell monolayer was harvested by scraping cells into the PBS-A. Either 
purified virus or virus infected Vero cells were used for RNA extraction. 
Virus purification 
Virus culture supernatant was collected in a 50 mL falcon tube and 
centrifuged at 2500 rpm in an IEC Centra-7R centrifuge (210 rotor) for 10 min at 4°C 
to remove cell debris. A 20 mL syringe and 19G x 1 ½ “ needle was used to fill a bell 
top tube (Beckman, USA) with virus culture supernatant. Tubes and space filler caps 
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were placed into a 55.2 Ti rotor (Beckman) and centrifuged at 50,000 rpm for 30 min 
at 10°C under vacuum, in a Beckman L8-80M ultracentrifuge. After centrifugation, 
supernatant was removed from the tube and the crude virus pellet was resuspended 
in 350 μL RLT buffer (QIAGEN, Germany). 
RNA extraction 
 RNA was extracted from crude virus pellets (from above) using the 
QIAshredder column and RNeasy kit (both from QIAGEN), according to 
manufacturer’s instructions. Viral RNA was extracted from virus infected Vero cells 
(from above) using the QIAamp Viral RNA Mini kit (QIAGEN), according to 
manufacturer’s instructions. 
Synthesis of cDNA 
Viral cDNA was synthesised from viral RNA using the Omniscript 
Transcriptase kit (QIAGEN). Each 40 μL reaction contained 1 μL of JPV or BeiPV 
RNA, 4 μL of 10X buffer, 4 μL of 5 mM dNTPs, 4 μL of a 1:50 dilution of random 
hexamers (Invitrogen), 2 μL of 10 U/μL RNAsin RNase inhibitor (Promega, USA), 2 
μL of Omniscript reverse transcriptase and H20. The reverse transcription reactions 
were incubated at 37°C for 1 hr, then cDNA was stored at -20°C. 
2.2.2 Construction of protein expression vectors 
Construction of bacterial expression vectors 
Three bacterial expression vectors were created for routine cloning and 
protein expression. The pHMN vector contained a His6 tag, the pBAN vector a biotin 
tag and the pGAN vector a GST tag. 
 The JPV TM gene was amplified from JPV cDNA by PCR, using DJ01 
(XhoI, MluI) and DJ02 (NotI, HindIII) primers. Restriction sites included in primers 
are displayed in parentheses and primer sequences are listed in Appendix 1. The 
pRSET-C vector (Invitrogen) and JPV-TM PCR product were digested with XhoI and 
HindIII, and ligated together. After cloning, the JPV-TM gene was removed from the 
pRSET-C vector by digestion with MluI and NotI, creating the pHMN vector. 
A fragment of the JPV L gene was amplified from JPV cDNA by PCR using 
DJ39 (SacI, AscI) and DJ40 (NotI, EcoRI) primers. The pDW363 vector (Tsao et al. 
1996) and JPV L fragment PCR were digested with SacI and EcoRI, and ligated 
together. After cloning, the JPV L gene fragment was removed from the pDW363 
vector by digestion with AscI and NotI, creating the pBAN vector. Inserts containing 
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either AscI/NotI or MluI/NotI restriction sites may be cloned into this vector, but once 
an insert containing MluI is cloned into AscI restriction site, the restriction sequence 
is disrupted and the insert cannot be removed with either enzyme. 
The JPV L gene fragment was also used for the modification of the pGD3 
vector. The pGD3 vector (Wang et al. 1996) and JPV L fragment PCR were 
digested with SacI and EcoRI and ligated together. After cloning, the JPV L gene 
fragment was removed from the pGD3 vector by digestion with AscI and NotI, 
creating the pGAN vector. As with the pBAN vector, inserts containing either 
AscI/NotI or MluI/NotI restriction sites may be cloned into pGAN. 
Construction of mammalian expression vectors 
The mammalian expression vector pCI-neo (Promega) was routinely used 
for transfection experiments. The pCI-neo vector contains both CMV and T7 
promotors, and JPV inserts were ligated into MluI and NotI sites of this vector.  
Minigenome studies utilised the pUC19 vector (Invitrogen). The NarI 
restriction site was deleted from the pUC19 vector by digesting the vector with NarI, 
blunting ends with Klenow polymerase (Promega) and re-ligating the modified 
vector. The pUC19dNar vector created was used for expression of GFP 
minigenomes. 
The JPV TM gene was amplified from JPV cDNA by PCR, using DJ49 
(SpeI, MluI) and DJ50 (NotI, XhoI) primers. The pTM1 vector (Halpin et al. 2004) 
and JPV-TM PCR were digested with SpeI and XhoI, and ligated together. After 
cloning, the JPV-TM gene was removed from the pTM1 vector by digestion with MluI 
and NotI, creating the pTM1 vector. 
2.2.3 Expression of recombinant polymerase proteins in E. coli 
Plasmids and bacterial strains 
The three vectors, pHMN, pBAN and pGAN, were used for the expression 
of recombinant proteins. The E. coli strains MC1061 (F- araD139 ∆(ara-leu)7696 
∆lac174 galU – galK - hsr – hsm + strA) and BL21(DE3) (Invitrogen) were routinely 
used for recombinant protein expression. 
Preparation of electrocompetent E. coli cells 
A single colony from freshly plated electrocompetent E. coli cells was used 
to inoculate 2 mL LB broth (1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract 
(Difco Laboratories, USA), 1% (w/v) NaCl, pH 7.0). The bacterial culture was 
incubated for 5 hr, at 37°C, with shaking. After incubation, 1 mL of culture was used 
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to inoculate 20 mL of LB broth. The 20 mL culture was incubated overnight, at 37°C, 
with shaking. 
After incubation, 12 mL of overnight culture was used to inoculate 1.2 L of 
pre-warmed LB broth (1:100 dilution). The culture was incubated at 37°C, with 
shaking, until the OD600 (UV-1201 Spectrophotometer, Shimadzu, Japan) reached 
0.6-0.9. Once bacterial cells were in log phase of growth, cultures were placed on 
ice. The cultures were transferred to 250 mL pre-cooled centrifuge tubes and 
centrifuged at 4000 g for 15 min, at 4°C. Bacterial pellets were resuspended in 10 
mL of sterile, ice-cold 10% glycerol and centrifuged at 4000 g for 15 min, at 4°C. 
The glycerol wash was repeated three times. After the final wash, bacterial pellets 
were resuspended in 2.5 mL of 10% glycerol and divided into Eppendorf tubes in 50 
μL aliquots. Competent cells were snap frozen in liquid nitrogen and stored at -80°C. 
Recombinant protein expression 
Recombinant proteins were produced by transforming competent cells with 
expression vectors. For expression of proteins in the pHMN vector, BL21(DE3) 
competent cells were transformed. For expression of proteins in either the pBAN or 
pGAN vectors, MC1061 cells were transformed. Purified plasmid DNA was 
transformed into 50 μL of competent cells by electroporation at 1.8 kV using Gene 
Pulser (Bio-Rad, USA). After electroporation, cells were allowed to recover in 250 
μL SOC medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2 , 20 mM MgSO4, 20 mM glucose) for 1 hr, at 37°C, with shaking. Once 
recovery time was complete, transformed cells were spread onto LB agar plates 
containing 100 μg/mL ampicillin, and incubated at 37°C, overnight. 
A single colony from the transformation plate was used to inoculate 2 mL of 
LB broth containing 100 μg/mL ampicillin. LB broth was additionally supplemented 
with 50 μM D-Biotin for cultures containing pBAN plasmids. Cultures were incubated 
at 37°C, overnight, with shaking. 
Following overnight incubation, 1 mL of culture was used to inoculate 49 
mL LB broth (1:50 dilution), supplemented with ampicillin and D-Biotin as above. 
Culture was incubated at 37°C, with shaking, until the OD600 reached 0.6-0.9. To 
induce expression, 500 μL of 100 mM isopropyl β-D-thiogalactoside (IPTG) was 
added to the culture. The cultures were incubated at 37°C, with shaking, for a further 
4 hr and then harvested. 
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2.2.4 Expression of recombinant polymerase proteins in mammalian cells 
Transfection of JPV polymerase proteins in Vero cells 
Genes were cloned into the pCIneo vector for protein expression in 
mammalian cells. Vero cells were seeded into 6 well plates, at 1 X 106 cells per well 
in 3 mL EMEM-10 and incubated overnight at 37°C with 5% CO2. For each 
transfection, Lipofectamine 2000 (Invitrogen) was added to the plasmid DNA in a 3:1 
ratio (3 μL Lipofectamine: 1 μg DNA), then serum free EMEM was added to bring 
the final sample volume to 500 μL. Routinely, 5 μg of DNA was used for each 
transfection. After incubation for 30 min at room temperature, a further 500 μL of 
serum free EMEM was added to the sample. This transfection mix was added to the 
Vero cells and incubated at 37°C with 5% CO2 for 6 hr, after which the transfection 
mix was removed and replaced with EMEM-10. 
2.2.5 Western blot analysis of recombinant polymerase proteins 
Preparation of bacterial cell lysates for SDS-PAGE 
Upon completion of induction (see section 2.2.3), bacterial cultures were 
centrifuged at 5000 rpm in JA 25.5 rotor (Beckman) for 10 min at 4°C. The bacterial 
pellet was resuspended in 2 mL of Native Binding Buffer (NBB) (20mM NaPO4, 500 
mM NaCl, pH7.8). The sample was kept on ice and sonicated three times, using the 
Microson Ultrasonic Cell Disruptor (Misonix, USA). After sonication, the cell lysate 
was centrifuged at 13000 rpm for 10 min at 4°C. The supernatant was transferred to 
a new tube and pellet was resuspended in 1 mL of NBB. Cell lysates were stored at 
-20°C.  
Preparation of mammalian cell lysates for SDS-PAGE 
To prepare mammalian cell lysates, media was removed from cells and 
replaced with 1 mL of PBS-A. Cells were scraped from plates with a cell scraper and 
collected with PBS-A in eppendorf tubes. Cells were centrifuged at 2000 rpm for 2 
min and PBS-A was removed. The cell pellet was resuspended in 100 μL of RIPA 
buffer (1 mM PMSF, 1% sodium deoxycholate, 50 mM Tris-HCl, pH 7.4, 1% Triton-
X, 0.1% SDS, 150 mM NaCl and H2O). Cells resuspended in RIPA buffer were lysed 
on ice for 20 min and clarified by centrifugation at 13,000 rpm for 10 min at 4°C. 
After centrifugation, supernatant was collected into a new eppendorf tube and either 
analysed be western blot immediately or stored at -20°C for later analysis. 
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Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS gels were cast in Mini-ProteanTM III dual slab cell apparatus (Bio-Rad). 
Gels for standard protein analysis were 75 mm in thickness and preparative gels for 
protein purification were 1.5 cm in thickness. Polyacrylamide separating gels 
contained 4.7 mL, 4 mL, 3.3 mL, 2.4 mL, or 1.4 mL of 30% (w/v) acrylamide/bis-
acrylamide solution (Bio-Rad) in 2.7 mL, 3.3 mL, 4 mL, 5 mL or 6 mL MilliQ® H20 
(Millipore, USA) for 8%, 10%, 12%, 15% or 18% gels, respectively. Added to the 
polyacrylamide solution was 2.5 mL of 1.5 M Tris-HCl pH 8.8, 100 μL of 10% (w/v) 
SDS, 50 μL of 10% (w/v) ammonium persulfate (Bio-Rad) and 5 μL of N, N, N’, N’ 
tetramethylethylenediamine (Bio-Rad). Polyacrylamide stacking gel containing 5% 
acrylamide/bis-acrylamide was prepared similarly using 1.2 mL of 0.5 M Tris-HCl pH 
6.8. 
Protein samples were analysed under reducing conditions. A 6X solution of 
reducing SDS-PAGE loading buffer (0.04% (w/v) bromophenol blue, 6% (w/v) SDS, 
190 mM Tris-HCl pH 6.5, 45% (v/v) glycerol, 15% (v/v) 2-β mercaptoethanol) was 
added to protein lysates, and lysates were boiled at 100°C, for 5 min prior to loading 
on the gel. Once lysates were loaded on the gel, proteins were separated by 
electrophoresis, at 200 V, in SDS-PAGE running buffer (25 mM Tris, 192 mM 
glycine, 1% SDS, pH 8.3) for 30-60 min using a Power Pac 3000 (Bio-Rad). 
Following electrophoresis, SDS gels were rinsed in H20 for 5 min then 
either stained or further analysed by Western blot. Gels were stained in BioSafeTM 
Coomassie Blue G250 Stain (Bio-Rad). Stained gels were preserved by soaking in 
gel drying solution (30% (V/V) methanol, 5% (v/v) glycerol) for 30 min, then sealing 
between sheets of gel drying film (Promega). 
Western blot 
Proteins separated by SDS-PAGE were transferred from gels onto 
Immobilon-P transfer membrane (0.45 μM pore size) (Millipore, USA). Proteins were 
transferred from gels to membranes in transfer buffer (1.44% (w/v) glycine, 0.3% 
(w/v) Tris, 20% (v/v) methanol) using a Mini-Protean II Trans-blot® cell (Bio-Rad) 
and a Power Pac 3000 (Bio-Rad) set on 250 mA, for 1 hr. Upon completion of the 
transfer, the Western blots were incubated in a blocking solution of 5% (w/v) skim 
milk in Tris-buffered saline (10 mM Tris-HCl pH 8.0, 150 mM NaCl) containing 
0.05% (v/v) Tween 20 (TBS-T) at room temperature for 1 hr or at 4°C, overnight. 
After the blocking incubation, the membranes were incubated for 1 hr at 
room temperature with the primary antibody, diluted in TBS-T. Prior to addition of 
the secondary antibody, the membranes were washed three times with TBS-T for 5 
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min. The secondary antibody, containing an AP conjugate, was also diluted in TBS-
T and incubated on the blots for 1 hr at room temperature. After antibody 
incubations, the blots were washed three times with TBS-T for 5 min and once with 
H2O for 5 min. When monitoring the production of antibodies, lysates containing 
insoluble bacterial proteins were loaded onto preparative 1.5 cm thick SDS gels and 
separated by electrophoresis. Proteins were transferred to membranes (as above) 
and the blots were cut into strips of 5 mm width. Membrane strips were individually 
incubated with different antibodies. 
An alkaline AP solution containing 33 μL 5-bromo-4-chloro-3-indolyl-
phosphate (Promega) and 66 μL nitro blue tetrazolium (Promega) in 10 mL AP 
buffer (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2) was prepared. The 
blots were incubated in development solution until the desired colour intensity was 
reached, and then were rinsed in H2O to stop the colour development reaction from 
proceeding. 
Purification of insoluble proteins 
Lysates containing insoluble bacterial proteins were loaded onto 
preparative 1.5 cm thick SDS gels and separated by electrophoresis, as described 
above. Upon separation, gels were rinsed in H20 and stained with ice-cold 0.3 M 
KCl. Protein bands were excised from the gels with a scalpel, diced into small 
pieces and placed into an eppendorf tube. To solubilise the protein, 600 μL of 
elution buffer (50 mM NH4HCO3, 0.1% SDS) was added to the gel pieces. The gel 
pieces and buffer solution were incubated overnight at room temperature on a 
rotating wheel. Protein elutions were removed and stored at -20°C and a further 600 
μL of elution buffer was added to the remaining gel pieces. The gel pieces were 
incubated once again at room temperature overnight on rotating wheel and protein 
elutions were removed and stored at -20°C. Quantitation of the level of protein in 
elutions was determined by SDS-PAGE where samples were loaded in conjunction 
with a molecular mass marker. 
2.2.6 Preparation of monospecific antiserum against the JPV L protein 
PCR amplification of a predicted antigenic region of the JPV L gene 
Primers were designed to amplify predicted antigenic regions of the JPV L 
gene. Protein antigenicity was predicted by analysing the Kyte and Doolittle 
hydrophilicity profile (Sci Ed Central Clone Manager 7, version 7.11, USA) (Kyte & 
Doolittle 1982) of the L protein and selecting a hydrophilic region for amplification 
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(Figure 2.1A). Two antigenic fragments, JPV L1 (Figure 2.1B) and JPV L2 (Figure 
2.1C) were predicted. The L1 gene fragment was amplified by PCR using DJ30 
(MluI) and DJ31 (NotI) primers and the L2 gene fragment was amplified by PCR 
using DJ31 (MluI) and DJ32 (NotI) primers. Both PCR reactions utilised the pHMN-
JPV-L clone as the template. 
Recombinant protein expression and purification 
The predicted antigenic JPV L gene fragments were cloned into the MluI 
and NotI sites of the pHMN, pBAN and pGAN expression vectors. The L protein was 
expressed from the pHMN vector and purified. The protein concentration was 
determined by SDS-PAGE analysis. 
Immunisation 
Two female New Zealand White rabbits (ID numbers 517 and 518), age 4 
months (Institute of Medical and Veterinary Science, Australia) were used for 
antibody production. Animals were housed in the small animal facility of the secure 
area of AAHL and procedures were assessed and approved by the AAHL Animal 
Ethics committee.  
Prior to immunisation, blood samples were taken from each rabbit via an 
ear bleed. Xylocaine ointment (AstraZeneca, Australia) was applied to the shaven, 
70% ethanol cleaned ear of the rabbit. Vaseline (Lever Rexona, Australia) was 
applied to the ear to prevent dispersal of blood, and Oil of Wintergreen (Sunspirit 
Oils, Australia) was applied to promote vasodilation of blood vessels. The lateral ear 
vein was nicked with a scalpel and blood droplets were collected in 9.5 mL 
Vacutainer SST tubes (Becton Dickinson, USA). Upon completion of the ear bleed, 
pressure was applied to the ear to allow clotting. Vacutainer tubes were gently 
inverted and blood was allowed to clot for 1 hr at room temperature, followed by a 
further 3 hr at 4°C. Tubes were then centrifuged at 1200 rpm in IEC Centra-7R 
centrifuge (210 rotor) for 10 min at 4°C, to separate the serum from the blood clot. 
Serum was collected and stored in 1 mL aliquots, at -80°C. 
For immunisations, 100 μg of JPV L protein in 500 μL of PBS and 500 μL of 
Montanide ISA 50V (Seppic, France) adjuvant was prepared. Rabbits were 
immunised with 500 μL of protein/adjuvant solution by intramuscular injection with a 
23 G X 1” needle, in each cranial thigh. Rabbits were boosted with an additional 100 
μg of the JPV L protein six weeks after the initial immunisation. This boost was 
performed by Eric Hansson and Gary Crameri. 
 68
 
 
 
 
 
Figure 2.1- Kyte & Doolittle Analysis of the JPV L Protein 
Kyte & Doolittle values fall within a range of +4 to -4, with hydrophilic residues 
having a negative score. Kyte and Doolittle hydrophilicity plots are shown for the full-
length JPV L protein (A), the JPV L1 fragment  encompassing amino acid residues 
587-747 of the JPV L protein (B) and the JPV L2 fragment  encompassing amino 
acid residues 1215-1374 of the JPV L protein (C). 
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Blood samples were collected from rabbits on days 21, 29 and 48, via ear 
bleeding as described above. Final blood samples were collected on day 51 via 
cardiac puncture. Rabbits were anesthetised with 500 μL Ketamine (Ilium Veterinary 
Ethical, Australia) and 500 μL Xylazil-20 (Ilium Veterinary Ethical, Australia) via 
intramuscular injection in the cranial thigh with a 23 G X 1” needle. Once 
anesthetised, rabbits were terminally bled by cardiac puncture with 16 G X 1 ½ “ 
needle. The terminal bleeds were performed by Gary Crameri. Blood was 
transferred to Vacutainer tubes, and serum samples were collected, as described 
above. 
2.2.7 Construction of a NiV minigenome with a GFP reporter gene 
Design of NiV minigenome 
The NiV minigenome pNiV-CAT, a gift from P. Rota (Halpin et al. 2004), 
was used as a template for the construction of the pNiV-GFP minigenome. The NiV 
GFP minigenome contained the same features as the JPV GFP minigenome (See 
Chapter 2, Section 2.2.8). The NiV N, P and L support plasmids were a generous 
gift from P. Rota (Halpin et al. 2004). 
PCR amplification of the NiV genome termini 
A DNA fragment containing the NiV L 5’ UTR, NiV trailer region and T7 
promotor sequence was amplified from the pNiV-CAT minigenome with the DM04 
(NotI, BamHI) and RSP (HindIII) primers. A second DNA fragment containing the 
NiV leader region, NiV N 3’ UTR, hepatitis delta virus ribozyme sequence and two 
T7 terminator sequences was amplified from the pNiV-CAT minigenome with the 
USP (SacI) and DM05 (NcoI, BamHI) primers. 
Construction of NiV GFP minigenome expression plasmid 
The DNA fragment containing the NiV L 5’ UTR, NiV trailer region and T7 
promotor sequence, representing the 5’ termini of the NiV minigenome, was cloned 
into the BamHI and HindIII sites of a pUC19dNar expression vector, creating the 
pNiV5’ plasmid. The DNA fragment containing the NiV leader region, NiV N 3’ UTR, 
hepatitis delta virus (HDV) ribozyme sequence and two T7 terminator sequences, 
representing the 3’ termini of the NiV minigenome, was digested with EcoRI and 
cloned into the EcoRI and SmaI sites of the pNiV5’ plasmid, creating the pNiV3’5’ 
plasmid. The pCI-EGFP plasmid was a gift from Luke Lambeth (Lambeth et al. 
2006) and contained the GFP reporter gene. The GFP reporter gene was removed 
 70
from the pCI-EGFP plasmid by digestion with NcoI and NotI, and was then ligated 
into the NcoI and NotI sites of the pNiV3’5’ plasmid, generating the pNIV-GFP 
minigenome. The pNIV-GFP minigenome differed from the pNiV-CAT minigenome 
in that the A residue at nucleotide 92 of the NiV genome was substituted with a G 
residue, due to a PCR induced mutation. 
2.2.8 Establishment of a JPV minireplicon system  
Design of the GFP minigenome 
The 5’ end of the GFP gene was flanked by the N gene 3’ UTR, gene start 
signal, viral leader, Hepatitis delta virus (HDV) cleavage sequence and two T7 
terminator sequences. The 3’ end of the GFP gene was flanked by the L gene 5’ 
UTR, gene stop sequence, viral trailer and T7 promotor (Figure 2.2). 
Construction of the JPV GFP minigenome expression plasmid 
The pNiV-GFP minigenome served as a template for the construction of the 
JPV minigenome. The JPV leader region and N 3’ UTR were amplified from JPV 
cDNA using the DM08 and DM09 (NcoI) primers. This PCR product was used as a 
template in a subsequent PCR reaction, with the DM03 (NarI) and DM09 (NcoI) 
primers. The DM03 primer extended the genome specific PCR into the HDV region 
and added a NarI site to the product. The PCR product containing the 3’ terminus of 
the JPV minigenome was cloned into the NarI and NcoI sites of the pNiV-GFP 
minigenome, hence replacing the 3’ NiV terminus with the 3’ JPV terminus. A DNA 
fragment containing the JPV L 5’ UTR and JPV trailer region was amplified from 
JPV cDNA with the DM13 (NotI) and DM12 (HindIII) primers. This PCR product, 
representing the 5’ terminus of the JPV minigenome, was cloned into the NotI and 
HindIII sites of the pNiV-GFP plasmid, completing the replacement of the NiV termini 
with the JPV termini, and generating the pJPV-GFP minigenome. One T residue at 
position 18,843 of the JPV genome was omitted from the pJPV-GFP plasmid during 
cloning to ensure the minigenome length was exactly divisible by six. 
A JPV minigenome that was not divisible by six was also generated. The 
JPV minigenome contained an NcoI restriction site within the N gene 3’ UTR. The 
pJPV-GFP plasmid was linearised by digestion with NcoI, overhangs created during 
digestion were filled in with Klenow polymerase, and then the plasmid was ligated 
with T4 ligase. The resulting plasmid, pJPV-GFP(+4), was no longer divisible by six. 
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Figure 2.2- GFP Minigenome Construct 
The schematic diagram of the GFP minigenome indicates the positions of the T7 
terminator, hepatitis delta virus ribozyme (HDV) sequence, leader, N 3’ untranslated 
region (UTR), EGFP, in reverse orientation, L 5’ UTR, trailer and T7 promotor. 
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PCR amplification and cloning of JPV N, P, PdC, L and C ORFs 
The JPV N ORF was amplified from JPV cDNA by PCR using DJ18 (MluI) 
and DJ08 (NotI) primers. The JPV P ORF was amplified from JPV cDNA using DJ19 
(MluI) and DJ10 (NotI) primers. The JPV N and P ORFs were cloned into the pTM1 
expression vector, creating pTM1-JPV-N and pTM1-JPV-P, respectively. The JPV C 
ORF was amplified by PCR from the JPV-P clone using DJ52 (MluI) and DJ53 (NotI) 
primers. The JPV C ORF was cloned into the pTM1 vector, creating pTM1-JPV-C.  
The JPV C ORF was silenced in the JPV P gene, creating the JPV-PdC 
clone. A fragment of the P gene was amplified by PCR using DJ43 and PJ03 
primers. The DJ43 primer contained a t1874c mutation to silence C protein ATG 
start codon. This PCR product was used as a template for another PCR reaction, 
using DJ52 (MluI) and PJ03 primers. The JPV-PdC PCR product and pTM1-JPV-P 
clone were both digested with MluI and NcoI, and the JPV-PdC fragment replaced 
the 5’ region of the JPV-P gene, silencing the C gene, and creating the pTM1-JPV-
PdC clone. 
The JPV L ORF was amplified in five fragments; fragment 1 using DJ23 
(MluI) and DJ41 (NsiI, NotI) primers, fragment 2 using PJ60 (NsiI) and DJ24 (SphI, 
NotI) primers, fragment 3 using DJ25 (SphI) and DJ26 (PpuMI, NotI) primers, 
fragment 4 using DJ27 (PpuMI) and DJ42 (AgeI, NotI) primers, and fragment 5 
using PJ38 (AgeI) and DJ28 (NotI) primers. The construct pHMN-JPV-L was created 
by inserting fragments 1-5 in a sequential manner, using the unique 3’ restriction site 
in combination with NotI as the 5’ restriction site. The JPV L ORF was removed from 
the pHMN-JPV-L construct by digestion with MluI and NotI, and then cloned into the 
pTM1 vector, creating pTM1-JPV-L. 
2.2.9 Establishment of a BeiPV minireplicon system 
Construction of the BeiPV minigenome expression plasmid 
The pJPV-GFP minigenome served as a template for the assembly of the 
BeiPV minigenome. The BeiPV leader region and N 3’ UTR were amplified from 
BeiPV cDNA using the DM10 and DM11 (NcoI) primers. This fragment was used as 
a template in a subsequent PCR reaction, with the DM03 (NarI) and DM11 (NcoI) 
primers. The PCR product containing the 3’ terminus of the BeiPV minigenome was 
cloned into the NarI and NcoI sites of the pJPV-GFP minigenome, thereby replacing 
the 3’ JPV terminus with the 3’ BeiPV terminus. A DNA fragment containing the 
BeiPV L 5’ UTR and BeiPV trailer region was amplified from BeiPV cDNA using the 
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DM13 (NotI) and DM12 (HindIII) primers. This fragment, representing the 5’ 
terminus of the BeiPV minigenome, was cloned into the NotI and HindIII sites of the 
pJPV-GFP plasmid, completing the replacement of the JPV termini with the BeiPV 
termini, and generating the pBeiPV-GFP minigenome. Two G residues at positions 
19,101 and 19,102 of the BeiPV genome were omitted from the pBeiPV-GFP 
plasmid during cloning so that the minigenome was divisible by six. The plasmid 
pBeiPV-GFP(+4), which was no longer divisible by six, was constructed using the 
same method as for pJPV-GFP(+4). 
PCR amplification and cloning of BeiPV N, P, PdC, L and C ORFs 
The BeiPV N ORF was amplified with DM23 (MluI) and DM24 (NotI) 
primers, and the BeiPV P ORF was amplified with DM25 (MluI) and DM26 (NotI) 
primers. Both BeiPV N and P products were cloned into the pTM1 vector, using the 
MluI and NotI restriction sites. The BeiPV PdC gene, where a silent mutation in the 
P gene knocked out the ATG start codon, was amplified with DM16 (MluI) and 
DM17 (AgeI) primers. The region between the MluI and AgeI sites of the pTM1-
BeiPV-P plasmid was replaced with the BeiPV-PdC fragment, creating the pTM1-
BeiPV-PdC plasmid. The BeiPV C ORF was amplified by PCR from the BeiPV-P 
clone, using DM43 (MluI) and DM44 (NotI) primers. The BeiPV C ORF was cloned 
into the pTM1 vector, creating pTM1-BeiPV-C.  
The BeiPV L ORF was cloned in multiple fragments. The 5’ section of the 
BeiPV L gene was amplified from BeiPV cDNA using DM18 (MluI) and DM22 (PvuII, 
NotI) primers, then cloned into the MluI and NotI sites of the pTM1 vector, creating 
the pTM1-BeiPV-L1 plasmid. The central region of the BeiPV L gene was amplified 
with B96 and B145 primers, and cloned into the SacI and NotI sites of the pGAN 
vector, generating pGAN-BeiPV-L2. The 3’ section of the BeiPV L gene was 
amplified by PCR using B35 and DM19 (NotI) primers and cloned into the StyI and 
SacI sites of the pGAN-BeiPV-L2 plasmid, generating pGAN-BeiPV-L2-L3. The 
BeiPV-L2-L3 fragment was cloned into the SalI and NotI sites of the pTM1-BeiPV-L1 
plasmid, generating pTM1-BeiPV-L1-L2-L3. To complete the cloning of the BeiPV L 
gene, the 900 bp region between the SalI sites of the BeiPV L ORF, which the 
pTM1-BeiPV-L1-L2-L3 plasmid lacked, was amplified by PCR using B152 and B153 
primers. The PCR product spanned the 1.4 kb region between the SacII and NheI 
sites of the L gene (encompassing the SalI to SalI region) and was cloned into the 
SacII and NheI sites of the pTM1-BeiPV-L1-L2-L3 plasmid, generating the pTM1-
BeiPV-L clone. 
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Sequencing 
All clones were confirmed by sequencing using the BigDye Terminator v1.0 
kit and ABI PRISM 377 DNA sequencer (both from Applied Biosystems, USA) in 
accordance with manufacturer’s recommendations. 
2.2.10 Minigenome functional studies 
FWPV-T7 infection of Vero cells 
The fpEFLT7pol virus (FWPV-T7) that stably expressed T7 RNA 
polymerase was kindly provided by M. Skinner (Britton et al. 1996). 
Vero cells were seeded into 96 well plates at 20,000 cells per well, in 200 
μL EMEM-10 and incubated overnight at 37°C with 5% CO2. After overnight 
incubation, media was removed and the cells were inoculated with 100 μL FWPV-T7 
in 2% FCS, at an m.o.i. of 5. The cells were incubated at 37°C for 2 hr. 
Transfection of Vero cells with minigenome and support plasmids 
After infection with FWPV-T7, virus inoculum was removed from the cells 
and replaced with transfection mix. The optimum ratio of plasmid concentrations in 
the minireplicon assay were pre-determined to be a mixture of 0.5 μg minigenome 
plasmid, 0.3 μg N plasmid, 0.2 μg P plasmid and 0.1 μg L plasmid. For each 
minireplicon assay, Lipofectamine 2000 (Invitrogen) was added to the plasmid DNA 
in a 3:1 ratio (3 μL Lipofectamine: 1 μg DNA) and then serum free EMEM was 
added to bring the final sample volume to 50 μL. After incubation for 30 min at room 
temperature, a further 100 μL of serum free EMEM was then added to the sample. 
This transfection mix was added to the FWPV-T7 infected cells and allowed to 
incubate at 37°C with 5% CO2 for 6 hr, after which time the transfection mix was 
removed and replaced with EMEM-10. Each minireplicon assay was performed in 
replicates of eight and each experiment was carried out at least three times. 
Transfected cells were incubated at 37°C with 5% CO2 for 72 hr and then observed 
using the IX71 microscope (Olympus, USA). 
Quantitation of GFP expression 
Cells were observed with the IX71 microscope (Olympus) and images were 
captured by the high resolution DP70 camera (Olympus) using the analysis® (Soft 
Imaging System, Germany) program. Cells expressing GFP were quantified using 
the Universal TEM Imaging Platform iTEM (Soft Imaging System) program. Briefly, 
individual fluorescent cells were detected by threshold analysis and subsequently 
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counted to determine the number of positive cells in each well. To ensure 
repeatability between images, all procedures were performed as a macro function 
with fixed parameters. The same magnification was used for each experiment and 
eight replicate wells were analysed for each condition. 
2.3 Results 
2.3.1 Production of the JPV L monospecific antibody 
Expression of recombinant JPV L protein 
The JPV L1 and L2 gene fragments were cloned into the pHMN vector and 
the recombinant L protein was expressed in E. coli. Proteins from cell lysates were 
separated by SDS-PAGE and a protein with a molecular mass of approximately 23 
kDa was detected. The recombinant JPV L2 protein was expressed at a high level in 
the insoluble fraction of the cell lysate (Figure 2.3A). The recombinant JPV L1 
protein failed to be expressed in E. coli, and was subsequently omitted from further 
experiments (data not shown). The 23 kDa JPV L2 protein (which will be referred to 
as JPV L from herein) was excised, and eluted from the SDS-PAGE gel. After 
several elutions (Figure 2.3B), sufficient protein, as determined by comparison with 
a known standard, was purified for immunisation of rabbits. 
Generation of antiserum 
The development of specific antibodies against the JPV L protein was 
evaluated by Western blot. Sera collected from rabbits on day 21 was analysed 
against the (His)6-tagged JPV L protein (the same protein used to immunise the 
rabbits) and a non-related viral protein, the (His)6-tagged SARS Nc protein. The 
Western blot demonstrated that antibodies in the sera from both rabbits readily 
detected the JPV L protein, but not the SARS Nc protein (Figure 2.4). These results 
indicated that the rabbits had mounted an immune response against the JPV L 
protein. Blood was collected from rabbits on days 0, 21 29, 48 and 51. 
To further demonstrate the specificity of the rabbit anti-sera, the samples 
were monitored against a GST-tagged JPV L protein. The Western blot provided 
evidence that antibodies in sera from both rabbits detected the JPV L protein (Figure 
2.5). Sera from both rabbits, at days 21 through 51, contained monospecific 
antibodies against the recombinant JPV L protein. 
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Figure 2.3- Expression and Purification of Recombinant JPV L Protein 
The insoluble fraction of the BL21(DE3), pHMN-JVP-L recombinant bacterial cell 
lysate was separated by SDS-PAGE (A). The 23 kDa JVP L band was excised and 
eluted from the gel in several fractions in order to determine the purity of the protein 
(B). The numbering (2.5 and 5) indicates the amount of protein (μL) loaded onto the 
gel. The arrows indicate the position of the predicted JVP L protein. The Precision 
Plus marker (Bio-Rad) was used to determine the MW (kDa) of proteins. 
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Figure 2.4- Evaluation of JPV L Antibody Production by Western Blot 
Sera samples collected from rabbits on day 21 were monitored against the (His)6-
tagged JPV L protein, and also a non-related viral protein, the (His)6-tagged SARS 
Nc protein on Western blot membrane strips. Dilutions of sera are indicated above 
each membrane strip. The anti-RGS-His6 MAb (+) was used as a positive control 
and pre-immune (PI) sera were used as a negative control. The goat anti-mouse 
(Chemicon) and goat anti-rabbit (Silenus) alkaline phosphatase conjugates were 
used for the detection of MAbs and rabbit sera, respectively. The arrow indicates the 
position of the predicted JVP L protein. The Precision Plus marker (Bio-Rad) was 
used to determine the MW (kDa) of proteins. 
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Figure 2.5- Evaluation of the Specificity of the JPV L Antiserum by 
Western Blot 
A Western blot containing the GST-tagged, JPV L protein was cut into strips and 
incubated with antisera collected from rabbits 517 and 518 on days (D) 21, 29, 48 
and 51 of the immunisation protocol. For each rabbit, pre-immune sera (PI) were 
included as a negative control and the anti-GST MAb as a positive control. One strip 
was incubated with rabbit JPV antiserum. The goat anti-mouse (Chemicon) and goat 
anti-rabbit (Silenus, Australia) alkaline phosphatase conjugates were used for the 
detection of MAbs and rabbit sera, respectively. The arrow indicates the position of 
the JPV GST-tagged protein. The Kaleidoscope marker (Bio-Rad) was used to 
determine the MW (kDa) of proteins. 
 79
2.3.2  Expression of recombinant JPV polymerase proteins 
JPV N, P and L polymerase genes were cloned into the pCIneo mammalian 
expression vector and transfected into Vero cells. Transfected cells were lysed and 
recombinant proteins were analysed by Western blot. To ensure that fowlpox virus 
expressing the T7 promotor did not interfere with the expression of JPV polymerase 
genes, JPV N transfected cells were also infected with FWPV-T7 and analysed. 
The rabbit JPV antiserum detected the recombinant JPV N (Figure 2.6) and JPV P 
(Figure 2.7) proteins. The JPV L protein was detected with the monospecific JPV L 
antiserum (Figure 2.8), from above. 
2.3.3 Construction of minireplicon systems 
Construction of minigenomes 
In each minigenome, the coding regions for all viral genes were replaced 
with a negative-sense copy of the GFP gene (Refer to Figure 2.2). The 5’ end of the 
GFP gene was flanked by the N 3’ UTR, gene start signal, viral leader, HDV 
cleavage sequence and two T7 terminator sequences. The 3’ end of the GFP gene 
was flanked by the L 5’ UTR, gene stop sequence, viral trailer and the T7 promoter. 
Transcription of the minigenome plasmids by the T7 polymerase generated RNA 
containing the GFP coding region, flanked by the viral genome terminal regions. The 
precise initiation site of the T7 promoter, and the self-cleavage of the RNA at the 3’ 
end by the HDV ribozyme, ensured that the minigenome RNA produced had the 
identical genome termini as the complete viral genomic RNA. 
Minigenome plasmids were constructed for NiV, JPV and BeiPV and 
designated pNiV-GFP, pJPV-GFP and pBeiPV-GFP, respectively. Sequence 
analysis showed that the pNiV-GFP contained a PCR induced mutation in NiV N 
UTR at position 92 of the NiV genome (a92g change), but this mutation seemed to 
have no effect on NiV minireplicon function (see Section 2.3.4). No mutations were 
generated in the construction of either JPV or BeiPV minigenomes. 
Construction of support plasmids 
The NiV support plasmids consisted of the NiV N, P and L genes, cloned 
individually into the pTM1 vector (pTM1-NiV-N, pTM1-NiV-P and pTM1-NiV-L, 
respectively) as previously described (Halpin et al. 2004). The NiV-P plasmid 
contained two mutations that eliminated both predicted translation start sites of the 
C ORF. A wild-type NiV-P construct was not generated.  
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Figure 2.6- Analysis of JPV N Expression in Mammalian Cells by 
Western Blot 
The Western blot was incubated with rabbit JPV antiserum and a goat anti-
rabbit (Silenus) alkaline phosphatase conjugate was used for the detection of the 
rabbit serum. The arrow indicates the position of the predicted JPV N protein. The 
Kaleidoscope marker (Bio-Rad) was used to determine the MW (kDa) of proteins. 
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Figure 2.7- Analysis of JPV P Expression in Mammalian Cells by 
Western Blot 
The Western blot was incubated with rabbit JPV antiserum and a goat anti-
rabbit (Silenus) alkaline phosphatase conjugate was used for the detection of the 
rabbit serum. The arrow indicates the predicted position of the JPV P protein. The 
Kaleidoscope marker (Bio-Rad) was used to determine the MW (kDa) of proteins.
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Figure 2.8- Analysis of JPV L Expression in Mammalian Cells by 
Western Blot 
The Western blot was incubated with rabbit JPV antiserum and a goat anti-
rabbit (Silenus) alkaline phosphatase conjugate was used for the detection of the 
rabbit serum. The arrow indicates the predicted position of the JPV L protein. The 
Kaleidoscope marker (Bio-Rad) was used to determine the MW (kDa) of proteins. 
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The N, P and L genes of JPV and BeiPV were amplified from cDNA and 
cloned into the pTM1 expression vector. The sequences of the cloned N, P and L 
genes of JPV and BeiPV were compared to the published genome sequences for 
each virus. The JPV N and P, PdC and C gene sequences were both identical to the 
wild-type sequences. The JPV L gene contained a silent mutation (c to t) at position 
4275 of the L ORF. 
Two mutations were present in the BeiPV N ORF. The BeiPV N gene 
contained a mutation that altered an amino acid in the N protein from an alanine to a 
proline (g424c), and a silent (c999t) mutation. The BeiPV P ORF also contained two 
mutations. One mutation altered an amino acid in the P protein from a threonine to a 
methionine (c404t), and the other mutation was silent (c1395t). As the BeiPV PdC 
gene was constructed from pTM1-BeiPV-P, the same two mutations that were 
present in the BeiPV P ORF were also present in the BeiPV PdC ORF. The BeiPV C 
gene contained a silent mutation (t234c) in the C ORF. There were four mutations 
generated in the cloning of the BeiPV L gene. Three of the mutations (a1422g, 
g1842a and t1491c) in the BeiPV L ORF were silent, and one (t5548a) substituted 
the amino acid threonine with a serine. Since the mutations in the BeiPV support 
plasmids were either silent or located in non-conserved regions of the BeiPV genes, 
these mutations were not corrected, given that all minireplicon systems seemed to 
function as expected (see Section 2.3.4). 
2.3.4 Functional minireplicon assays 
NiV, JPV and BeiPV minireplicon systems 
GFP expression was observed 72 hr after transfection of pNiV-GFP into 
Vero cells that had been previously infected with FWPV-T7 and co-transfected with 
the NiV N, P and L support plasmids (Figure 2.9A). This result demonstrated that 
transfection of the pNiV-GFP minigenome, in conjunction with the NiV N, P and L 
genes produced a functional minireplicon system. Each of the NiV N, P and L 
plasmids was required for the formation of the vRdRp, and GFP was not 
synthesised when any of these plasmids were omitted from the NiV minireplicon 
system (Figure 2.9B). As with the homotypic combination of the pNiV-GFP 
minigenome and NiV support plasmids, GFP was synthesised in FWPV-T7 infected 
cells, 72 hr after transfection of the pJPV-GFP minigenome and the JPV N, P and L 
support plasmids (Figure 2.9C). The JPV minireplicon system was not functional 
when any of the JPV support plasmids were omitted from the transfection mix 
(Figure 2.9D).  
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Figure 2.9- GFP Expression in NiV, JPV and BeiPV Minireplicon 
Systems 
Vero cells in 96 well plates were used for transfection. The pNiV-GFP plasmid was 
transfected with the NiV N, P and L support plasmids (A), and with the NiV N and P 
support plasmids, without the L support plasmid (B). The pJPV-GFP plasmid was 
transfected with the JPV N, P and L support plasmids (C), with the JPV N and P 
support plasmids, without the L support plasmid (D). The pBeiPV-GFP plasmid was 
transfected with the BeiPV N, P and L support plasmids (E), with the BeiPV N and P 
support plasmids, without the L support plasmid (F). Photographs were taken at 72 
hr post-transfection, at a magnification of 40X. 
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Although the JPV minireplicon system was functional, the level of GFP 
expression was lower than that of NiV minireplicon system. Similar results were 
obtained for the BeiPV minireplicon system (Figure 2.9E and F). These results 
indicated that the minireplicon systems for NiV, JPV and BeiPV were functional and 
when the minigenome plasmid was provided with homotypic support plasmids, 
synthesis of GFP occurred, although not at equivalent levels. 
Examination of the ‘rule of six’ for JPV and BeiPV  
JPV and BeiPV minigenomes of differing lengths were constructed. The 
minigenomes which contained an additional four nucleotides in the N UTR, (pJPV-
GFP(+4) and pBeiPV-GFP(+4)) were transfected with homotypic support plasmids 
in order to determine if the minireplicon systems were functional when the 
minigenome was not evenly divisible by six. In these cases, GFP was not produced 
in either JPV or BeiPV minireplicon system (data not shown), demonstrating that 
both JPV and BeiPV minigenomes must be divisible by six, suggesting that these 
viruses obey the ‘rule of six’. 
Effect of the C protein on the replication of the JPV and BeiPV minireplicon 
There is evidence that C protein expression from the P gene is inhibitory in 
minireplicon ststems. There is also evidence that the inhibiton is dose dependent 
(Malur et al. 2004). To determine the effect of the C protein on the JPV and BeiPV 
minireplicon systems, either the pJPV-GFP or pBeiPV-GFP plasmid was transfected 
with homotypic support plasmids, including the P gene or the P gene with the C 
ORF silenced (PdC). Transfection studies with the two different versions of the P 
genes showed that although GFP was expressed in both JPV and BeiPV 
minireplicon systems, the level of GFP expression was lower when the ‘wild-type’ P 
support plasmid was used. To further analyse the effect of the C protein on 
replication, the minireplicon systems were supplemented with the C gene in a dose 
dependant manner, with the C plasmid supplied at concentrations ranging from 0.02 
ng to 2000 ng. Results demonstrated that as the level of C plasmid increased, the 
level of GFP expression significantly decreased. In both JPV and BeiPV minireplicon 
systems, the C protein had an inhibitory effect at plasmid levels of 100 ng and 
above. At plasmid levels of 0.02 ng to 100 ng, the level of GFP expression was 
variable. GFP expression, normalised to mean fluorescence for the minireplicon 
containing the PdC support plasmid, which was set at 100%, is given in Figure 
2.10A for JPV and Figure 2.10B for BeiPV.  
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Figure 2.10- Effect of the C Protein on JPV and BeiPV Minireplicon 
Systems 
The pJPV-GFP and pBeiPV-GFP plasmids were transfected with homotypic JPV 
and BeiPV support plasmids, including the P gene or the P gene with the C ORF 
silenced (PdC). The JPV and BeiPV minireplicon systems were supplemented with 
the C plasmid at a range of 0.02 ng to 2000 ng. Levels of GFP expression, 
normalised to mean fluorescence for the minireplicon containing the PdC support 
plasmid (set at 100%) are shown for the JPV (A) and BeiPV (B) minireplicon 
systems. 
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The levels of GFP expression in both JPV and BeiPV minireplicon systems, 
where 200 ng of C plasmids were added with the PdC support plasmids, were 
similar to GFP expression level in the minireplicon systems with the ‘wild-type’ P 
support plasmids. As the P support plasmid was fixed at a concentration of 200 ng 
in the minireplicon system, this result indicated that the C protein was expressed 
from both the P plasmid and the C plasmid, at comparable levels. 
2.4 Discussion 
The gene expression strategy utilised by NNSV involves replication of the 
ribonucleoprotein complex and sequential synthesis of mRNA. Neither the genomic 
nor antigenomic RNA alone is capable of initiating an infectious cycle. Reverse 
genetics allows genetic manipulation of the viral genome and rescue infectious virus 
particles from entirely engineered clones. Minireplicon systems are generated by 
replacing the entire protein coding region of a viral genome with a reporter gene. 
Minireplicon systems allow the function of cis and trans-acting sequences at the 
terminal ends of the viral genome to be determined. Function of the proteins that 
form the polymerase complex (derived from the N, P and L genes) may also be 
studied using a minireplicon system. 
Minireplicon systems utilising GFP as a reporter gene were created for NiV, 
JPV and BeiPV. In all minigenomes, the coding regions of the virus were replaced 
with the GFP gene, but the viral genomic termini remained intact. Insertion of either 
the genome or antigenome into a full-length infectious clone leads to the production 
of infectious virus (Kato et al. 1996). The expression of a reporter gene in a 
minireplicon system is also possible when the minigenome is engineered in negative 
or positive polarity, but the polarity of foreign genes determines the efficiency of 
gene expression. Hybridisation of negative-sense, genomic RNA, and positive-
sense RNA from protein-encoding plasmids, produced simultaneously during 
transcription, is detrimental (Epstein et al. 2006), may evoke an IFN response in the 
host cell, (Conzelmann 1998) and should be avoided. For these reasons, the GFP 
gene was engineered in the reverse orientation in the NiV, JPV and BeiPV 
minigenomes. 
Reporter genes in minireplicon systems function in the quantitation of 
rescued synthetic RNA. Vast arrays of reporter genes are available and the CAT 
gene has historically been the gene of choice in the construction of minireplicon 
systems since this reporter gene was first expressed in a SeV minigenome (Park et 
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al. 1991). Protocols involving construction of CAT plasmids have been modified in 
attempts to optimise the rescue of this foreign gene via reverse genetics techniques. 
High background levels of CAT expression in conventional assays have been 
avoided by using radioactive methods in the detection of CAT, rather than enzyme-
linked immunosorbent assay (ELISA) (Khromykh & Westaway 1997). Green 
fluorescent protein (Watanabe et al. 2004), β-glucuronidase (Izeta et al. 1999) and 
fire fly luciferase (Kato et al. 1996) are all reporter molecules that are detected by 
chemiluminescence. Secreted placental alkaline phosphatase (SAEP) (Barretto et 
al. 2003) and β-galactosidase (Tang et al. 2001) also function as reporters. The 
GFP reporter gene was chosen for the NiV, JPV and BeiPV minireplicon systems as 
GFP is able to be visualised in live cells, hence allowing real-time observation of 
experiments, without disrupting cells. Background fluorescence is not observed in 
cells where GFP is not expressed, making experimental results easier to quantify. 
Support plasmids (N, P and L) were required to form the vRdRp, and the 
genes encoding the polymerase proteins were cloned individually into the pTM1 
expression vector (or supplied, in the case of NiV). Polymerase genes were under 
the control of a T7 promotor. The bacteriophage T7 RNA polymerase has been 
integrated into the FWPV genome by Britton et al. (1996), under the control of the 
VACV early/late promotor. The recombinant virus, fpEFLT7pol, able to stably 
express T7 RNA polymerase in avian and mammalian cells, undergoes abortive 
replication in mammalian cells, and infectious virus is not produced. FWPV-T7 was 
chosen as the source of the T7 polymerase, as FWPV is less cytopathic than VACV, 
and a stable cell line expressing T7 was not readily available. 
The ‘rule of six’ states that the replication of paramyxoviruses is more 
efficient when the total number of nucleotides in the viral genome is divisible by six 
(Calain & Roux 1993). This is because the RNA polymerase initiates more efficiently 
when cis-acting promotor sequences are found in the correct context with relation to 
N subunits, determined by the length of the entire genome (Hausmann et al. 1996). 
The ‘rule of six’ not only applies to genome replication, but also transcription of a 
minigenome. The sequence corresponding to the viral 3’ terminal region, 
representing the end of a paramyxovirus genome must also be present for the 
genome to be functional. This criterion, in conjunction with the requirement for the 
genome/reporter to obey the ‘rule of six’, was able to be fulfilled by inserting a 
ribozyme sequence, providing a template for autocatalytic cleavage of the genome. 
The HDV ribozyme sequence is more efficient than the hammerhead ribozyme 
(Fearns et al. 1997), with a higher rate of cleavage. The HDV ribozyme sequence 
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mediates efficient self-cleavage of the 3’ terminus of the minigenome RNA, and was 
engineered to ensure that the minigenomes were divisible by six. 
In a NiV-CAT replication system, CAT was only produced when the 
minigenome was divisible by six (Halpin et al. 2004). In the same study, CAT was 
produced when a HeV minigenome divisible by six was transfected with the NiV 
support plasmids. This phenomenon was also observed for SeV (Tapparel et al. 
1997) and NDV (Barretto et al. 2003). Minigenomes of JPV and BeiPV, with four 
additional nucleotides, were not divisible by six, and subsequently failed to express 
GFP. These results indicated that in order to maintain efficient replication, both JPV 
and BeiPV comply with the ‘rule of six’. The length of the genomes of NiV, JPV and 
BeiPV are multiples of six. The conclusion that a functional reverse genetics system 
for paramyxoviruses must obey the ‘rule of six’ is supported. 
The majority of studies indicate that the expression of the C protein inhibits 
the transcription of a minigenome, and results from JPV and BeiPV minireplicon 
experiments confer with these previous studies. Silencing of the C gene from the 
JPV and BeiPV P support plasmids resulted in increased GFP expression from the 
minigenomes. When the C protein from either JPV or BeiPV was incorporated into 
the JPV and BeiPV minireplicon assay, respectively, by expression from a separate 
plasmid, GFP expression decreased. The decrease in GFP expression, in both JPV 
and BeiPV minireplicon systems, occurred in a dose dependent manner. Similarly, 
the decrease in luciferase activity when either the HPIV3 or SeV C gene was 
included in a HPIV3 minireplicon system was also dose dependent (Malur et al. 
2004). 
There is overwhelming support for the conclusion that the C protein of 
paramyxoviruses is inhibitory to transcription in reverse genetics systems. Although 
inhibitory, the non-structural C protein may have an essential role in paramyxovirus 
replication. The formation of virus-like particles (VLPs) can be used as a model for 
virus budding. The SeV C protein interacts with AIP1/Alix, a host protein involved in 
apoptosis and endosomal membrane trafficking, and this interaction facilitates 
budding of SeV VLPs (Sakaguchi et al. 2005). Co-expression of the SeV C gene 
with the M, N, F and HN genes resulted in enhanced VLP release, suggesting that 
the SeV C protein has a role in virus budding (Sugahara et al. 2004). The SeV C 
protein co-localises with the M protein in the cytoplasm and may act as a chaperon 
to convert newly synthesised M proteins into assembly initiating forms (Hasan et al. 
2000). Taken together, these studies with the SeV C protein support the hypothesis 
that the C protein is essential in virus assembly. There is a possibility that the C 
protein is only inhibitory once expression levels reach a threshold, and in a viral 
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infection this expression level is likely to be regulated. In order to draw any 
conclusion about the effect of C protein expression on viral replication of JPV or 
BeiPV, it would be necessary to study the protein in the context of a full-length 
infectious clone, as research on paramyxovirus C proteins varies depending on 
reverse genetics system or particular virus used. 
The studies described in this chapter aimed to generate functional reverse 
genetics systems for JPV and BeiPV, two recently characterised rodent 
paramyxoviruses. The successful establishment of these reverse genetics systems 
have allowed JPV and BeiPV to be further characterised and have aided in the 
classification in these rodent viruses, as described in subsequent chapters. 
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CHAPTER 3 
Use of Minireplicon Systems to Study Virus Evolution 
and Classification 
3.1 Introduction 
The family Paramyxoviridae is taxonomically placed within the order 
Mononegavirales together with three other families- Filoviridae, Bornaviridae, and 
Rhabdoviridae. All members of these viral families contain a NNS genome. The 
family Paramyxoviridae is divided into two subfamilies- Paramyxovirinae and 
Pneumovirinae. Classification of viruses at the subfamily level is based on 
morphological appearance, genome organisation, biological activity of proteins and 
the sequence relationship between encoded proteins (Lamb et al. 2000). At present, 
the subfamily Paramyxovirinae is divided into five genera- Morbillivirus, 
Respirovirus, Rubulavirus, Avulavirus and Henipavirus (Pringle 2005). 
At least four novel paramyxoviruses, NarPV (Tikasingh et al. 1966), MosPV 
(Campbell et al. 1977), JPV (Jun et al. 1977) and BeiPV (Li et al. 2006) have been 
isolated from rodents since the 1960s. JPV was isolated on four separate occasions 
via kidney autoculture of trapped wild mice (Mus musculus), during an investigation 
into the pathology of feral rodents in northern Queensland, Australia, in 1972 (Jun et 
al. 1977; Mesina et al. 1974). The entire genome of JPV has been sequenced and 
contains 18,954 nucleotides (Jack et al. 2005). BeiPV was initially identified in a 
human mesangial cell line, but was later isolated from a rat mesangial cell line, 
which is believed to be the original source of the virus (Li et al. 2006). The genome 
of BeiPV has been completely sequenced and the genome organisation is similar to 
JPV. At 19,212 nucleotides in length the BeiPV genome is the largest in the family 
Paramyxoviridae sequenced to date. In fact, the BeiPV genome is also the largest 
among all known NNSV in the order Mononegavirales. 
NiV and HeV both belong to the genus Henipavirus. Recently, the 
suggestion was made that BeiPV is closely related to the henipaviruses, and should 
be classified as a member of this genus (Schomacker et al. 2004). Previous studies 
have demonstrated that in a reverse genetics system, replication of a viral 
minigenome can be driven by the polymerase complex of another closely related 
virus within the same genus (Pelet et al. 1996). 
Reverse genetics systems for NiV, JPV and BeiPV were established as 
detailed in Chapter 2. Using these reverse genetics systems, the evolutionary 
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relatedness of NiV, JPV and BeiPV was investigated by exchanging individual viral 
minigenomes and polymerase complexes. The relatedness between JPV and BeiPV 
was further investigated by exchanging individual viral polymerase proteins and 
examining the effect on polymerase complex formation. The NiV and JPV reverse 
genetics systems were also used to examine the function of the conserved 
GDNE/GDNQ motif of the NiV and JPV L polymerase proteins. 
3.2 Materials and Methodology 
3.2.1 Construction of minireplicon systems 
Construction of NiV, JPV and BeiPV minireplicon systems 
Minireplicon systems were constructed for NiV, JPV and BeiPV, as detailed 
in Chapter 2, Sections 2.2.7 (NiV), 2.2.8 (JPV) and 2.2.9 (BeiPV), respectively. 
Construction of JPV and BeiPV hybrid minigenomes 
Hybrid minigenomes were generated, where the leader and trailer regions 
of JPV and BeiPV were exchanged. The JPV minigenome, pJPV-GFP, was used as 
a template for the construction of both hybrid minigenomes. As the leader and trailer 
region of JPV contain the same number of nucleotides as the respective leader and 
trailer region of BeiPV, both hybrid minigenomes were divisible by six. 
The first hybrid minigenome was constructed by replacing the 3’ N gene 
UTR of JPV with the BeiPV 3’ N gene UTR. The BeiPV 3’ N UTR was amplified from 
cDNA with the DM10 and DM11 (NcoI) primers. This PCR product was used as a 
template in a subsequent PCR reaction, with the DM03 (NarI) and DM11 (NcoI) 
primers. The DM03 primer extended the BeiPV genome specific PCR into the HDV 
region and added the NarI restriction site to the product. The PCR product 
containing the 3’ terminus of the BeiPV minigenome was cloned into the NarI and 
NcoI sites of the pJPV-GFP minigenome, hence replacing the 3’ JPV terminus with 
the 3’ BeiPV terminus. The hybrid GFP minigenome, pBle-GFP-Jtr, contained the 
BeiPV 3’ terminus, and the JPV 5’ terminus (Figure 3.1A). 
The second hybrid minigenome was constructed by replacing the L 5’ UTR 
of JPV with the BeiPV L 5’ UTR. The BeiPV L 5’ UTR was amplified from cDNA with 
DM12 (HindIII) and DM13 (NotI) primers. The PCR product containing the 5’ 
terminus of the BeiPV minigenome was cloned into the HindIII and NotI sites of the 
pJPV-GFP minigenome, consequently replacing the 5’ JPV terminus with the 5’ 
BeiPV terminus. The hybrid GFP minigenome, pJle-GFP-Jtr, contained the JPV 3’ 
termini and the BeiPV 5’ terminus (Figure 3.1B). 
 93
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1- JPV and BeiPV Hybrid Minigenomes 
Hybrid minigenomes were generated where the leader and trailer regions of 
JPV and BeiPV were exchanged. The hybrid GFP minigenome, pBle-GFP-Jtr, 
contained the BeiPV 3’ terminus, with the JPV 5’ terminus (A). The hybrid GFP 
minigenome, pJle-GFP-Btr, contained the JPV 3’ terminus, with the BeiPV 5’ 
terminus (B). 
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3.2.2 Mutagenesis of the NiV and JPV L genes 
Mutagenesis of the NiV L gene 
To obtain the GDNQ mutation in the NiV L gene, site directed mutagenesis 
was performed. The pTM1-NiV-L plasmid was used as a template for PCR, with the 
primers DM28 (BsiWI) and DM29 (BstBI). These primers amplified a 1616 bp 
fragment, spanning from the BstBI restriction site to the BsiWI restriction site of the L 
gene. A second PCR of 217 bp was amplified with the DM29 (BstBI) reverse primer 
and DM30 (StyI) forward primer containing point mutations to alter the E residue of 
the conserved GDNE sequence into a Q residue. Each of the forward primers in the 
mutagenesis PCR reactions contained a StyI restriction site. The GDNE sequence 
contained a StyI site that was unique between the BstBI and BsiWI sites of the NiV L 
gene. The two PCR products were digested with StyI, ligated together, and the 
ligation product was used as a template for a third PCR, with the primers DM28 
(BsiWI) and DM29 (BstBI). Both the pTM1-NiV-L vector and the GDNQ PCR 
products were digested with BstBI and BsiWI, and ligated. The resulting pTM1-NiV-L 
clone contained the GDNQ motif, as a replacement for the GDNE motif. 
Using the strategy above employed to create the GDNQ mutant, NiV L 
plasmids were constructed to contain GDND, GDNA, GDNN, GDNI and GDNG 
motifs. Forward primers used for the mutagenesis of the GDNE motif were DM37 
(StyI), DM38 (StyI), DM39 (StyI), DM40 (StyI) and DM41 (StyI) for GDND, GDNA, 
GDNN, GDNI and GDNG, respectively. 
Mutagenesis of JPV L gene 
To obtain the GDNE mutation in the JPV L gene, site directed mutagenesis 
was performed. The pHMN-JPV-L plasmid was used as a template for PCR with the 
primers PJ53 and PJ138. These primers amplified a 499 bp fragment, spanning 
from the PciI restriction site to the BlpI restriction site of the JPV L gene. A second 
fragment of 459 bp was amplified with the DM27 (PstI) and PJ138 primers. Primer 
DM27 contained point mutations to alter the Q residue of the conserved GDNQ 
sequence into an E residue. The two PCR products were digested with PstI, ligated 
together and the ligation product was used as a template for a third PCR with the 
primers PJ53 and PJ138. Both the pCIneo-JPV-L construct, and GDNE PCR 
product, were digested with PciI and BlpI and ligated. The resulting pCIneo-JPV-L 
clone contained the GDNE motif as a replacement for the GDNQ motif. The JPV-L 
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fragment containing the GDNE motif was then removed from the pCIneo plasmid 
and cloned into the pTM1 plasmid, using the MluI and NotI restriction sites. 
3.2.3 Functional studies using JPV, NiV and BeiPV minigenomes 
Functional studies were carried out with NiV, JPV and BeiPV minireplicon 
systems. All minireplicon assays were performed under the same conditions as 
described in Chapter 2, Section 2.2.10, unless otherwise stated. 
3.2.4 Detection of the NiV L protein by radioimmunoprecipitation 
Antibodies 
The NiV rabbit antiserum, supplied by Chris Morrissy, was obtained from 
rabbits immunised at AAHL. 
Transfection and infection of Vero cells 
Vero cells were seeded into 6 well plates at 5 X 105 cells per well in 3 mL 
EMEM-10 and incubated overnight at 37°C, with 5% CO2. Cells were transfected 
with 2 μg of plasmid DNA using Lipofectamine 2000 (Invitrogen), as described in 
Section 2.2.4. Following a 6 hr transfection, cells were infected with VACV-T7 
(Fuerst et al. 1986), at an m.o.i. of 10, in EMEM containing 2.5% FCS. After allowing 
infection to proceed for 6 hr, the NiV proteins were metabolically labelled.  
35S labelling of transfected Vero cells 
Transfected NiV proteins were metabolically labelled with [35S] Methionine-
Cysteine (Amersham Pharmacia Biotech, USA). For 35S metabolic labelling, the 
virus and media were removed from transfected cells and replaced with L-
methionine and L-cysteine free EMEM (MP Biomedicals), containing 2.5% FCS and 
100 μCi of 35S-Met/Cys. Cells were incubated overnight at 37°C, with 5% CO2. 
Radioactive media was removed and replaced with EMEM-10 for a 2 hr chase. 
Lysis of 35S metabolically labelled Vero cells 
Cells were harvested by centrifugation and lysed in ice-cold lysis buffer 
containing 100 mM Tris-HCL (pH 8.0), 100 mM NaCl and 1% Triton-X-100. Nuclei 
were removed by centrifugation and supernatant was incubated with Protein G–
Sepharose (Amersham Biosciences) for 45 min to pre-clear. Following the 45 min 
pre-clear, 2 μL of rabbit NiV antiserum was added to each immunoprecipitation 
mixture, and incubated at 4°C for 1 hr. Following the incubation, Protein G–
Sepharose (Amersham Biosciences) was added and incubated for a further 45 min. 
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Bead complexes were washed three times with lysis buffer, and boiled at 100°C in 
reducing buffer (0.04% (w/v) bromophenol blue, 6% (w/v) SDS, 190 mM Tris-HCl pH 
6.5, 45% (v/v) glycerol, 15% (v/v) 2-β mercaptoethanol) for 5 min. Proteins were 
separated by SDS-PAGE on a 4-12% NuPage Novex Bis-Tris gradient gel 
(Invitrogen). Following SDS-PAGE, gels were fixed overnight, in a solution 
containing 40% methanol and 10% acetic acid. 
Autoradiography 
Fixed, radioactive gels were dried onto filter paper using a vacuum gel drier 
(Labconco, USA) at 80°C, for 60 min, and then exposed to Blue XB-1 Kodak 
Scientific Imaging film (Kodak, USA) for autoradiography. Autoradiographs were 
developed using Ilford Phenisol High Contrast Film Developer and Ilford Rapid Fixer 
(Ilford, UK). 
3.3 Results 
3.3.1 Exchange of leader and trailer regions of JPV and BeiPV 
In order to ascertain the degree of functional similarity between the non-
coding regions of JPV and BeiPV, hybrid minigenomes were generated where the 
leader or trailer region was exchanged between the two viruses. The leader region 
of the BeiPV minigenome was replaced with the JPV leader region in the pJle-GFP-
Btr minigenome, and the leader region of the JPV minigenome was replaced with 
the BeiPV leader region in the pBle-GFP-Jtr minigenome. Hybrid minigenomes were 
transfected with JPV support plasmids, and transfected cells were observed 72 hr 
post transfection. Both hybrid minigenomes were efficiently transcribed by the JPV 
support plasmids. There was no significant difference in level of GFP expression 
between the hybrid minigenomes, or between each hybrid minigenome and the JPV 
minigenome (data not shown). 
Comparative analysis of the minigenomes at the nucleotide level revealed 
the combined leader region and N gene UTR of JPV and BeiPV were the same 
length, and share 64% homology. In contrast, the combined trailer region and L 
gene UTR of JPV and BeiPV, although the same length, were only 55% identical. 
3.3.2 Exchange of NiV, JPV and BeiPV minigenomes and polymerase 
proteins 
To determine the relatedness between NiV, JPV and BeiPV, the 
functionality of each minigenome was analysed when support plasmids were 
 97
supplied in heterotypic combinations in the minireplicon systems. Results from 
Chapter 2, Section 2.3.4 demonstrated that the minireplicon systems for NiV, JPV 
and BeiPV were functional. When the NiV, JPV or BeiPV minigenome plasmids 
were provided with homotypic support plasmids, synthesis of GFP occurred, 
although not at equivalent levels (Figure 3.2A, E and I for NiV, JPV and BeiPV, 
respectively). When the pJPV-GFP minigenome was co-transfected with the BeiPV 
N, P and L support plasmids, GPF expression was observed, indicating that the 
BeiPV N, P and L plasmids formed a polymerase complex capable of transcribing 
the minigenome of JPV (Figure 3.2H). To prove that the JPV polymerase complex 
could transcribe the BeiPV minigenome, the JPV N, P and L support plasmids were 
co-transfected with the pBeiPV-GFP minigenome. Cells were analysed 72 hr after 
transfection, and GFP expression was observed (Figure 3.2F). The level of GFP 
expression for the heterotypic minireplicon combinations was generally higher than 
that of the homotypic combinations. These results indicated that the polymerase 
complexes of JPV and BeiPV were interchangeable, suggesting that the relatedness 
of these viruses was high enough for them to share replication machinery. 
In contrast, when the pNiV-GFP minigenome was co-transfected with either 
BeiPV or JPV N, P and L support plasmids, GFP expression was not detected 
(Figure 3.2D and G). The same was true when the NiV N, P and L support plasmids 
were co-transfected with either JPV or BeiPV minigenomes (Figure 3.2B and C). 
These results indicated that the NiV polymerase complex was not capable of 
supporting the replication of either the BeiPV or JPV minigenomes. 
3.3.3 Exchange of individual JPV and BeiPV polymerase proteins  
The exchange of JPV and BeiPV polymerase proteins did not impinge on 
the functionality of either the JPV, or the BeiPV minireplicon system. In order to 
determine whether a functional polymerase could be produced through heterotypic 
protein-protein interactions between individual JPV and BeiPV polymerase proteins, 
support plasmids were exchanged in JPV and BeiPV minireplicon systems. There 
were six possible support plasmid combinations to be used in conjunction with the 
JPV and BeiPV minigenomes, and these combinations are listed in Table 3.1. GFP 
expression was not evident in any of the twelve combinations (data not shown). 
These results indicated that although the JPV and BeiPV polymerase complexes 
could be exchanged, the individual N, P and L proteins were not interchangeable 
between the viral minireplicon systems. The results suggested that that the JPV and 
BeiPV polymerase proteins were unable to interact to form a functional polymerase 
complex. 
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Figure 3.2- Exchange of NiV, JPV and BeiPV Minigenomes and 
Polymerase Proteins 
The pNiV-GFP minigenome plasmid was transfected with the NiV, JPV and 
BeiPV support plasmids (A, D and G, respectively). The pJPV-GFP minigenome 
plasmid was co-transfected with the NiV, JPV and BeiPV support plasmids (B, E 
and H, respectively). The pBeiPV-GFP minigenome plasmid was co-transfected with 
the NiV, JPV and BeiPV support plasmids (C, F and I, respectively).  
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Table 3.1- Minireplicon Support Plasmid Combinations 
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3.3.4 Mutagenesis of NiV and JPV L gene 
Mutagenesis of the E residue in the conserved GDNE motif of the NiV L 
protein 
Replacement of the E residue of the NiV L GDNE motif with a Q residue 
was achieved by site directed mutagenesis. The activity of NiV L-GDNE (wild-type) 
was compared with that of NiV L-GDNQ, the sequence motif common to most other 
NNSV. Replacing the NiV-L plasmid with NiV-L-GDNQ did not result in a loss of 
GFP production from the minigenome in Vero cells. There was no significant 
difference in the GFP expression level between the minireplicon system containing 
the NiV L-GDNE plasmid (Figure 3.3A) and the minireplicon system containing the 
NiV L-GDNQ plasmid (Figure 3.3B). GFP expression was not evident in the negative 
control, where the L plasmid was omitted from the minireplicon system (Figure 
3.3C). 
To establish whether activity of the NiV polymerase could be affected by 
introducing a bulky, positively charged residue, or a residue known to disrupt protein 
secondary structure, two additional L gene mutants, GDNK and GDNP, were 
constructed. These amino acid substitutions abolished GFP expression, 
demonstrating that the K and P residues were not tolerated at this position (Figure 
3.4). 
To further determine the tolerance range of amino acid substitutions of the 
E residue in the GDNE motif of the NiV L protein, five additional L gene mutants 
were constructed. NiV L plasmids were constructed to contain GDND, GDNA, 
GDNN, GDNI and GDNG motifs. The mutant L plasmids replaced the wild-type L 
plasmid in the NiV minigenome assay, and although GFP expression was evident, 
the level of GFP produced was significantly lower (P < 0.01). GFP fluorescence of 
these minireplicon assays are displayed in Figure 3.4. The mean number of 
fluorescent cells per field of view for the GDND, GDNA, GDNN, GDNI and GDNG 
minigenome assays were 29%, 8%, 4%, 40% and 2% of wild-type, respectively 
(Figure 3.5). Although actual levels of GFP expression were considerably variable 
between minireplicon assays, these results were representative of the general trend 
observed across experiments.  
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Figure 3.3- Exchange of the E Residue with a Q Residue in the 
Conserved NiV GDNE Motif 
The NiV minigenome plasmid and the NiV N and P support plasmids were 
transfected with the NiV L-GDNE plasmid (A) and the NiV L-GDNQ plasmid (B), or 
the L plasmid was omitted from the minireplicon system (C). 
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Figure 3.4- Amino Acid Substitutions of the E Residue in the 
Conserved NiV GDNE Motif 
The NiV minigenome plasmid and the NiV N and P support plasmids were 
transfected without the NiV L plasmid (-L) or with the NiV L plasmids containing the 
GDNE, GDNQ, GDNK, GDNP, GDND, GDNA, GDNN, GDNI and GDNG motifs.  
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Figure 3.5- Quantitation of GFP in NiV Minireplicon Assays with 
Modified GDNE Motif 
The NiV minigenome plasmids were provided with mutant NiV L support 
plasmids, in minireplicon assays. The mean number of fluorescent cells per field of 
view for GDNE, GDNQ, GDNK, GDNP, GDND, GDNA, GDNN, GDNI and GDNG 
minireplicon assays are given. 
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The results from the NiV minireplicon assays demonstrated that the E 
residue within the GDNE motif was interchangeable with a Q residue. Furthermore, 
although the E residue could be replaced with D, A, N, I and G residues, albeit with 
considerable reduction in activity, replacement with K or P residues resulted in 
complete abrogation of polymerase activity in the NiV minireplicon system. 
Attempted quantitation of expression of the mutant NiV L proteins 
A radioimmunoprecipitation assay was performed using a rabbit anti-NiV 
antibody to compare the expression of the mutant NiV L proteins. The NiV L genes 
were transiently transfected into Vero cells, and gene expression was driven by 
VACV T7 polymerase. Proteins were metabolically labelled with [35S] Methionine-
Cysteine and precipitated with the anti-NiV antibody. Proteins were separated by 
SDS-PAGE and visualised by autoradiography. The predicted molecular mass of the 
NiV L proteins was 257 kDa. The NiV L protein was not visible on the 
autoradiograph (data not shown). 
Mutagenesis of the Q residue in the conserved GDNQ motif of the JPV L 
protein 
The Q residue of the JPV L GDNQ motif was replaced with an E residue by 
site directed mutagenesis. The level of GFP expression in a minireplicon system 
containing the JPV L GDNQ (wild-type) plasmid was compared with a minireplicon 
system containing the JPV L GDNE plasmid. There was no significant difference in 
the GFP expression level between both minireplicon systems across several 
experiments. The mean number of fluorescent cells per field of view in a 
representative minireplicon assay is given in Figure 3.6A. This data, where the 
mean fluorescence of the JPV L GDNE minireplicon is expressed as a percentage 
of the wild-type JPV L GDNQ minireplicon is given in Figure 3.6B. These results 
demonstrated that the JPV L GDNQ and GDNE residues were interchangeable. 
3.4 Discussion 
The replication of a minigenome from one virus can be driven by the 
support plasmids of another virus, providing that the support plasmids belong to a 
closely related virus in the same genus (Pelet et al. 1996). The replication of a HeV 
minigenome has been shown to be able to be maintained by support plasmids of 
NiV, validating the inclusion of these viruses in the same genus (Halpin et al. 2004). 
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Figure 3.6- Exchange of the Q Residue with an E Residue in the 
Conserved JPV GDNQ Motif 
The level of GFP expression in a minireplicon system containing the JPV L 
GDNQ (wild-type) plasmid was compared with a minireplicon system containing the 
JPV L GDNE plasmid. The mean number of fluorescent cells per field of view in a 
representative minireplicon assay is given (A). The data, where the mean 
fluorescence of the JPV L GDNE minireplicon is expressed as a percentage of the 
wild-type JPV L GDNQ minireplicon, is given (B). 
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To determine the relatedness between NiV, JPV and BeiPV, the 
functionality of each minigenome was analysed when support plasmids were 
supplied in heterotypic combinations in the minireplicon systems.  
To exclude JPV and BeiPV from the genus Henipavirus based on 
sequence disparity, heterotypic combinations of minireplicon systems using NiV 
were assembled. When either the NiV minigenome was transfected with JPV or 
BeiPV support plasmids, or, JPV or BeiPV minigenomes were transfected with NiV 
support plasmids, GFP expression was not evident. These results indicated that 
JPV and BeiPV were not structurally similar to NiV, as the replication machinery of 
these viruses could not be interchanged. On the other hand, when the JPV 
minigenome was transfected with the support plasmids of BeiPV, or where the 
BeiPV minigenome was transfected with the support plasmids of JPV, expression of 
GFP occurred. These results indicated that JPV and BeiPV were structurally similar, 
and adequately divergent from NiV to be excluded from the genus Henipavirus. 
GFP expression in Vero cells, after transfection with a heterotypic plasmid 
combination using JPV and BeiPV, was generally higher than when a homotypic 
plasmid combination was transfected. Although the exact mechanism of this 
heterotypic enhancement was not clear, similar results were observed when a HeV 
minigenome was driven by NiV support plasmids (Halpin et al. 2004). Also using a 
CAT minireplicon system, the Reston strain of EBOV produced a higher level of 
CAT expression when the minigenome was driven by support plasmids from the 
more pathogenic Zaire strain, and even the more distantly related Marburg virus 
(Groseth et al. 2005). EBOV and Marburg are both viruses that belong to the 
Filoviridae family, another family in the order Mononegavirales. As an explanation 
for these results, the authors suggest that pathogenic members of the Filovirus 
family may be more transcriptionally active than their apathogenic counterparts 
(Groseth et al. 2005). Similarly, although not quantified, MeV produced syncytia 
earlier, and in higher numbers, when support plasmids from RPV were supplied in 
the reverse genetics system, than when MeV support plasmids were supplied 
(Brown et al. 2005a). The authors suggest that dominant-negative effects, such as 
the generation of non-physiological levels of N protein, may occur when homotypic 
support plasmids are supplied in reverse genetics rescue systems (Brown et al. 
2005a). When support plasmids from closely related viruses are supplied in a 
reverse genetics system, negative effects may not be as pronounced as when 
homotypic support plasmids are supplied. The heterotypic proteins may not compete 
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with viral proteins produced from the rescued genome and hence would not interfere 
with the balance between transcription and replication. 
In order to determine the level of structural similarity that exists between 
JPV and BeiPV, the leader and trailer regions of the minigenomes were exchanged. 
Research with RSV indicated that residues in the first 13 nucleotides of the leader 
region, in conjunction with the 3’ terminus of the N gene, were responsible for the 
recruitment of the polymerase (Cowton & Fearns 2005). As both JPV and BeiPV 
minigenomes were capable of functioning with heterotypic polymerase complexes, 
and as polymerase recruitment signals were seemingly present in the leader region, 
the hybrid JPV/BeiPV minigenomes should also be efficiently transcribed. 
Transfection of polymerase complexes consisting of JPV polymerase proteins, along 
with hybrid JPV/BeiPV minigenomes, resulted in GFP expression from both 
minireplicon systems containing hybrid minigenomes. 
Previous studies with EBOV indicated that cis-acting signals can be 
exchanged between the Reston and Zaire strains as the 3’ and 5’ promotor regions 
of these viral strains display a high degree of structural similarity (Boehmann et al. 
2005). These results were in accordance with published research indicating 
replication complexes are specific for autologous RNA, but can occasionally 
transcribe RNA from closely related viruses. Further studies revealed that the EBOV 
replication promotor is bipartite and the viral leader does not interact with the trailer 
(Weik et al. 2005). Taken together, the generation of functional JPV and BeiPV 
minireplicon systems, with heterotypic support proteins and also hybrid 
minigenomes, provides evidence for the lack of interaction between the viral leader 
and trailer regions. 
The ability to successfully exchange support plasmids in the JPV and 
BeiPV minireplicon systems provided evidence that polymerase complexes of the 
viruses were functionally similar. Additional evidence for the functional similarity of 
the JPV and BeiPV polymerase complexes was provided by the successful 
replication of both JPV/BeiPV hybrid minigenomes, by the JPV polymerase proteins. 
To examine the structural compatibility between JPV and BeiPV polymerase 
proteins, the JPV and BeiPV support plasmids were interchanged in an attempt to 
produce a functional heterogeneous polymerase complex. The lack of GFP 
expression in the JPV and BeiPV minireplicon systems, utilising all possible 
combinations of support plasmids, suggested that JPV and BeiPV polymerase 
proteins were not structurally compatible. 
The JPV and BeiPV polymerase proteins share variable levels of amino 
acid homology. The sequence identity between the JPV and BeiPV N, P and L 
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proteins is 48%, 47% and 73%, respectively (Li et al. 2006). Although the JPV and 
BeiPV proteins share some sequence homology, minireplicon results indicated that 
these proteins were unable to interact to form a functional polymerase complex. 
Similar results were observed when two morbillivirus minigenomes, MeV and RPV, 
were transfected with combinations of MeV, CDV and RPV support plasmids (Brown 
et al. 2005a). In this study, low levels of CAT expression were detected when the 
RPV minigenome was transfected with the CDV N plasmid and RPV P and L 
plasmids, but the result could not be consistently repeated across experiments. 
Higher and more constant levels of CAT expression were observed when the MeV 
minigenome was transfected with MeV N and P plasmids in conjunction with the 
RPV L plasmid. Although low levels of CAT expression were detected from 
minireplicon systems where support plasmids combinations from different viruses 
were used, rescue of infectious virus was not possible (Brown et al. 2005a). 
Together, these results provide evidence that although the N, P and L support 
plasmids are able to maintain minigenome expression from closely related viruses, 
they are not, with the exception of one morbillivirus minireplicon, able to form 
heterogeneous polymerase complexes. 
Consequently, based on the fact that replication machinery was 
interchangeable between JPV and BeiPV, but not with NiV, the conclusion was 
reached that these viruses were evolutionarily closely related, and significantly 
divergent from the henipaviruses. This data provided further support for the 
classification of JPV and BeiPV into a new genus. 
The L genes of NNSV have a high level of amino acid sequence 
conservation. For paramyxoviruses, sequence comparison of the L genes of SeV, 
NDV and MeV identified six conserved domains (I-VI), separated by variable 
regions, suggesting that the structure consisted of concatenated functional domains 
(Poch et al. 1990). Insertion of the EGFP gene between domains II and III of the L 
protein of RPV (Brown et al. 2005b) and MeV (Duprex et al. 2002) did not disrupt 
polymerase function, suggesting that the polymerase was a multi-domain protein. 
Domain II is essential for RNA recognition and domain III contains a pentapeptide 
motif, QGDNQ, which has been hypothesised to be an active site for phosphodiester 
bond formation. The QGDNQ sequence is located within the C motif of domain III 
and contains a β-turn-β structure critical for polymerase activity (Poch et al. 1989). 
Specific locations of amino acid residues in these tight turns may be critical for 
correct orientation, cation binding, template specificity and catalytic processes. 
Prior to the discovery of HeV in 1994, all known NNSV contained the highly 
conserved GDNQ sequence motif in domain III of their respective L proteins. For the 
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henipaviruses, the Q residue has been replaced by an E residue, giving rise to a 
GDNE sequence motif. This alternate motif has also been found in two recently 
characterised paramyxoviruses, TuPV (Wang et al. 2001) an MosPV (Miller et al. 
2003). This amino acid change introduces a second negatively charged residue into 
a predicted functionally important area of the L protein. The GDNE motif was initially 
thought to be associated with paramyxoviruses with a relatively large genome size, 
but this now seems unlikely, as JPV and BeiPV, with genome sizes of approximately 
19,000 nucleotides, contain the conserved GDNQ motif in their L proteins (Jack et 
al. 2005; Li et al. 2006).  
The role of the Q residue in the conserved GDNQ motif in the function of 
the L protein was examined. The E residue in the GDNE motif of the NiV L protein 
was replaced with either a Q residue, or other amino acid residues, and the activity 
of the L protein was assessed using the NiV-GFP minigenome replication assay. 
The Q residue of the GDNQ motif in the JPV L protein was replaced with an E 
residue, and the activity of the L protein was assessed using the JPV-GFP 
minigenome replication assay. NiV and JPV minireplicon assay results 
demonstrated that the Q residue within the GDNQ motif was interchangeable with 
an E residue. 
The tolerance for amino acid substitutions at the Q residue position of the 
GDNQ motif appears to be virus dependent. Results in the JPV minireplicon system 
demonstrated that the Q residue in the GDNQ motif was interchangeable with an E 
residue. However, when the Q residue of RPV L protein was mutated to an E 
residue, activity in the minigenome assay decreased to 33% of wild-type 
(Chattopadhyay et al. 2004). The same Q to E alteration in the GDNQ motif of 
RABV resulted in a drastic reduction of activity to 0.4% of wild-type GDNQ in a 
minigenome assay (Schnell & Conzelmann 1995). While RPV was able to retain a 
functional minireplicon system with an E residue in the GDNQ motif, the same 
mutation in RABV, a rhabdovirus, dramatically reduced minigenome functionality. 
Hence, the ability of the polymerase to tolerate an E residue in the GDNQ motif may 
be unique to paramyxoviruses.  
Although the E residue of the NiV L GDNE motif could be replaced with D, 
A, N, I and G residues, albeit with considerable reduction in activity, replacement 
with K or P residues resulted in complete abrogation of polymerase activity in the 
NiV minireplicon system. A radioimmunoprecipitation assay was performed to 
ensure that differences observed between NiV the minireplicon systems were not 
due to differences in L gene expression. The radioimmunoprecipitation was 
unsuccessful, with the quality of the NiV antiserum most likely the basis of the 
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failure. As the rabbit NiV antiserum was unlikely to contain sufficient antibodies 
directed against the NiV L protein, the recombinant NiV L proteins were not able to 
be immunoprecipitated. The GFP expression levels were analysed comparatively to 
the wild-type NiV minireplicon system. The introduction of the A, N or G residue 
reduced the polymerase activity by more than 90%. On the other hand, the 
functionality of the NiV minireplicon system was retained when the E residue was 
substituted with D or I residues. When the Q residues of the VSV and RABV GDNQ 
motif were substituted with an N residue, the RABV minigenome lost all activity 
(Schnell & Conzelmann 1995) and the VSV minigenome only retained 5% activity 
(Sleat & Banerjee 1993). Conversely, the same Q to N substitution in the RPV 
GDNQ motif resulted in 42% activity in the minigenome (Chattopadhyay et al. 2004). 
Taken together, the retention of minireplicon function in RPV with a Q to N mutation 
in the GDNQ motif further highlights a difference between viral L proteins, within the 
same or different viral families, in their ability to tolerate point mutations at this 
critical site. 
The results presented suggested that the NiV L protein functioned similarly 
with either an E or Q residue in the GDNE motif. Results also proved that the same 
was true for JPV, where the JPV L protein functioned equally well with either an E or 
Q residue in the GDNQ motif. Considering that the E residue carries a negative 
charge in comparison to the non-charged Q residue, it appears unlikely that the E/Q 
residue is directly involved in catalysis. This was further supported by the fact that 
replacement of the E residue with D, A, N, I or G did not abolish L protein function in 
the NiV minireplicon system. However, when residues known to disrupt protein 
secondary structures (P and K) were introduced at this site, the NiV L polymerase 
activity was abolished. Together these results suggested that the amino acid at the 
E position played an important role in maintaining structure, not catalytic activity. 
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CHAPTER 5 
Development of Assays for the Detection of Rodent 
Paramyxoviruses 
5.1 Introduction 
In addition to the well characterised SeV, at least four other 
paramyxoviruses have been isolated from rodents in the past fifty years, including 
NarPV, MosPV, JPV and BeiPV. NarPV was isolated from the brains of forest 
rodents, Zygodontomys b. brevicauda, trapped in the Nariva swamp of Eastern 
Trinidad in 1962 and 1963 (Tikasingh et al. 1966). MosPV was isolated in 
Queensland, Australia, on three occasions from 1970-1971 from pooled organs of a 
female rat (Rattus leucopus), a male rat (Rattus fuscipes) and a pool of mites 
(Laelaps echidninus) (Campbell et al. 1977). JPV was isolated on four separate 
occasions from wild mice (Mus musculus) in Queensland, Australia, in 1972 (Jun et 
al. 1977). BeiPV was isolated from a human mesangial cell line in 2003, but a rat 
mesangial cell line from the same laboratory was believed to be the original source 
of the virus (Li et al. 2006). There have been no reported disease outbreaks 
associated with any of these rodent paramyxoviruses, and for JPV, no disease was 
demonstrated upon experimental infection of mice (Miller 2004). 
 Currently, there is no evidence of human infection with any rodent 
paramyxoviruses, however, this does not rule out the possibility that these viruses or 
viruses closely related to them may still pose a threat as zoonotic agents. In recent 
years several paramyxoviruses have emerged, including NiV and HeV, the only 
zoonotic paramyxoviruses fatal to humans, and NiV in particular caused significant 
disease in humans and pigs (Eaton et al. 2006). Both asymptomatic and 
symptomatic rodent populations have also been associated with transmission of 
disease to humans. Cowpox virus, an orthopoxvirus, does not induce any obvious 
clinical disease in rodents, yet is zoonotic (Begon et al. 2003). Members of the 
Arenaviridae family are associated with rodent-transmitted disease and, recently, 
the arenavirus Lymphocytic choriomeningitis virus (LCMV) was transmitted through 
organ transplantation. Organs from one person who was infected with LCMV were 
transplanted into four people, and three of the four organ recipients subsequently 
acquired the LCMV infection and died (Fischer et al. 2006). Hantaviruses are 
regularly transmitted from rodents to humans, and Puumala virus, a rodent 
hantavirus, was shown to be infectious for up to fifteen days in urine, faeces, saliva 
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and nesting material (Kallio et al. 2006). If in the future, rodent paramyxoviruses 
adapt to infect humans, the availability of rapid, specific and sensitive detection 
assays would greatly aid in disease diagnosis and outbreak control. 
The prevalence and distribution of paramyxovirus infection in wild rodent 
populations is not known. To monitor the seroprevalence of JPV, BeiPV and MosPV 
in Australian and Malaysian wild rodent populations, a multiplex microsphere assay 
for measuring virus-specific antibodies in sera from potentially infected animals was 
developed. Specifically, JPV and MosPV RNP, and recombinant BeiPV P protein, 
were purified and coupled to different microspheres for use on the Bio-Plex platform. 
To assess viral tropism in tissue from animals experimentally infected with JPV, a 
real-time PCR assay was developed. Specifically, a TaqManTM-based fluorogenic 
assay for the detection of JPV RNA was established. As MosPV, NarPV, and BeiPV 
experimental animal infections have not been attempted, similar assays were not 
developed for all rodent paramyxoviruses. With further refinement and validation, 
the multiplex microsphere assay, as well as the real-time PCR assay, may be useful 
for serology and agent identification purposes, respectively. 
5.2 Materials and Methodology 
5.2.1 Rodent tissue samples 
Experimental infection of mice with JPV was performed at AAHL by 
Philippa Jack (Miller 2004). Briefly, 21-day-old specific pathogen free BALB/c inbred 
mice were exposed to an aerosol containing 7 x 107 TCID50 of JPV in normal saline. 
Control mice were exposed to an aerosol containing only normal saline. Mice were 
euthanised at various time points and blood samples were taken prior to euthanasia. 
At autopsy the brain, lungs, liver, kidneys and spleen were removed, and tissue 
samples were stored at -80°C, in RNAlater (Ambion, USA). Sera obtained from 
these animals were also used in the multiplex microsphere assay (see below). 
5.2.2 Isolation of total RNA from rodent tissue 
The MagNA Pure LC RNA isolation kit III [Tissue] (Roche, Germany) was 
used for the extraction of total RNA from mouse tissue that had been stored in 
RNAlater (Ambion, USA). Tissues from which RNA was extracted were lung, liver, 
kidney, spleen and brain. Tissue samples were weighed and 10 mg sections were 
removed, diced and added to MagNA Lyser Green Bead tubes (Roche). A volume of 
400 μL of Tissue Lysis Buffer from the RNA Isolation Kit III [Tissue] (Roche) was 
added to each sample. The tissues were homogenised using the MagNA Lyser 
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(Roche) at 6500 rpm for 60 sec, cooled on ice for 2 min, then homogenised for a 
further 60 sec, at 6500 rpm. The homogenised lysates were incubated at room 
temperature for 30 min, before centrifuging at 13000 rpm, in a Biofuge pico bench 
top centrifuge (Heraeus, Germany) for 2 min to clarify the lysate. 
After centrifugation, 350 µL of each homogenate was transferred to a 
sample cartridge well and placed in the MagNA Pure LC (Roche) instrument where 
RNA isolation was performed, as outlined in the Roche MagNA Pure LC RNA 
Isolation Kit III [Tissue] instruction manual. RNA was eluted into a final volume of 50 
µL of elution buffer. 
RNA concentrations of samples were measured using the GeneQuant II 
RNA/DNA calculator (Pharmacia Biotech, USA).  
See Chapter 2, Section 2.2.1 for cDNA synthesis method. 
5.2.3 Design of TaqMan primers and probe for JPV assay 
The primers and probes were designed using ABI PRISM Primer 
Express™ Version 1.5 software (Applied Biosystems, USA), taking into account the 
guidelines outlined in the Applied Biosystems publication “Sequence Detection 
Systems Quantitative Assay Design and Optimization”.  
The target region for viral amplification was in the N gene of JPV (GenBank 
Accession number AY900001). The 18S ribosomal RNA (rRNA) was utilised for 
normalisation, for which the primers and probe were supplied in the TaqMan® 
Ribosomal RNA Control Reagents kit (Applied Biosystems). The JPV probe 
contained the fluorescent reporter dye, 6-carboxy-fluorescein (FAM) located at the 5’ 
end and the quencher 6-carboxy-tetramethyl-rhodamine (TAMRA) located at the 
3’end. The 18S rRNA probe contained a proprietary fluorescent reporter dye, VIC, 
located at the 5’ end and the quencher TAMRA located at the 3’end. Primer and 
probe sequences are given in Table 5.1. 
5.2.4 TaqMan real-time PCR assay 
The TaqMan® real-time PCR reactions were carried out in 96 well Optical 
Reaction Plates (Applied Biosystems). Each 25 µL reaction contained 4.375 µL H2O, 
12.5 µL TaqMan® Universal PCR Master mix (2X), 2.25 µL JPV-N F primer (10 µM), 
2.25 µL JPV-N R primer (10 µM), 1.25 µL FAM labelled JPV-N probe (5 µM), 0.125 
µL 18S rRNA F primer (10 µM), 0.125 µL 18S rRNA R primer (10 µM) and 0.125 µL 
VIC labelled 18S rRNA probe (40 µM). 2 µL of JPV cDNA was added to each 
sample reaction, 2 µL of SARS cDNA was added to each ‘No Amplification Control’ 
reaction and 2 µL of H2O was added to each ‘No Template Control’ reaction. 
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Table 5.1- JPV and 18S rRNA Primer and Probe Sequences 
 
 
 
 
 
 
 
Primer/Probe Reporter 5’3’ Sequence Quencher 
JPV-N F - CTT CTG CAG GTC CGT CGA A - 
JPV-N R - GGG CAC AGC TCT TGA TAC TCT TG - 
JPV-N Probe FAM TGC CTC TCC CTA CCC AT TAMRA 
18S F - CGG CTA CCA CAT CCA AGG A - 
18S R - GCT GGA ATT ACC GCG GCT - 
18S Probe VIC TGC TGG CAC CAG ACT TGC CCT C TAMRA 
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Reactions were run on the ABI PRISM™ 7700 Sequence Detection System 
(Applied Biosystems) to detect fluorescence emitted during amplification of the 
cDNA template. Cycling conditions were as follows: 2 min at 50°C, 10 min at 95°C, 
and then 45 cycles of 15 sec at 95°C followed by 1 min at 60°C. 
5.2.5 Generation of real-time PCR efficiency curve 
A dilution series of JPV cDNA (see Chapter 2, Section 2.2.1, for cDNA 
synthesis) was analysed to determine the efficiency of JPV amplification, compared 
with the amplification of 18S rRNA. The slope of the curves were given in the 
equation y=mx+c, where m is the slope. The slope of the curve was used to 
calculate the efficiency of the real-time PCR reaction, according to the efficiency 
equation (Pfaffl 2001): 
 
E (Efficiency) = 10 (-1/slope) 
 
5.2.6 Normalisation of real-time PCR data by Q-Gene 
Upon completion of all real-time PCR assays, results were analysed using 
the Q-Gene program (Muller et al. 2002). Q-Gene was downloaded from 
www.BioTechniques.com and consisted of three Microsoft® Excel® based 
documents. The three documents were the Q-Gene Core Module (qgene96.xls, a 
template for analysing 96 well plates and qgene384.xls, a template for analysing 
384 well plates), Q-Gene Database (qgenedb.xls, a database to compile 
experimental results obtained from Q-Gene Core Modules) and Q-Gene Statistics 
Add-in (qstats.xla, a collection of frequently used statistics programs). 
As the JPV real-time PCR assays were performed in 96 well plates, the Q-
Gene Core Module used for analysis of data was qgene96.xls. This Excel® 
document contained four worksheets. The first worksheet completed was the ‘Plate 
Setup’ worksheet, where all sample names were entered into the spreadsheet, 
along with primer and probe names. The ‘Amplification Efficiency Plot’ worksheet 
was completed by inputting values obtained from the slope of the JPV (target) and 
18S rRNA (reference) plots, obtained from the efficiency curve (see Section 5.3.1). 
Using the data provided from the slopes of the efficiency curves, the spreadsheet 
also denoted a value for the amplification efficiency (E) of the target and reference 
samples. These values were found to match those manually calculated, hence the 
Etarget=2.0893 and Ereference=2.0732. Sample labelling information, efficiency 
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calculations and standard curves were exported by the program into the ‘Data 
Analysis’ worksheet. The ‘Data Analysis’ worksheet, once Ct values of JPV samples 
and their 18S rRNA counterparts were entered, calculated the ‘Mean Normalised 
Expression’ (MNE) of the samples. This information was used to compare levels of 
JPV RNA, relative to 18S rRNA within a sample, and then to determine differences 
between samples. It is important to note that the mean values can be calculated 
many different ways and the calculation chosen to derive the mean must be kept 
constant when comparing experiments. 
The calculation chosen to determine the mean was taken from Muller et al 
(2002) as follows: 
 
(Etarget)Ct target,well1 (Etarget)Ct target,well2 (Etarget)Ct target,well3
MNE= (Eref)Ct ref,well1 (Eref)Ct ref,well2 (Eref)Ct ref,well3
3
+ +
 
 
A Q-Gene Core Module file was created for each real-time PCR assay. 
Once data from each experiment was entered into a module, results were manually 
evaluated. All results derived from positive samples were compiled in a Q-Gene 
Database spreadsheet. The database worksheet calculated the mean normalised 
expression of a sample relative to a calibrator. A calibrator was a sample against 
which expression levels of the target gene RNA were compared. The mean 
normalised expression of each sample was divided by the mean normalised 
expression of the calibrator. 
5.2.7 Animal sera 
Rodent field sera samples 
Rodent sera were sourced from laboratories located in Australia and 
Malaysia. The rodent sera, kindly provided by Greg Smith and Ina Smith of the 
Queensland Health Scientific Services (Public Health Virology department), were 
obtained from rodents captured in Queensland, Australia. A list of the sera, which 
includes details about rodent species and capture location, is given in Appendix 2. 
The rodent sera kindly provided by Kaw Bing Chua and Sazaly Abu Baker of the 
University of Malaya (Department of Medical Microbiology) were obtained from 
rodents captured in two fishing settlements in Pulau Ketam and Port Klang, 
Malaysia. 
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Control sera 
The JPV rabbit antiserum is described in Chapter 2, Section 2.2.1. The 
BeiPV P antiserum was raised in rabbits and antibodies were targeted against a 
recombinant N-terminal fragment of the BeiPV P protein (Liang et al. 2003). The 
rodent negative control sera, SARS rat and mouse antisera, were provided by Meng 
Yu, and produced at AAHL. 
5.2.8 Purification of JPV and MosPV RNP 
For the purification of JPV RNP, two 840 cm2 roller bottles containing 
monolayers of Vero cells were infected with 9.5 x 105 TCID50 of JPV. Roller bottles 
were incubated at 37°C, until syncytia were observed. After the observation of 
syncytia, the media was decanted (see below for virus purification from supernatant) 
from the infected cells, and cells were washed with ice-cold PBS-A. After washing, 
50 mL of ice-cold PBS-A was added to the roller bottles and cells were scraped into 
the solution. Cells were centrifuged at 1500 rpm in an IEC Centra-7R centrifuge 
(210 rotor) for 20 min, at 4°C, and the supernatant was discarded. The cell pellet 
was resuspended in ice-cold TNM buffer (10 mM Tris, 10 mM NaCl, 1.5 mM MgCl2, 
pH 7.5) and 10% NP-40 was added to a final concentration of 1%. The cell solution 
was homogenised in a Dounce homogeniser and then the nuclei were removed by 
centrifugation at 13,000 rpm, for 1 min, at 4°C. After centrifugation, EDTA (pH 7.2) 
and sodium deoxycholate were added, to a final concentration of 10 mM and 1%, 
respectively. 
A sucrose and caesium chloride (CsCl) gradient column was prepared, 
containing (from bottom to top) 40% CsCl, 30% CsCl, 20% CsCl and 5% sucrose. 
The RNP virus suspension was added to the top of the gradient, tubes were placed 
into a SW41 Ti rotor (Beckman) and centrifuged at 25,000 rpm, overnight (18-24 hr), 
at 10°C, under vacuum, in a Beckman L8-80M ultracentrifuge. After overnight 
centrifugation, the visible RNP bands were collected, diluted in TNE buffer, placed 
into a 55.2 Ti rotor (Beckman) and centrifuged at 40,000 rpm for 90 min, at 10°C, 
under vacuum, in a Beckman L8-80M ultracentrifuge. The JPV RNP was 
resuspended in TNE buffer. 
JPV was purified from cell culture supernatant (from above). Once 
decanted from cells, the supernatant was centrifuged at 1500 rpm, in JA 25.5 rotor 
(Beckman) for 20 min, at 4°C, to remove cell debris. A 50% (w/v) solution of 
polyethylene glycol (PEG, MW 6000) was prepared in TNE buffer. The PEG solution 
was added to virus supernatant at a final concentration of 10% and the solution was 
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gently stirred overnight, at 4°C. Following overnight stirring, the PEG solution was 
centrifuged at 1500 rpm, in JA 25.5 rotor (Beckman), for 20 min, at 4°C, and the 
supernatant was discarded. 
The viral pellet was resuspended in ice-cold TNE buffer and added to the 
top of a 20% sucrose cushion. The tubes were placed into a 55.2 Ti rotor (Beckman) 
and centrifuged at 40,000 rpm, for 90 min, at 10°C, under vacuum, in a Beckman 
L8-80M ultracentrifuge. The viral pellet was resuspended in TNE buffer, and then 
added to the top of a 20-50% sucrose gradient. The tubes were placed into a 55.2 Ti 
rotor (Beckman) and centrifuged at 35,000 rpm, for 90 min, at 10°C, under vacuum, 
in a Beckman L8-80M ultracentrifuge. The visible bands were removed from the 
gradient and stored at -20°C. 
MosPV RNP was provided by Gary Crameri (Stocks prepared in 1999 and 
2000). 
5.2.9 Purification of recombinant BeiPV P protein 
Recombinant BeiPV P protein expressed from the pHMN-BeiPV-P 
construct was purified. See Chapter 2, Section 2.2.3, for the method for expression 
of proteins in bacterial cells, and Chapter 2, Section 2.2.5, for the method for 
analysis of protein by Western blot and protein purification. 
5.2.10 Multiplex microsphere assay equipment, software and calibration 
Multiplex microsphere assays were performed on a Bio-Plex Protein Array 
System integrated with Bio-Plex Manager Software (v 3.0) (Bio-Rad). The high 
setting was used for the reporter target channel (RP1) and fluorescent identification 
of microspheres. A Bio-Plex calibration kit (Bio-Rad) was used to maintain reporter 
conjugate emission wavelengths. A Bio-Plex validation kit (v 3.0) (Bio-Rad), was 
used to assure consistent optical alignment, fluidics performance, doublet 
discrimination and identification of individual bead signatures. The coefficient of 
variation for bead discrimination and reporter channel identification did not exceed 
7.0% and 8.0%, respectively. The Bio-Plex equipment was maintained at AAHL, and 
routinely calibrated by John White, Gary Crameri and Vicky Boyd. 
5.2.11 Coupling of purified JPV and MosPV RNP and BeiPV P protein to 
microspheres 
The methods for protein coupling to microspheres and multiplex 
microsphere assays were adapted from protocols previously established at AAHL 
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(Katharine Bossart, personal communication). Katharine Bossart and Jennifer 
McEachern assisted with protein coupling and bead activation. 
Purified JPV RNP, MosPV RNP and BeiPV P recombinant protein were 
coupled to 1x106 carboxylated (COOH) beads (Bio-Rad), on bead sets #46, #43 and 
#42, respectively. Prior to protein coupling, beads were sonicated, vortexed and 
activated. For bead activation, each bead set was added to a well of a MultiScreen-
BV 1.2 μm hydrophilic, low protein binding, 96-well filter plate (Millipore, Australia), 
pre-wet with PBS-A. Liquid was removed using a vacuum manifold and the beads 
were washed twice in the bead activation buffer, supplied in the Amine Coupling Kit 
(Bio-Rad). Beads were incubated in the dark for a further 20 min, in activation buffer 
containing 5 mg/mL 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (Pierce, 
USA) and 5 mg/mL N-hydroxysulfosuccinimide (Pierce), at room temperature, with 
shaking. 
Liquid was removed using a vacuum manifold, and JPV RNP, MosPV RNP 
and BeiPV P recombinant protein were added to bead sets #46, #43 and #42, 
respectively, in 100 μL of PBS-A. Beads and antigen were incubated for 2 hr, at 
room temperature, with shaking, in the dark. Beads were washed twice with 0.05% 
Tween-20 in PBS-A, and removed from the filter plate by resuspension in storage 
buffer (1% BSA/PBS-A/0.05% sodium azide containing protease inhibitor cocktail) 
(Roche Diagnostics, Australia). 
5.2.12 Multiplex microsphere assay 
Test sera, biotinylated rodent conjugates and streptavidin-phycoerythrin 
(QIAGEN) were diluted in PBS-A. Wells of 96-well filter plates were pre-wet with 
PBS-A. Activated, protein-coupled beads were vortexed and sonicated (Ultrasonic 
cleaner, Model K42-752, Ultrasonics, Australia) for 1 min prior to use. PBS-A was 
removed from filter plates using a vacuum manifold and 100 μL of PBS-A, 
containing approximately 1500 microspheres of each bead set, were added per well. 
Buffer was removed from the microspheres using a vacuum manifold. For detection 
of JPV, MosPV or BeiPV antibodies, 100 μL of sera (at a 1:50 dilution) was added to 
appropriate wells and incubated with the beads for 30 min, at room temperature, 
with shaking, in the dark. Liquid was removed using the vacuum manifold and 100 
μL of either biotinylated goat anti-mouse (Pierce), or biotinylated goat anti-rat 
(Pierce) conjugate, at a 1:500 dilution in PBS-A, was added to each well, and 
incubated for 30 min as described above. Liquid was removed using a vacuum 
manifold and 100 μL of streptavidin-phycoerythrin (QIAGEN,) at a 1:1000 dilution, 
was added to each well and incubated for 30 min, as described above. Following 
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incubation, 30 μL of PBS-A was added to each well. Samples were read for median 
fluorescence intensities (M.F.I.) using a protocol template for bead sets #46, #43 
and #42 on the Bio-Plex Protein Array System. 
5.3 Results 
5.3.1 JPV real-time PCR optimisation 
JPV Primer optimisation 
Primer optimisation was performed according to the manufacturer’s 
instructions. Variable forward and reverse primer concentrations were analysed. The 
primer concentrations that gave the lowest Ct (threshold cycle) value and highest 
∆Rn were determined. A probe concentration of 250 nM was used in the primer 
optimisation assay and a 1:10,000 dilution of JPV cDNA was selected as the 
template for amplification. Standard real-time PCR cycling conditions were used for 
the reaction. Results were analysed after a baseline of 3-15, and a threshold of 0.2 
were manually set. Samples were analysed in triplicate, and the average Ct values 
of the primer concentrations are shown in Table 5.2. The primer concentrations that 
gave the lowest average Ct values were 300F/900R (23.30), 300F/300R (23.40) and 
900F/900R (23.44). Although the Ct values were similar, the ∆Rn differed between 
samples. The primer concentration with the highest ∆Rn was 900F/900R (Figure 
5.1). This primer concentration was used in all subsequent experiments. The primer 
optimisation assay ensured optimal performance of the primers in a real-time PCR 
assay where a probe concentration of 250 nM was used.  
JPV probe optimisation 
A probe optimisation was carried out to determine if the real-time PCR 
assay could be run with a probe concentration under 250 nM. This was done not to 
improve the assay, but to reduce running costs associated with the experiment. The 
probe optimisation analysed the differences in probe concentrations, ranging from 
50 to 250 nM.  
A primer concentration of 900 nM was used for both forward and reverse 
primers in the assay, and the template for amplification was JPV cDNA, at a dilution 
of 1:10,000. Standard real-time PCR cycling conditions were used for the reaction. 
Results were analysed after a baseline of 3-13 and a threshold of 0.1 were manually 
set.
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Table 5.2- Average Ct Values from the JPV N Primer Optimisation 
 
 
 
 
 
 
 
JPV N Forward Primer (nM) JPV N Reverse 
Primer (nM) 50 300 900 
50 25.91 24.50 25.59 
300 25.08 23.40 23.62 
900 25.41 23.30 23.44 
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Figure 5.1- Primer Optimisation Assay 
The JPV N primer optimisation was performed according to the 
manufacturer’s instructions. Results from the primer optimisation assay display the 
Ct values, and ∆Rn of the samples in the primer matrix. The primer optimisation 
assay is displayed on a logarithmic scale (A) and a linear scale (B), with Ct values 
on the x-axis, and ∆Rn on the y-axis. 
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Samples were analysed in triplicate and average Ct values obtained for the 
different probe concentrations are shown in Table 5.3. As observed in the primer 
optimisation experiment, the Ct values between assays with different probe 
concentrations did not vary greatly, but the ∆Rn differed between samples. The Ct 
values and ∆Rn values are displayed in Figure 5.2. 
These results demonstrated that a JPV real-time PCR assay could be 
successfully performed with the JPV probe at concentrations lower than 250 nM, but 
higher than 50 nM. Using a lower probe concentration would reduce the cost of the 
assay, however as the probe concentration must never be limiting, and a high ∆Rn 
must be achieved, the decision was made that all subsequent reactions would be 
carried out with a probe concentration of 250 nM. 
Determination of efficiency curve for JPV real-time PCR assay 
For a highly sensitive and reproducible real-time PCR assay with cDNA as 
the substrate for amplification, Applied Biosystems recommends a primer 
concentration of 900 nM and a probe concentration of 250 nM. These 
recommendations were verified by the primer and probe optimisation experiments. It 
should be noted that in both optimisation experiments 18S rRNA primers and probe 
were included in the PCR reactions. The 18S rRNA primers and probe were 
duplexed to ensure experimental results would be comparable to optimisations. 
In addition to primer and probe optimisations, the real-time PCR reactions 
were analysed to ensure that the housekeeping gene and target sample nucleic acid 
were amplified with equal efficiencies. The efficiency, at which the sample and 
reference real-time PCR reactions occurred, relative to each other, determined how 
the data were normalised. 
A standard curve was generated for both the JPV N gene and 18S rRNA 
amplification. Reactions were carried out in the same tube, using standard real-time 
PCR conditions. Dilutions of JPV cDNA, ranging from 10-2 to 10-8, were prepared for 
amplification. The 10-8 dilution of JPV cDNA was omitted from the standard curve as 
the Ct values obtained varied significantly between replicates, due to the low 
amount of template nucleic acid present in the reaction. The Ct values obtained from 
the JPV N and 18S RNA assays were plotted against the relative amount of JPV 
cDNA present in the different dilutions (Figure 5.3). 
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Table 5.3- Average Ct values from the JPV N Probe Optimisation 
 
 
 
 
 
 
 
 
Probe Concentration (nM) Average Ct Value 
50 22.56 
100 22.17 
150 21.82 
200 21.98 
250 21.83 
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Figure 5.2- Probe Optimisation Assay 
The JPV N probe optimisation assay was performed according to the 
manufacturer’s instructions. Results from the probe optimisation assay display the 
Ct values, and ∆Rn of the samples on a logarithmic scale (A) and a linear scale (B), 
with Ct values on the x-axis, and ∆Rn on the y-axis. 
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Figure 5.3- JPV N and 18S rRNA Efficiency Curve 
A dilution series of JPV cDNA was analysed to determine the efficiency of 
JPV and18S rRNA amplification. The slope of the curves were given in the equation 
y=mx+c, where m was the slope. The efficiency of template amplification in the real-
time PCR reactions was calculated using the equation E (Efficiency) = 10 (-1/slope). 
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The efficiencies of JPV N and 18S rRNA amplification were 2.089 and 
2.073 for JPV N and 18S rRNA, respectively. These calculations demonstrated that 
JPV and 18S rRNA were amplified in the real-time PCR reaction with equal 
efficiency. An efficiency value of 2.0 signifies that a decrease in Ct value by 1 leads 
to an increase of viral genetic material by a factor of 2.0. 
5.3.2 Detection of JPV in rodent tissue by real-time PCR 
RNA was obtained from tissue samples removed from JPV infected mice, 
and subsequently converted to cDNA. A summary of tissues removed from mice is 
given in Table 5.4. Real-time PCR assays were performed on all tissues, but brain 
samples were not included in the analysis as there was a possibility that cross-
contamination between brain and lung samples may have occurred during excision 
of tissue from mice (Philippa Jack, personal communication). All real-time PCR 
assays utilised standard cycling conditions. Prior to data analysis, the baseline and 
threshold were manually set in order to display the real-time PCR amplification plot. 
For analysis of JPV N amplification, the baseline was set at 3-15 and the threshold 
at 0.2. To view 18S rRNA amplification, the baseline was set at 3-8 and the 
threshold at 0.15. These parameters remained constant throughout experiments to 
eliminate variation between samples and reaction plates. An example of real-time 
PCR results, for different mouse tissues, is given in Figure 5.4. The JPV 
amplification curves are given in Figure 5.4A, and the corresponding 18S rRNA 
amplification curves are given in Figure 5.4B.  
A Q-Gene Core Module file was created for each real-time PCR 
experiment. Once the data from each experiment was entered into a module, results 
were manually evaluated. The negative control samples were negative for viral RNA 
amplification in each experiment. . All data pertaining to brain samples (which may 
have been contaminated), controls (SARS cDNA, negative H20 and positive JPV 
cDNA) and negative samples (triplicates with Ct values of 45) were removed to 
facilitate analysis of positive results. 
All results derived from positive samples were compiled in a Q-Gene 
Database spreadsheet. The JPV RNA amplification data were normalised against 
18S rRNA amplification, then the amplification of each sample was compared, 
relative to a calibrator. The calibrator chosen was the tissue sample to which 
amplification of the JPV N RNA, for each of the experimental samples, were 
compared against.  
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Table 5.4- Mouse Tissue Samples 
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Figure 5.4- JPV N and 18S rRNA Real-Time PCR 
An example of real-time PCR results for different mouse tissues displaying 
JPV amplification curves (A) and the corresponding 18S rRNA amplification curves 
(B) are shown. 
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Lung tissue from Mouse 1 at Day 0 (TT1) was chosen as the calibrator for 
analysis, as this was the earliest sample from which JPV was isolated (Miller 2004). 
The mean normalised expression of each tissue sample was divided by the mean 
normalised expression of the calibrator. Numerical values obtained for tissue 
samples were expressed as ‘Mean Normalised Expression Relative to Calibrator’, 
which indicated amount of viral RNA in the sample compared with the amount of 
viral RNA present in the lung sample of Mouse 1 at Day 0. A value higher than 1.0 
indicated more viral RNA was present in the sample than the lung tissue of Mouse 1 
at Day 0. For example, lung tissue of Mouse 9 at Day 3 had a value of 148, 
indicating that Mouse 9 had approximately 148 times the amount of viral nucleic acid 
in the lung at time of sacrifice than Mouse 1. A value below 1.0 indicated less viral 
nucleic acid was present in the sample than the lung tissue of Mouse 1 at Day 0. 
The ‘Mean Normalised Expression Relative to Calibrator’ of all positive samples is 
displayed graphically in Figure 5.5. 
5.3.3 Purification of antigens for multiplex microsphere assay 
Purification of RNP 
JPV RNP was purified from JPV infected cells. The JPV RNP band was 
removed from the sucrose, CsCl gradient and resuspended in TNE buffer. The JPV 
RNP purification was performed in duplicate and these RNP samples were analysed 
by Western blot. The intensity of proteins in purified JPV, crude JPV and JPV RNP 
were compared when detected by JPV antiserum (Figure 5.6). Although the protein 
level in the JPV RNP samples was less than that of the purified JPV samples, only 
the JPV RNP was coupled to microspheres, considering that purity was most 
important in this context. The RNP samples were combined, before coupling to bead 
set #46. The MosPV RNP was purified by Gary Crameri and provided as five 
aliquots, which were combined before coupling to bead set #43. 
Purification of recombinant BeiPV P protein 
The BeiPV P gene was cloned into the pHMN vector and the recombinant 
P protein was expressed in E. coli. Six colonies were selected for IPTG induction. 
Proteins from cell lysates were separated by SDS-PAGE and a His-tagged protein 
with a molecular mass of approximately 58 kDa was detected by Western blot 
(Figure 5.7A), and also on a Coomassie stained gel (Figure 5.7B). The recombinant 
BeiPV P protein was expressed at equivalent levels in bacterial cells with, and 
without, IPTG induction.  
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Figure 5.5- Graphical Presentation of Mouse Tissue Containing JPV 
RNA 
Results derived from positive samples were compiled in a Q-Gene 
Database spreadsheet. Lung tissue from Mouse 1 at Day 0 (TT1) was chosen as 
the calibrator for analysis. Numerical values were expressed as ‘Mean Normalised 
Expression Relative to Calibrator’, which indicated amount of viral RNA present in 
the sample, compared with the amount of viral RNA present in the lung sample of 
Mouse 1 at Day 0. Purple bars represent lung samples, green bars represent kidney 
samples, red bars represent liver samples and blue bars represent spleen samples.  
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Figure 5.6- Analysis of JPV RNP by Western Blot 
The Western blot was incubated with rabbit JPV antiserum and a goat anti-
rabbit (Silenus) alkaline phosphatase conjugate was used for the detection of the 
rabbit serum. The JPV samples in lanes 1 and 2 were purified from tissue culture 
supernatant. The crude JPV in lane 3 was harvested by ultracentrifugation. Two 
samples of purified JPV RNP are shown in lanes 4 and 5. The Benchmark marker 
(Invitrogen) was used to determine the MW (kDa) of proteins. 
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Figure 5.7- Analysis of Recombinant BeiPV P Protein Expression 
The recombinant BeiPV P protein was analysed by Western blot after 
separation by SDS-PAGE (12% gel). The Western blot was incubated with an anti-
His MAb (Qiagen) and the MAb was detected with a goat anti-mouse (Chemicon) 
alkaline phosphatase conjugate (A). The same samples were analysed after 
Coomassie staining (B). Six colonies were selected for IPTG induction. A sample of 
the overnight bacterial culture, from colony 2 culture, was harvested (lane 1) as was 
a pre-induction sample (lane 2). Lanes 3-8 contained protein samples from 
inductions from colony 1-6 cultures, respectively. The arrows indicate the position of 
the predicted BeiPV P protein. The Benchmark marker (Invitrogen) was used to 
determine the MW (kDa) of proteins. 
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The 58 kDa BeiPV P protein was excised and eluted from the SDS-PAGE gel. After 
several elutions, sufficient protein was purified for coupling to microspheres. The 
BeiPV P protein was coupled to bead set #42. 
5.3.4 Detection of JPV, MosPV and BeiPV antibodies using a multiplex 
microsphere assay  
Spectrally distinct microsphere subsets that excite at one wavelength but 
emit at slightly different wavelengths allow each microsphere subset to be 
individually identified, gated and quantified using Luminex® technology (Luminex 
Corporation, USA). Multiplexed assays rely upon the incorporation of different 
microsphere subsets within an individual test. Purified JPV RNP, MosPV RNP and 
BeiPV P protein were coupled to three different bead sets under identical conditions. 
Samples were measured and analysed using the Bio-Plex Protein Array System and 
the median fluorescence intensities (M.F.I.) were calculated for each sample. 
A total of 384 rodent field serum samples were analysed. Of these, 80 were 
from rats captured in Malaysia and 216 were from rats captured in Australia. The 
remaining 88 serum samples were from mice captured in Australia. Initially, the 80 
rat serum samples from Malaysia were analysed to assess the multiplex assay. In 
preliminary assays, two antibodies were used sequentially to detect rodent serum; 
the first was a mouse anti-rat antibody and the second was a biotinylated goat anti-
mouse antibody. Through incubation with the mouse anti-rat antibody, and 
subsequent incubation with biotinylated goat anti-mouse antibody, serum from either 
rats or mice would be detectable. The 80 rat samples were screened in the multiplex 
assay. Serum samples with M.F.I. values higher than 2000 were chosen for further 
analysis. In all subsequent assays, only one antibody, (either biotinylated anti-rat or 
biotinylated anti-mouse), was used for species-specific detection of antibodies. 
Rodent serum samples were systematically screened in the multiplex 
microsphere assay. An arbitrary M.F.I. value of 1000 was selected as the lower limit 
where rat serum samples were putatively positive for JPV, BeiPV or MosPV 
antibodies. Rat serum samples where the M.F.I. were above 1000 and the number 
of microsphere events was above 50 for one or more of the bead subsets are listed 
in Table 5.5 and these results are displayed graphically in Figure 5.8. In the 
Malaysian rat samples, there were four samples putatively positive for BeiPV 
antibodies and four samples putatively positive for MosPV. In the Australian rat 
samples there were five, six and twelve samples putatively positive for JPV, BeiPV 
and MosPV antibodies, respectively. 
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Table 5.5- Multiplexed Detection of JPV, MosPV and BeiPV in Rat 
Serum 
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Figure 5.8- Multiplexed Detection of JPV, MosPV and BeiPV in Rat 
Serum 
Serum samples from rats captured in Australia and Malaysia were mixed 
with JPV RNP, MosPV RNP and BeiPV P protein coupled microspheres. 
Biotinylated goat anti-rat and streptavidin-phycoerythrin were added to each sample 
and samples were analysed using the Bio-Plex Protein Array System. Only samples 
where the Median fluorescence intensities (M.F.I.) were above 1000 and the number 
of microsphere events were above 50 for at least one microsphere population are 
displayed. Sera from Queensland and Malaysia are abbreviated Q and M, 
respectively. 
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The M.F.I. values obtained were generally higher in multiplex assays 
containing mouse sera as compared to those containing rat sera. An arbitrary M.F.I. 
value of 3000 was selected as the lower limit where mouse serum samples were 
putatively positive for JPV, BeiPV or MosPV antibodies. Mouse serum samples 
where the M.F.I. were above 3000 and the number of microsphere events was 
above 50 for one or more of the bead subsets are listed in Table 5.6 and these 
results are displayed graphically in Figure 5.9. In the Australian mouse serum 
samples there were nine samples putatively positive for BeiPV antibodies and six 
samples putatively positive for MosPV antibodies. These data suggested that the 
rodent paramyxoviruses JPV, BeiPV and MosPV may be circulating in rodent 
populations throughout Australia and southern Asia. 
5.4 Discussion 
Molecular and serological assays are required for a wide variety of 
applications, including disease diagnosis and basic research such as pathogenesis 
studies. Ideally these assays are sensitive, specific, rapid and cost effective. In the 
case of new or emerging infectious diseases, there are many unknown aspects of 
the pathogen, such as genetic sequence, which can cause significant delays in the 
generation of reagents required for disease diagnosis. In the past fifty years, several 
rodent paramyxoviruses have been isolated. The real-time PCR assay for the 
detection of JPV and multiplex microsphere assay for the detection of JPV, MosPV 
and BeiPV were developed to facilitate future diagnosis and research pertaining to 
these rodent paramyxoviruses and potential new viruses related to them.  
The stop/start model of paramyxovirus transcription (see Chapter 1, 
Section 1.6.1) results in a gradient of mRNA production inversely proportional to the 
distance of the gene from the 3’ end of the genome (Lamb & Kolakofsky 2001). The 
N gene was chosen as the target for JPV real-time PCR, as mRNA from this gene is 
likely to be the most abundant in infected tissues. The N protein produced in MeV 
has been shown to aggregate and bind with cellular or MeV RNA (Kühne et al. 
2006), suggesting that assays requiring RNA may be inhibited. Under these 
conditions, real-time PCR reactions can be treated with proteinase K to increase the 
quantity of RNA free from viral protein (Rzezutka & Mizak 2002). The JPV real-time 
PCR assay established within was functional as protease treatment of tissues 
occurred during extraction of RNA using the MagNA Pure LC RNA isolation kit. 
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Table 5.6- Multiplexed Detection of JPV, MosPV and BeiPV in Mouse 
Serum 
Serum samples from rodents captured in Australia and Malaysia were 
mixed with JPV RNP, MosPV RNP and BeiPV P protein coupled microspheres. 
Biotinylated goat anti-mouse and streptavidin-phycoerythrin were added to each 
sample and samples were analysed using the Bio-Plex Protein Array System. 
Median fluorescence intensities (M.F.I.) are shown for each microsphere population 
and numbers in parentheses represent number of microsphere events. Serum 
samples where the MFI was above 3000 and the number of microsphere events 
was above 50 are shaded in pink and blue, for BeiPV and MosPV, respectively. 
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Figure 5.9- Multiplexed Detection of JPV, MosPV and BeiPV in Mouse 
Serum 
Serum samples from mice captured in Australia were mixed with JPV RNP, 
MosPV RNP and BeiPV P protein coupled microspheres. Biotinylated goat anti-
mouse and streptavidin-phycoerythrin were added to each sample and samples 
were analysed using the Bio-Plex Protein Array System. Only samples where the 
Median fluorescence intensities (M.F.I.) were above 3000 and the number of 
microsphere events were above 50 for at least one microsphere population are 
displayed.  Sera from Queensland and Malaysia are abbreviated Q and M, 
respectively. 
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Normalisation of data is an integral part of the analysis process when using 
real-time PCR, as there may be differences in efficiencies of primer and probe 
affinities to cDNA, and these differences could be sample or tissue specific. 
Normalisation of data can help compensate for experimental variation. The JPV 
real-time PCR assay was designed in such a way that there were three possible 
means to normalise data. The first method in which data could be normalised was 
the correlation of PCR amplification results with initial amount of tissue (10 mg) used 
for each RNA extraction. This method was the least reliable of the three as tissue 
weight can vary slightly, depending on the precision of the scales used to weigh 
samples. Also, the weight of tissue does not necessarily correspond to the number 
of cells present in the tissue. In the second method, RNA concentrations could be 
normalised to each other. As each cDNA synthesis reaction contains 200 ng of 
template RNA, theoretically each real-time PCR reaction would contain the same 
amount of cDNA template for amplification. This method assumes that all cDNA 
reactions are equally efficient and real-time PCR amplification does not vary 
between samples.  
The method of normalisation whereby data were eventually analysed was 
the third method. Here, data were normalised by comparison of amplification of viral 
RNA in samples with the gene expression of a housekeeping gene within the same 
sample. The presumption was made that the expression of housekeeping genes 
remained constant throughout different tissues, stages of cell cycle and 
experimental conditions.  
The selection of a housekeeping gene for normalisation purposes was 
important as control genes should be constantly expressed, independent of 
experimental conditions. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
gene is widely used as in internal control and was considered for use in the JPV 
real-time PCR assay. Although widely used, GAPDH expression is variable across 
tissue types and levels of expression have been shown to vary with experimental 
conditions. In many instances, GAPDH has been reported as an unsuitable 
reference gene for expression studies. For example, research on neutrophils (Zhang 
et al. 2005), Atlantic salmon tissue (Olsvik et al. 2005), chicken muscle (Mozdziak et 
al. 2003) and normal human tissue (Barber et al. 2005) demonstrated that GAPDH 
was not an acceptable reference gene. The expression level of GAPDH was directly 
compared with β-actin, cyclophilin and 28S rRNA. Of these control genes, 28S rRNA 
displayed negligible variation across the four cell lines tested, in both hypoxic and 
normoxic experiments, but the use of GAPDH as a control was deemed unsuitable 
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(Zhong & Simons 1999). The 18S rRNA is the most abundant RNA in the cell and, 
although reported as variable in some studies, 18S rRNA expression was also 
reported as consistent, and use of 18S rRNA as a control demonstrated as reliable. 
For example, as reference genes, 18S and 25S rRNA exhibited stable expression in 
plants grown under various environmental conditions (Jain et al. 2006) and 
expression level of 18S rRNA in rice correlated with total RNA (Kim et al. 2003). 
During gene expression analysis in islet grafts, only 18S gene expression remained 
stable in all conditions (Rodriguez-Mulero & Montanya 2005). In order to measure 
expression levels accurately, normalisation by multiple housekeeping genes has 
been suggested (Vandesompele et al. 2002). Although normalisation with multiple 
housekeeping genes may permit a more accurate analysis of experimental data, the 
cost of the experiment would significantly increase. With these considerations in 
mind, 18S rRNA was chosen as the reference for the JPV real-time PCR assay. The 
amplification of JPV RNA was compared to that of 18S rRNA using a Microsoft® 
Excel®-based software application called Q-Gene (Muller et al. 2002). Q-Gene 
normalised RNA amplification was directly proportional to the amount of target RNA, 
relative to the amount of RNA of the housekeeping gene. Results were analysed by 
Q-Gene and the efficiencies of JPV N and 18S rRNA amplification in real-time PCR 
assays were found to be equivalent. 
As described in Section 5.3.1, the Q-Gene worksheet calculated the mean 
normalised expression of each sample relative to a calibrator. Lung tissue from 
Mouse 1 at Day 0 (TT1) was chosen as the calibrator for analysis. Mouse TT1 was 
inoculated with JPV and immediately euthanised. The lung tissue from this mouse 
represented the earliest sample from which JPV was detected by virus isolation 
(Miller 2004). Although JPV was isolated from the lungs of this mouse, the amount 
of virus detected does not represent infection in the animal, but the virus from the 
aerosolised inoculum. 
Numerical values obtained for tissue samples were expressed as ‘Mean 
Normalised Expression Relative to Calibrator’. A value higher than 1.0 indicated 
more viral RNA was present in the sample than the lung tissue of Mouse TT1 and a 
value below 1.0 indicated less viral RNA was present in the sample than the lung 
tissue of Mouse TT1. When the results were displayed graphically in Figure 5.5, four 
samples (T4 Day 1 liver, T8 Day 2 kidney, T10 Day 3 spleen and T22 Day 21 lung) 
had MNE values of less than 1.0. These values were not negative, but 
demonstrated that these four samples contained less viral nucleic acid than the 
lungs of mouse TT1 at day 0. As mentioned above, the amount of viral RNA in the 
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lung of mouse TT1 at day 0 represented initial viral inoculum, explaining why 
subsequent samples contained lower levels of viral RNA. 
Lung (days 1-7) was the only tissue from which JPV was detected by virus 
isolation (Miller 2004). Conversely, through analysis by real-time PCR, JPV was 
detected in not only lung tissue, but also liver, spleen and kidney. JPV RNA was 
present in both lung and liver samples from days 1 through 21. Detection of JPV 
RNA only occurred in spleen tissue between days 3 and 5, and JPV was not 
detectable in kidney tissue after day 2. The highest level of JPV RNA was detected 
in the lung of mouse TT14, on day 4, where the level of viral RNA was almost 32 
thousand times that of the amount detected in mouse TT1. Although JPV was 
detected in the tissues of infected mice by real-time PCR and virus isolation, these 
animals did not show any clinical signs of disease (Miller 2004), contrasting original 
studies by Jun (Jun et al. 1977), where extensive haemorrhagic lesions were 
present in lungs of infected mice. Taken together, this work demonstrated that the 
real-time PCR assay was more sensitive than virus isolation in detecting the 
presence of virus in tissue. 
Diagnostic real-time PCR assays have been developed for many 
paramyxoviruses, such as MuV (Kubar et al. 2004), RSV (Hu et al. 2003) and CDV 
(Elia et al. 2006). Rapid, specific and sensitive results from real-time PCR assays 
allow diseases to be detected earlier, making quarantine or treatment options 
available sooner. Studies on NDV demonstrated that detection of virus by real-time 
PCR correlates well with virus isolation, but has the advantage of being quicker 
(Wise et al. 2004). Real-time PCR assays have been shown to be more sensitive 
and quicker than convention PCR based assays, a factor which is especially 
important when diagnosing infection with zoonotic agents, such as RABV (Nagaraj 
et al. 2006) and HeV (Smith et al. 2001). Although further validation is required 
before the JPV real-time PCR assay can be used as a diagnostic assay, the test is 
currently useful as a tool for the detection of virus, for research purposes. The 
development of a real-time PCR assay for BeiPV, or any other rodent 
paramyxovirus, should be straightforward, using the same parameters as those 
used for the design of the JPV assay. 
Multiplexed assays can deliver rapid, economical, and accurate results. 
The microsphere assay for the detection of rodent paramyxovirus antibodies was 
established to determine the seroprevalence of JPV, BeiPV and MosPV in rodents 
in Australia and Malaysia. The preliminary multiplex microsphere assay for the 
detection of JPV, BeiPV and MosPV antibodies was performed with an additional 
incubation step. Incubation with a mouse anti-rat antibody was included prior to the 
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incubation with the biotinylated goat anti-mouse antibody. This method would 
theoretically allow sera from either rats or mice to be detectable. This procedure was 
initially adopted to allow analysis of rodent sera, without the need to distinguish 
whether the sample originated from a rat or a mouse. There are many reasons why 
this approach would be advantageous. Diagnostic specimens may be submitted for 
analysis and the origin of the sample may not be known. An animal may have been 
incorrectly identified; hence incorrect reagents may be used in a diagnostic assay. 
The multiplex assay may be completed more rapidly if species from which serum 
samples were obtained does not have to be determined. Although there were valid 
reasons for developing the multiplex microsphere assay in a manner in which 
differentiation of rodent samples was not required, this approach was not pursued. 
There was a possibility that the addition of the mouse anti-rat antibody interfered 
with the kinetics of the assay. As specificity and sensitivity were important, the 
decision was made to omit the mouse anti-rat antibody from subsequent assays. 
The data obtained from the multiplex microsphere assay suggested that the 
rodent paramyxoviruses, JPV, BeiPV and MosPV, may be circulating in rodent 
populations throughout Australia and southern Asia. It must be noted that the data 
presented is preliminary and further validation of this assay would be required to 
definitively determine the presence of antibodies to JPV, BeiPV and MosPV in the 
Australian and southern Asian rodent population. Adequate rodent positive controls 
are also required to determine the specificity of the multiplex assay. Ideally, 
recombinant proteins, instead of RNP, would be more suitable JPV and MosPV 
antigens to couple to each bead set, and may offer a higher level of specificity within 
the multiplexed assay. Furthermore, the level of protein expression can be easily 
quantified and, once induction conditions are optimised, recombinant protein is 
easier to produce and purify than RNP. 
Several multiplex microsphere assays for use on the Bio-Plex Luminex® 
platform have been developed for a variety of applications. Foot and mouth disease 
is an economically important disease affecting cloven hoofed animals. A serological 
assay has been developed to enable the differentiation between animals infected or 
vaccinated with foot and mouth disease virus (Clavijo et al. 2006). Microsphere 
assays have been used for the detection of donor-specific antibodies following 
organ transplantation. This assay may assist in identifying patients that require 
immune monitoring or immunosuppressive therapy following transplantation (Gibney 
et al. 2006). 
Bead-based molecular technology has been utilised to develop a molecular 
assay to detect and differentiate different animal pestivirus strains (Deregt et al. 
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2006). In a highly specific and sensitive molecular assay, all 22 types of human 
papillomavirus were detected (Schmitt et al. 2006). Multiplex microsphere assays 
are not only useful in the detection of disease. This technology has been used to 
examine microRNA profiles to classify human cancer (Lu et al. 2005).  
In conclusion, two assay platforms were established, one for the molecular 
detection of JPV, and another multiplexed serological assay to test rodent species 
for antibodies to JPV, BeiPV and MosPV. The JPV real-time PCR assay was utilised 
to monitor the experimental infection of mice with JPV. The multiplex microsphere 
assay was established to determine the seroprevalence of JPV, BeiPV and MosPV 
in Australian and southern Asian rodent populations. Both assays require further 
validation, but may be valuable tools for research involving rodent paramyxoviruses. 
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CHAPTER 6 
General Discussion and Future Directions 
In the past fifty years there have been many instances where new viruses 
have either emerged or been discovered, often accompanied by spectacular 
disease outbreaks. Several of these emerging infectious diseases were caused by 
paramyxoviruses and the emergence of HeV and NiV, both zoonotic, highlighted the 
severity of disease that could be caused by infection with viruses from this family. In 
addition to causing disease outbreaks, several newly discovered paramyxoviruses 
were found to have unique genetic features or novel genes. JPV, a newly 
characterised rodent paramyxovirus, together with BeiPV, a recently discovered 
rodent paramyxovirus, represent a new lineage of paramyxoviruses. Although there 
is no evidence to date that JPV and BeiPV cause disease, the unique genome 
characteristics of these viruses provided an excellent opportunity to research the 
genetic diversity within the paramyxovirus family. 
JPV was originally isolated from wild mice captured in northern 
Queensland, Australia, in 1972 (Jun et al. 1977). Apart from initial studies, JPV 
remained uncharacterised for two decades until the emergence of HeV and NiV. 
Both HeV and NiV exhibited unique genetic and biological features, unlike other 
previously characterised paramyxoviruses, and renewed interest in the unclassified 
rodent paramyxovirus. When the genome of JPV was sequenced, two novel genes, 
SH and TM, and a second ORF within the attachment protein gene were revealed 
(Jack et al. 2005). Following the characterisation of the JPV genome, another rodent 
paramyxovirus, BeiPV, was isolated and sequencing of the BeiPV genome revealed 
that this virus also contained two novel genes, SH and TM, and an extended 
attachment protein gene (Li et al. 2006). 
JPV and BeiPV are unique within the family Paramyxoviridae, and BeiPV 
contains the largest genome, which is, in fact, larger than that of any virus within the 
order Mononegavirales. The research presented within initially outlined the 
establishment of reverse genetics systems for JPV, BeiPV and NiV. These GFP 
minireplicon systems were constructed to aid in the taxonomic classification of JPV 
and BeiPV, and to determine the relationship between these viruses and the 
paramyxoviruses formerly containing the largest genomes, the Henipaviruses.  
Prior to complete genetic characterisation of the virus, the suggestion was 
made that BeiPV should be classified within the genus Henipavirus (Schomacker et 
al. 2004). In order to provide more evidence for taxonomic classification, 
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experiments were conducted using the newly constructed BeiPV and JPV 
minireplicon systems. Replication of the BeiPV minigenome was possible when 
either BeiPV or JPV polymerase proteins were co-transfected, but replication did not 
occur upon co-transfection of NiV polymerase proteins. The same results were 
observed when a JPV minigenome was co-transfected with JPV, BeiPV or NiV 
polymerase proteins. Replication of the JPV minigenome only occurred when JPV or 
BeiPV polymerase proteins were supplied, not NiV polymerase proteins. The NiV 
minigenome was not functional when either JPV or BeiPV polymerase proteins were 
co-transfected, demonstrating that the replication machinery was not 
interchangeable between NiV, a henipavirus and either JPV or BeiPV. These results 
provided support for the classification of BeiPV and JPV into a new genus. 
Importantly, these data also demonstrated that the BeiPV and JPV minireplicon 
systems were constructed correctly and were functional. 
Once established, practical applications of the JPV, BeiPV and NiV 
minireplicon systems were used to conduct more detailed molecular and functional 
analyses. These minireplicon systems were utilised to demonstrate that both JPV 
and BeiPV were compliant with the ‘rule of six’ (Calain & Roux 1993). Previous 
studies demonstrated that a NiV minireplicon system was only functional when the 
NiV minigenome was compliant with the ‘rule of six’ (Halpin et al. 2004). By 
comparison, the addition of four nucleotides to either the JPV or BeiPV 
minigenomes rendered both JPV and BeiPV minireplicon systems non-functional. 
Like other paramyxoviruses, both JPV and BeiPV must obey the ‘rule of six’ to 
replicate. 
The minireplicon systems were used to study the relatedness of the BeiPV 
and JPV polymerase proteins at the molecular level, specifically how they 
recognised the genome. A previous study demonstrated that the genomic termini of 
the Reston and Zaire strains of EBOV were interchangeable (Boehmann et al. 
2005). The 3’ and 5’ genomic termini of JPV and BeiPV were interchanged in the 
minigenome plasmids and under these conditions, the JPV and BeiPV minireplicon 
systems were fully functional. Both chimeric JPV and BeiPV minigenomes were 
transcribed by either JPV or BeiPV polymerase proteins, again indicating that these 
viral polymerases were structurally similar. To examine the structural similarity of the 
JPV and BeiPV polymerase complexes, the individual N, P and L proteins were 
combined and co-transfected with both JPV and BeiPV minigenomes. Although the 
JPV and BeiPV proteins share some sequence homology, individual JPV and BeiPV 
proteins were unable to interact in heterotypic combinations to form functional 
polymerase complexes. 
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The transcription and translation of the P gene is a complex process for 
paramyxoviruses and can give rise to several different proteins, including P, V, C, 
and W. Expression of the C protein, produced through RNA editing of the P gene 
(Thomas et al. 1988), has been shown to have a negative effect on minireplicon 
systems (Curran et al. 1992; Cadd et al. 1996; Malur et al. 2004). Using the 
minireplicon for BeiPV and JPV, similar results demonstrated that the C proteins 
expressed from the viral P genes had inhibitory effects on the replication of these 
minigenomes. Mutation of the start codons within the C genes of both JPV and 
BeiPV P genes prevented expression of the JPV and BeiPV C proteins. Both JPV 
and BeiPV minireplicon systems functioned with higher efficiencies when the C 
deletions were incorporated into the P support plasmids. Upon addition of JPV and 
BeiPV C-encoding plasmids, the replication efficiencies of the JPV and BeiPV 
minireplicon systems decreased in a dose dependent manner. Although these 
results demonstrated the both JPV and BeiPV C proteins were disadvantageous to 
the functionality of the JPV and BeiPV minireplicon systems, respectively, results 
may not necessarily correlate with what would be seen in a natural infection. Studies 
on SeV and MeV have demonstrated that the C protein, previously regarded as an 
accessory protein, is essential for the replication of virus (Sugahara et al. 2004; 
Sakaguchi et al. 2005; Hasan et al. 2000; Takeuchi et al. 2005). Construction of a 
full-length infectious clone would be necessary to analyse the effect of C protein 
expression on viral replication of JPV or BeiPV.  
All known NNSV contain the highly conserved GDNQ sequence motif in 
domain III of their respective L polymerase proteins, with the exception of NiV, HeV, 
TPMV (Wang et al. 2001) and MosPV (Miller et al. 2003), which contain a GDNE 
sequence motif. Like most paramyxoviruses, JPV contains GDNQ in this region. 
Domain III of the NNSV L protein has been determined as functionally important for 
catalytic activity of the polymerase protein (Poch et al. 1990). To determine the 
effect mutations have within this region, the sequence motifs of NiV and JPV were 
interchanged and function was evaluated using minireplicon systems. The 
substitution of the JPV L protein containing the GDNQ to a JPV L protein containing 
the GDNE motif did not have a significant effect on the JPV minireplicon system. 
Similarly, the substitution of the NiV L protein containing the GDNE to a NiV L 
protein containing the GDNQ motif did not have a negative effect on the NiV 
minireplicon system. Upon further evaluation, substitution of the E residue in the NiV 
GDNE motif with K, P, D, A, N, I and G residues all reduced or abolished the 
functionality of the NiV minireplicon system. Together, these results suggested that 
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the amino acid at the E position plays an important role in maintaining structure not 
catalytic activity in the L polymerase protein.  
Together, the research outlined thus far has demonstrated the application 
of reverse genetics systems for the classification of JPV and BeiPV, and for the 
functional studies of viral polymerase proteins and specific domains within these 
proteins. Reverse genetics systems have other attractive applications including the 
capability to generate recombinant viruses for pathogenesis studies. Construction 
and identification of attenuated recombinant viruses may represent potential vaccine 
candidates. Although JPV and BeiPV have not caused disease outbreaks thus far, a 
vaccine candidate would potentially be very beneficial in the event of an outbreak. 
Reverse genetics has been utilised to engineer NDV and avian influenza virus, 
creating attenuated recombinant viruses that when used as vaccines protect against 
both diseases (Veits et al. 2006; Park et al. 2006). As JPV and BeiPV have not been 
associated with disease, they could potentially be used as carrier vaccines, 
encoding other viral proteins. Recombinant HPIV3 was constructed to express the 
EBOV structural glycoproteins and when used as a vaccine, protected guinea pigs 
against a lethal-dose EBOV challenge (Bukreyev et al. 2006). Recombinant HPIV3 
has also been modified to express a SARS envelope glycoprotein and this virus 
induced a systemic immune response, resulting from mucosal immunisation 
(Bukreyev et al. 2004).  
Although several successful examples have been listed, vaccine 
development is a complicated process and several factors must be taken into 
account if reverse genetics will be used. The source of the polymerase required to 
initiate virus replication, such as the FWPV-T7 polymerase used in these studies, 
adds another virus to the system and may limit downstream applications, such as 
vaccine development. An alternate method to viral infection providing T7 RNA 
polymerase for expression of genes under the control of T7 promotors is the 
utilisation a stably transfected cell line. A BHK cell line stably expressing T7 RNA 
polymerase, BHK/T7-9, was created to eliminate detrimental effects of viral infection 
on cells used in reverse genetics experiments (Ito et al. 2003). Although BHK cells 
have been engineered to stably express T7 RNA polymerase, to date, the only live 
virus vaccine licensed for human use, derived from a continuous cell line, was 
produced in Vero cells (Rotavirus Vaccine, RotaTeq, Merck & Co., USA, License 
#0002). An efficient system has been developed for the rescue of recombinant 
paramyxoviruses from Vero cells, and this system does not rely on helper virus, but 
on plasmid-expressed T7 RNA polymerase (Witko et al. 2006). 
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Perhaps the most important consideration for vaccines generated with 
reverse genetics is the construction of a full-length infectious clone for use as the 
viral backbone. For JPV, the construction of a full-length infectious clone is currently 
underway and is expected to be completed in the near future. As mentioned above, 
JPV represents a promising viral backbone for vaccine development as there is 
currently no evidence that JPV causes disease and it is unlikely that animals, 
besides rodents, would have neutralising antibodies against JPV. Significantly, 
incorporation of foreign genetic material into the JPV attachment protein gene has 
been demonstrated without affecting the incorporation of this new fusion protein into 
the mature JPV virions. Specifically, the incorporation of a fragment of the SARS 
spike gene into the JPV G gene did not have a negative effect on G protein 
expression or virus particle formation. Together these data demonstrated that JPV 
had the potential to express foreign genes and be used as a potential vaccine 
candidate. A complete understanding of the novel genetic characteristics of the JPV 
genome and all encoded proteins will aid any attempts of vaccine development 
using this virus. Such studies will also help to understand the new lineage of 
paramyxoviruses that JPV and BeiPV represent. 
As mentioned previously, the genomes of JPV and BeiPV were found to 
contain two genes, SH and TM, not common to other viruses within the 
paramyxovirus family, as well as extended attachment protein genes. The presence 
of an SH gene is only found in JPV, BeiPV, MuV and SV-5 and no sequence 
homology between these SH proteins has been identified. The deletion of the SH 
gene of RSV, a member of the subfamily Pneumovirinae, did not affect virus growth 
(Bukreyev et al. 1997), suggesting the SH protein may have an accessory function. 
The SH protein of MuV is capable of inhibiting host cytokine signalling pathways 
(Wilson et al. 2006) and appears to function similarly to the SH protein of SV-5, 
which is capable of blocking apoptosis (He et al. 2001). The SH proteins of JPV and 
BeiPV may also function to inhibit host defence mechanisms upon virus infection. 
The epitope tagging studies on the JPV SH and TM proteins did not provide 
definitive evidence for the localisation of these proteins, but did substantiate 
evidence that they are surface glycoproteins (Jack et al. 2005). Once the 
construction of the full-length infectious clone for JPV is complete, deletion of the SH 
and TM genes from the JPV genome may provide insight into the function of the SH 
and TM proteins. Given the functions of the SH protein of MuV and SV-5 in the 
inhibition of host cell defences, it seems likely that the SH proteins of JPV and 
BeiPV will function through a similar mechanism. There is no homolog to the JPV 
TM gene in any other paramyxovirus, with the exception of BeiPV; hence it is 
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difficult to speculate on the function of the JPV and BeiPV TM proteins. The only 
other paramyxovirus containing a unique gene is FDLV, the reptilian paramyxovirus 
that contains a U gene between the N and P genes (Kurath et al. 2004). Although 
not experimentally tested, a small transmembrane protein was predicted to be 
expressed from the U gene (Kurath et al. 2004). The function of this U gene has not 
been determined, and it would be interesting to investigate whether there is any 
similarity in the functionality of the JPV and BeiPV TM proteins with the FDLV U 
protein, considering they are all predicted transmembrane proteins. 
The JPV attachment gene produces a protein containing 709 amino acids, 
structurally similar to other paramyxovirus attachment proteins, and also contains a 
long 3’ extension of 2,218 nucleotides after the stop codon (Jack et al. 2005). The 3’ 
extension of the attachment gene consists of a 2,115 nucleotide second ORF, ORF-
X, which begins directly after the stop codon. JPV may utilise an unconventional 
mechanism to translate a protein from ORF-X, but so far there is no evidence to 
suggest this is the case. The stop codon separating the two ORFs of the G gene 
may be a recent mutation, and prior to the mutation event a protein of 1,414 amino 
acids in length may have been translated from the JPV G gene. If this hypothesis is 
correct JPV could represent an ancient lineage of paramyxoviruses. The 
mutagenesis of the stop codon separating ORF-G and ORF-X, and subsequent 
incorporation of the resulting GX protein into mature virions supports the hypothesis 
that JPV may have once encoded an attachment protein twice the size of the current 
version of the attachment protein. 
The constitution of the BeiPV attachment gene further supports the 
hypothesis that JPV and BeiPV represent an ancient lineage of paramyxoviruses. It 
is tempting to speculate that a paramyxovirus, precursory to JPV, encoded a large 
attachment protein from the G gene. Subsequently, JPV evolved from this virus 
when a smaller attachment protein encoded from the G gene made JPV more 
evolutionarily ‘fit’ than the precursor. Additional mutations introduced throughout the 
G gene and the genome may represent the evolution of BeiPV from JPV. Within the 
BeiPV G gene there are two ORFs and with sufficient time these viruses may further 
evolve to completely eliminate the excessive RNA contained within the G gene in 
order to maintain a compact genome organisation, which offers a selective 
advantage for an RNA virus where the genome is replicated rapidly and frequently 
(Domingo & Holland 1997). However, as the genome can accommodate a large G 
gene, this may represent the ideal site to insert a foreign gene for vaccine 
development.  
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The above hypotheses rely upon the presumption that the full-length G-X 
protein produced from the G gene was somehow disadvantageous to the precursor 
virus. The attachment proteins are the major determinants of tissue tropism for NDV 
(Huang et al. 2004) and TuPV (Springfeld et al. 2005), so perhaps the loss of G-X 
significantly altered tissue tropism somehow enabling increased fitness. 
Constructing a JPV full-length infectious clone containing the G-X attachment 
protein may redirect the tissue tropism of JPV, as was the case when the MeV H 
attachment protein was restructured (Hadac et al. 2004). Additionally, the overall 
fitness of viruses that encode G and G-X attachment proteins can be compared 
using reverse genetics, including their influence on disease status. Perhaps viruses 
that encode G-X attachment proteins are more pathogenic in an infected host. Host 
antibodies directed against surface glycoproteins are critical for maintaining viral 
immunity. Recently, the pathogenicity of MeV was shown to be enhanced by 
antibodies directed against the H protein (Iankov et al. 2006). Infection of animals 
with JPV containing the G or G-X genes may demonstrate a similar effect on host 
immunity. The advent of a reverse genetics system utilising full-length infectious 
clones for JPV and BeiPV will facilitate studies that shed light on the evolutionary 
relationship between these viruses and other paramyxoviruses.  
Once a JPV reverse genetics systems is constructed, the diagnostic tools 
developed for the detection of JPV, as outlined within, could be utilised to monitor 
the success of the system. The level of JPV nucleic acid could be monitored using 
the JPV real-time PCR assay, and experimental infection of host rodents could be 
monitored using the multiplex microsphere assay. Although the real-time PCR assay 
and multiplex microsphere assay were mainly developed to monitor tissue tropism of 
JPV and seroprevalence of JPV, BeiPV and MosPV in rodents, respectively, the 
diagnostic tests could also be used to examine the functionality of a JPV reverse 
genetics system. Full-length reverse genetics systems for JPV and BeiPV may not 
only be used to study the evolutionary relationship of these paramyxoviruses, or the 
development of paramyxovirus vaccine vectors, but in many other applications. For 
example, paramyxoviruses may be engineered by reverse genetics to function as 
anti-cancer agents (Kirn et al. 2001; Grote et al. 2001; Suter et al. 2005). 
In summary, the work presented within, in its entirety, has pioneered new 
tools and assays which have proved to be valuable for providing answers to many 
interesting and intriguing questions pertaining to two previously uncharacterised 
rodent paramyxoviruses. Firstly, the establishment and requirements of functional 
reverse genetics systems for JPV and BeiPV were described. These reverse 
genetics systems were primarily utilised to provide evidence for the classification of 
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JPV and BeiPV into a new genus. Additionally, to better understand the biology of 
the viruses, novel viral surface proteins from JPV were expressed and evaluated. 
The attachment gene of JPV provided the strongest evidence in support of the 
hypothesis that JPV and BeiPV may represent an ancient lineage of viruses within 
the family Paramyxoviridae. In order to understand tissue tropism of JPV in vivo and 
to aid future work relating to JPV pathogenesis, a real-time PCR assay for JPV was 
developed and utilised. Finally, to address the risk JPV and BeiPV pose in native 
rodent populations, a multiplex microsphere assay for JPV and BeiPV serology was 
used to analyse the seroprevalence of these viruses in Australian and Malaysian 
rodents. Although there is no evidence for disease caused by JPV or BeiPV, this 
does not preclude the emergence of a zoonotic rodent paramyxovirus related to 
these viruses. Importantly, if such a situation was to occur, the tools for virus 
detection and serological monitoring are now established. 
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Appendix I: Primer Sequences 
 Minigenome Primer (DM) Sequences 
DM01 CGGACACGCTGAACTTGTGG 
DM02 CCAACGAGAAGCGCGATCAC 
DM03 AGCCGGCGCCAGCGAGGAGGCTGGGACCATGCCGG 
DM04 TCGCGGATCCATGCGGCCGCTTTAACCTTCCAAATCCA 
DM05 ACGCGGATCCTCACCATGGATGATATATTTCTTG 
DM06 GCCCAAGCTTAATACGACTCACTATAAACCTAACAAAGTAGGT 
DM07 GTAAAGCGGCCGCAGTTGGTGACAACTCG 
DM08 CTGGGACCATGCCGGCCACCAAACAAAGAAGTG 
DM09 CTCACCATGGTGTGGAGCAACCAAGTC 
DM10 CTGGGACCATGCCGGCCACCAAACAAAGATGTA 
DM11 CTCACCATGGTTTGGTTATCCCAAACC 
DM12 GCCCAAGCTTAATACGACTCACTATAAACCAGACAAAGGATAT 
DM13 GTAAAGCGGCCGCATTTTGAGTTAACGGG 
DM14 GTCGACGCGTCAATCATGTCTGGGGTGC 
DM15 GTTAGCGGCCGCAATTGTAAACAAAGCTA 
DM16 GTCGACGCGTCAATCATGTCAGATTATAATCCTGACGTCCTCCA 
DM17 ATTACCGGTGTAATCATGATCG 
DM18 GTCGACGCGTCAATCATGGCGCACCCGACTA 
DM19 GTTAGCGGCCGCCCGTTAACTCAAAATCC 
DM20 GTTAGCGGCCGCCCTCACCGAGGAATAGTC 
DM21 GTTAGCGGCCGCCTGATGCATAACTTTCTGC 
DM22 GTTAGCGGCCGCAGCTGCTAAAGCT 
DM23 GTCGACGCGTCAATCATGTCCCGACTTGGA 
DM24 GTTAGCGGCCGCAAGTGTGTATTTATGA 
DM25 GTCGACGCGTCAATCATGTCAGATTATA 
DM26 GTTAGCGGCCGCATCTAATCACTAT 
DM27 AGATAGCTGCAGTGGTACAAGGGGACAATGAGGCCATTG 
DM28 CTTTCGTACGTTTGGCCATCCTAT 
DM29 CATAATGAATTTTCTTCGAATAA 
DM30 GCTGCAATTGTCCAAGGAGACAATCAATCAATTGCTATCACT 
DM31 ACAGGCTCTTCTAAATCAATTGCTATCACT 
DM32 ACAGGCTCTTCATTTATTGTCTCCTTGGAC 
DM33 GCTGCAATTGTCCAAGGAGACAATAAATCAATTGCTATCACT 
DM34 GCTGCAATTGTCCAAGGAGACAATCCATCAATTGCTATCACT 
DM35 GTCGACGCGTCAATCATGGAAACGAATTGT 
DM36 GTTAGCGGCCGCATCTAATCACTAT 
DM37 GCTGCAATTGTCCAAGGAGACAATGATTCAATTGCTATCACT 
DM38 GCTGCAATTGTCCAAGGAGACAATGCATCAATTGCTATCACT 
DM39 GCTGCAATTGTCCAAGGAGACAATAATTCAATTGCTATCACT 
DM40 GCTGCAATTGTCCAAGGAGACAATATATCAATTGCTATCACT 
DM41 GCTGCAATTGTCCAAGGAGACAATGGATCAATTGCTATCACT 
DM42 GTTAGCGGCCGCATTTAGCTGCCTTGATTC 
DM43 GTCGACGCGTCAATCATGTCCTCCAGCAGCTTGTCA 
DM44 TGCGGCCGCATGATTATCTGATTATACTCTCGAGC 
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 JPV Primer (DJ) Sequences 
DJ 01 GCTCGAGACGCGTTGATAATGACATCAACAGTG 
DJ 02 CAAGCTTGCGGCCGCTATCACTTGCTTGCTGG 
DJ 03 CTCGAGACGCGTCGATCATGGATATCGACG 
DJ 04 AAGCTTGCGGCCGCTATATACAGGTTACTA 
DJ 05 GACGCGTCAAAAATGGCAAGCAATCAGGAG 
DJ 06 TGCGGCCGCTTACCACCATCCCTTCAAGTAA 
DJ 07 GACGCGTTGCTCCACAATGTCGAAACTT 
DJ 08 TGCGGCCGCATTGTAGGTTTAGCCATT 
DJ 09 GAGGCGTCACCATGAACTCCTATAGTGTTCAG 
DJ 10 TGCGGCCGCATTGATTTGTTAGTTCTCGT 
DJ 11 GACGCGTAAGGTACGATGGCTGGTAA 
DJ 12 TGCGGCCGCAAGTAATTTCATTTCA 
DJ 13 GACGCGTACAATCATGAAACCTGTAGCTT 
DJ 14 TGCGGCCGCATAGGATTGTGTTTCAGCCAAC 
DJ 15 GACGCGTCACCATGAATCCCGTTGCCATGTCGA 
DJ 16 TGCGGCCGCAGTGGATTAATTGTGCCCTAT 
DJ 17 GACGCGACAATCATGAAACCTGTAGCTT 
DJ 18 GACGCGTGCTCCACAATGTCGAAACTT 
DJ 19 GACGCGTTCACCATGAACTCCTATAGTGTTCAG 
DJ 20 GACGCGTTCACCATGAATCCCGTTGCCATGTCGA 
DJ 21 GTCGACGCGTCAATCATGAAACCTGTAGCTT 
DJ 22 GACGCGTTCACCATGAATCCCGTTGCCATGTC 
DJ 23 GTCGACGCGTTCACCATGTCACTCCTTACAATGGAT 
DJ 24 GTTAGCGGCCGCTCCAACCCATCTACTGAAC 
DJ 25 ATCGTGGATGAGACTCGATCTGC 
DJ 26 GTTAGCGGCCGCCTGTTGTTTGGCTAAATC 
DJ 27 TAATGTTGCTGGGGCTTGCATC 
DJ 28 GTTAGCGGCCGCAACTGATCAATCCTCAGAATAAAG 
DJ 29 GACGCGTCCATGGTCAAGGACGAGCATGA 
DJ 30 TGCGGCCGCTACTTTATAAAGATTTGTTTA 
DJ 31 GACGCGTCCATGGTAGCCCATGAGTCCAACA 
DJ 32 TGCGGCCGCTACACGGTGTTCTCAGAACCT 
DJ 33 CATCTGAGCTCGGCGCGCCATAAATTATC 
DJ 34 CAGAGGATCCAAGCATTGCCCCCATAGGGCACAATTCATCCACT 
DJ 35 GTTAGCGGCCGCGTTGGTATTCCTTTC 
DJ 36  AGACATTGCTGAGCCGATTC 
DJ 37 GGC CAA GAT TGG TAG AAA GG  
DJ 38 TGCATGCCAGAGACTGAGAC  
DJ 39 CTCTGAGCTCAGGCGCGCCCATGGTAGCCCATGAGT 
DJ 40 ATATGAATTCGCGGCCGCTACACGGT 
DJ 41 GTTAGCGGCCGCACCGGCTTGTCTACATGGTC  
DJ 42 GTTAGCGGCCGCCCCACTAAACCTGTAT  
DJ 43 CCTATAGTGTTCAGGCACTAGAACAATTGGTGAACGACGGAATCA 
DJ 44 GGTGTCGACCACTCCAGAGA 
DJ 45 TGGTCGACACCATCTTGTTC 
DJ 46 GAGCTCCTCGAGAGGCGCGTCTGGTGTTATT 
DJ 47 GTTAGCGGCCGCTAAGTCAAAGCTGGGTATTGTATACAGGTTACTACTGAT 
DJ 48 GTTAGCGGCCGCTAGCGCCAAGCTGGTGTGAGTATACAGGTTACTACTGAT 
DJ 49 ATTCACTAGTACGCGTTGATAATGACATCAAC 
DJ 50 CTAGCTCGAGCGGCCGCTATCACTTGCTTGC 
 217
DJ 51 GTTAGCGGCCGCTAGCGCCAAGCTGGTGTGAGCTTGCTTGCTGGATTGAGAT 
DJ 52 GACGCGTTCACCATGGAATCAAAACTGCCCAAT 
DJ 53 TGCGGCCGCATGATCAAATATCATCATTTGC 
DJ 54 GTTAGCGGCCGCTAGCGCCAAGCTGGTGTGAGGCCATTGATAGCTGAGAGGT 
 JPV Primer (PJ) Sequences 
PJ1 AGACAGACGCTCCAGAGGATGTCA 
PJ2 TAAGGTCTCCAGCATCAACTGTTC 
PJ3 GCACATTGGGGATTGCACCACTCC 
PJ4 TGTGCACCCATCACTGTTACTCCT 
PJ5 CCCTAGTAGTAAGTCAATCTTGCC 
PJ6 GAAAGATTACAACATGAGAGCAGG 
PJ7 TGACAGTTCGATCAACAAGTTGAA 
PJ8 CATGTTCATCTGAATTACACTCCA 
PJ9 TTCTTGCACAACTTGTTAGGTTAC 
PJ10 CACTGTTTGTNGAGTCWCCRGG 
PJ11 GCAGCAACTTGCTCCTCTGAGAA 
PJ12 CTACAGACACACCTAAACAG 
PJ13 TTGGTAGTCCAATTGCACTT 
PJ14 GAGTCATCAATCCTGGAAGA 
PJ15 GCTTCTCTTCTATGATTCC 
PJ16 AAATGGCTTACAAACTGTCC 
PJ17 CACTGTCCGTGTAGTGCATT 
PJ18 GTGCGACAGGTAACCTAACA 
PJ19 CTCTCATGGAGCCACTCATT 
PJ20 CAATGAGTGGCTCCATGAGA 
PJ21 CGGGAGGAAACAAGTCAGTG 
PJ22 GGCTCTTGGAGGATCTGTAA 
PJ23 GAGACGCTCATTCACTCCTA 
PJ24 TGTGGGCAAGGTAGCAATGG 
PJ25 CTGCTACCCATTGCTACCTT 
PJ26 CACTTGCTTGCTGGATTGAG 
PJ27 CTCAATCCAGCAAGCAAGTG 
PJ28 CTGGTGGGTGTGTCCGACTA 
PJ29 CATGGAGGGTTGGCTTCTCA 
PJ30 TCATTGTGGGCAAGGTAGCA 
PJ31 TTGGTGGTGAGCTCTCTAGT 
PJ32 GTATGTAGCCGATCCACACT 
PJ33 TGGTAGATTAGGGTGCACTC 
PJ34 CGGACAGTCACCTTGTGAAT 
PJ35 AAGAACGTGCTCATCGTCTC 
PJ36 CCTGAGAGCAATGAGGAGTA 
PJ37 TCCCATCTGTTGTGAGTAGG 
PJ38 TGGAACCCTCACTTCCTACT 
PJ39 CCCTGAAGCTACATCATGTC 
PJ40 TCTTGAGCCCTATCCACTTC 
PJ41 TGGCACCAACTGATCAATCC 
PJ42 GATATGGTGGAAGATTGTTG 
PJ43 TCTGAGGATTGATCAGTTGG 
PJ44 CGCTAAGAAAAACTTAGGAGT 
PJ45 CGCACTCCTAAGTTTTTCTTA 
PJ46 TGGTTTACCCTYAARACAGAGATGAG 
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PJ47 AGACATGGRGGARCWTGGCCTCC 
PJ48 GCTTTATCTTTCAKRTACAT 
PJ49 CAGGGTCGAATGAGGTATCC 
PJ50 ACCAAGACATCCGGGACCTC 
PJ51 AGCAGCCATAGCGACCAAGA 
PJ52 TCCCAGATCTTCAGCAACAG 
PJ53 GGCTTGAAGACAGAGAGGTA 
PJ54 TTGTTTCCTCCCGGTGTCTC 
PJ55 CCTCTCTAACCGGCTTGTCT 
PJ56 GGCACAGCTCTTGATACTCT 
PJ57 CTGCAGAAGCCATTCTCATC 
PJ58 TCCAGATGGCACTCAGGATA 
PJ59 GGGTTCTATCATGGCTACGA 
PJ60 GTCCGGGCTCACATGAATAA 
PJ61 CTTGCCGAACATATGGGTAG 
PJ62 CAGCTTGCCTGTGACTATGG 
PJ63 AGGGTCTGGTGCGTAAGTAT 
PJ64 CAACCTCCTGCTTTGCCTAT 
PJ65 AGTGACATGCACAGGCTTCT 
PJ66 GTGCTGTCACTGGCCCTACT 
PJ67 GTGGCTGCTTAAGAGGATCG 
PJ68 ATGCCGTTAGAGGTGTACCC 
PJ69 ATCGTTTGACCGTGTCCTTC 
PJ70 AGCTCCTGAAGAAAGGTCTG 
PJ71 TGCAGGAGTATCTGCTAAGG 
PJ72 TGATCAGTTGGTGACAACTC 
PJ73 CCAGACCCAGCAAGGTTCTA 
PJ74 AATACCAACGCACCCAGAGG 
PJ75 GACCGTTCTCGTCCCAGTAG 
PJ76 CTCTCTCGACCTTCCAACTA 
PJ77 CTTGTTGTAGGGCTGAGATG 
PJ78 GGTAGTGCCTCTGGTAATCA 
PJ79 TGCTGTACGGAGGCTGACTT 
PJ80 ACCAGAGGCACTACCCAATC 
PJ81 AGCCTCCGTACAGCAGTATT 
PJ82 ACTGCCCTTTAGGATATCGG 
PJ83 GAAGGGATGGTGGTAAACTC 
PJ84 GTTCCCTCCATAATGGTAGG 
PJ85 CCCAACCAAAGGAGAACTAC 
PJ86 GGAGAACTACTTTGCTCCTAAG 
PJ87 CTTGGTTGCTCCACAATGTC 
PJ88 TGAGCCGCTATGAGAATGAC 
PJ89 TGGCTGGATTCTTCCTAACC 
PJ90 CGTCCTCTATGTCCCTTATG 
PJ91 CTGGGTTTCGGTCCAGTCAT 
PJ92 CTACTTTGCTCCTAAAGGTTGA 
PJ93 ACCAAACAAAGAAGTGTGGGAT 
PJ94 GTATGGGATGGTCCGAATGT 
PJ95 TCCGCGTCCAGTCTTTCTAT 
PJ96 CCTGGTGATACACCTGAAGT 
PJ97 GTTCCGAGCTGTGTTTCTCA 
PJ98 GAGGATCCGTACCGTTATCT 
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PJ99 CCTAACTCCAGGCACACCAT 
PJ100 ACTGGTCTTTGGGCCAAACT 
PJ101 CTGATAGCGCTGATTCAGGA 
PJ102 GCTTCAATTCCGACCTCTTC 
PJ103 AAGGAAGCAGCGAGGATGAA 
PJ104 CATGATCCGCAATTCTTCCG 
PJ105 CCGGGATGTCAATCTCCAAC 
PJ106 GGGTGCGTTGGTATTCCTTT 
PJ107 GGTGTTGCCTGGGTCAGAAT 
PJ108 CTCAACCCCATTCCTTATCC 
PJ109 TGAGGTCTGACTGGAGGTAT 
PJ110 TCCTCCAAGCTGGGATGGAA 
PJ111 AGACATTGCTGAGCCGATTC 
PJ112 AAACCTCCCGCTATAAGACC 
PJ113 GAGAACTACTTTGCTCCTAA 
PJ114 CATCAACCATGGCAAGCAATCAGGAGAA 
PJ115 ACGTTGGAATTCCCTTCAAGATTCAACC 
PJ116 ATCAGACCATGGATATCGACGCAGCCAT 
PJ117 GATTAGATGCATGAATTCAC 
PJ118 CACTGACCATGGCATCAACAGTGTATGAGGA 
PJ119 TGGAGTGAATTCTAGGTTGAGGAGTGTATGT 
PJ120 GTCATTGACAGGTGCAAGAC 
PJ121 AGGTCCTCCAGCGATGCAAG 
PJ122 GGTTCCACCACTGAAGAAAG 
PJ123 ACCATGCCGAGATGAACAGA 
PJ124 AGTCTCTGGCATGCACGATA 
PJ125 GATAGAGGCAGCAAAGACAG 
PJ126 CCAGAGATGATTCCGTATCG 
PJ127 CAGCTTCACCTGAGTGCTAT 
PJ128 GGCGGGTCATCAGTGAGAGA 
PJ129 GCCACACAAGCACTCAACAG 
PJ130 GCTGCGATAAAGCCAGAGTG 
PJ131 GCTCGTCCTTGACCATTCCA 
PJ132 AACTCCATGGATGTGGGCCCTGATGGAT 
PJ133 ACAGAGCCCATGGAAGCAGCGAGGATGAA 
PJ134 CGCGGATCCATGGATATCGACGCAGCCAT 
PJ135 AGCCCTTGAAGCAGATCGAA 
PJ136 TTGCATCGCTGGAGGACCTT 
PJ137 GGGCAAAGAGTGTTCCAAGT 
PJ138 GAGAATCGGCTCAGCAATGTC 
 BeiPV Primer (B) Sequences 
B1 GCGCATCAGCGAAGAACAAC 
B2 AGACACCGCATTAGCCATCC 
B3 CGTAGGGCTTGATGTTACCG 
B4 GAGAAGCGAGGGAGCTAAAG 
B5 CTGAGTAGACGAGCCCAAAG 
B6 GGCTGGAGAAAGAGGGTATC 
B7 AAGGTAGATATGGCCGGAATGCTGG 
B8 GTTAGCGGCCGCCTTCATGATCTTCCCAGT 
B9 AAGGTACATATGGCGGTCATCGGTGGAG 
B10 GTTAGCGGCCGCACCCACGAATCCGGAG 
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B11 GGGTGTCTGACTCCATGAAC 
B12 TATAACCGGCACTCTTCCTG 
B13 AAGGCACCATACATGGT 
B14 CTATGGAGCTATGCAATGGG 
B15 CCTTGACAAGCTGCTGG 
B16 CTAATTATAACTGCTATGG 
B17 AATAGACCCAACTTGAAGG 
B18 GAGTGCCATCTGGATAGYCCYAT 
B19 TGCATTTAAACCAAAAYARAAA 
B20 ACTTTTGAAATGGNGCTAATG 
B21 TGCTTTGTCYTTCATRTACAT 
B22 TTCTTTTCATGGCTRCAYAAACG 
B23 AATGTTGCTRCATGCAGATC 
B24 CCTAGAGCTGCACATGARAT 
B25 GTTAATTGGGACAAARAACCA 
B26 CTATGATTAGCAATGAYAATYT 
B27 AGACTGTTGATATCRTCRTC 
B28 CGAAGAGGTAYAATYAARCA 
B29 GCATTCTGGTTTYCCATTRAA 
B30 GCTTTTCTTGAGCCCTAYCC 
B31 TAACCAACARYCTTCCACCA 
B32 AATCTCTTGGCGTGCACCAG 
B33 CGGGTGTTTAACAACCTG 
B34 CCGTCTCTGGTAAAGTTC 
B35 AGGATAAGGAGGTGGAGAAC 
B36 ATCAAAGAGGAGATCAGGAA 
B37 TGAAATCCAGGTCTTGAGTC 
B38 CCAGGTGGTTGCTAATACAC 
B39 AAGTCCCTCTAACCAACAGC 
B40 CTTGGAGGATTCAATTA 
B41 GACCCAGTGACTGCATC 
B42 ATGCATCAAGAACCTGG 
B43 GGGCATATGGTGATACTGAT 
B44 ATGTTTGGATTGTACTA 
B45 TGTTTAATTGTACCTCT 
B46 CAGCTCTGGATACTGCT 
B47 TTTGCCCCGGGAAATTA 
B48 GTCTCGTCGCAGCCTGATTA 
B49 CTGTCGAAAACCAGTGTGAA 
B50 GCGCAGCATATGTTCTGGGGGGCGGTCATCGGT 
B51 GACATGGMGGAGCMTGGCC 
B52 CCCAATVACTTGACATGC 
B53 CGTTCTTDACWACKGAT 
B54 ACGATWGTYTCTGACCA 
B55 CTCTTGATCAAGGMTCKCAT 
B56 GTGCTAATGTWBTGTGATGT 
B57 CCGCTAACAATGAGGCTCT 
B58 CTTGAATTGGAATCCCACAA 
B59 TTGGCAATAGCCCTCAATAC 
B60 GCCAAAAGAAGTTCCTGTGTT 
B61 CTAAATGATCCMGAYMTTG 
B62 TAAAGTTGGCTDSSAGAGG 
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B63 TTGTGAGCAGKRTCCAKA 
B64 CCCATTGCAWARCTCCA   
B65 GGGACAGATCTACCGTGTCG 
B66 TGGCAGTGAGAGTTCCTCCT 
B67 GCTGTTCTCCAGCCATCTGT 
B68 AGCTCACTGAGGGCCAACT 
B69 GAGAACACCGGWGTTRTARWA 
B70 CCCTTCGTAYAGYAAYCCRG 
B71 GAAGAGAACTGCTGCGTGAT 
B72 TGCGTGATAGAAATGGAAGA 
B73 TCCTTATTTGTCTCTTTCATGT 
B74 CCCTGAGTACTTTCCCTCTAA 
B75 TCTGACACTTCGGCAATCTG 
B76 GCACATCAATGTCAGGGTCA 
B77 GTCAGCAAACATCGAGAGCA 
B78 AACTGCCATTGACACAGCAC 
B79 CAGGTTGTTGACAGCTCGAT 
B80 CTTGGACTGACAGGTGAGCA 
B81 GCAAATTGCCCAGATCAAAG 
B82 AAGTCTTCCGGACTCTGCTG 
B83 TCGGGGTTATGTTGGGATTA 
B84 TGGAGGAAGCATGGGTAGTC 
B85 GAGGTTCAATCATAGCCACCA 
B86 CGCGGAGAAGGAGTGAATC 
B87 GAAGAGGCTGCAGACAAGGT 
B88 GACCCAGTCACAGCCTCATT 
B89 AGGGAGCTGATGGACTCATT 
B90 CAGCGCAAAAAACYTAGG 
B91 CAGCGCTCCTARGTTTTT 
B92 GGTCTCCGGTGATTTCTCAA 
B93 TGGCTATTAACTGGTCCTTTGA 
B94 GCAATGGATAAGCCCATTGTA 
B95 GTAGTCGGGCACCGACAGT 
B96 CAAAGAGAACGGAATGGTCAA 
B97 TTGGTTATCCCAAACCCAGA 
B98 GGGTCTTGTCATTCAGTTCTTCT 
B99 GACCGGATCATGTACAAACG 
B100 GTTTTGGTGAACGGACCAC 
B101 TGCTGCCTGAGAGTGTACAAG 
B102 GCTCCTAAGATATTAAATT 
B103 CTACATAATCATCTCCATGG 
B104 GATCAAGATTGTTCATGCGA 
B105 AGAATGTCAGAAGGCTGAAC 
B106 ATGGAGAGATGTGTCATTAC 
B107 GCTCCATCGATGGCTCAATG 
B108 AATTACACCAGAGATCTCTC 
B109 TATATGATTACACATATACC 
B110 ACAGTGTCGCCCACTACAAC 
B111 TTATATCTGGAACCATGTCC 
B112 TTTCATTATTGCAGGTGTAG 
B113 TGTTGATGAACTGTGCTGAG 
B114 CGGAATCAGCAGTGGAATCC 
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B115 GATCTCACTTCTTGTGTAA 
B116 TTACGACGACCGCAACTCC 
B117 AAGCAACACCAGCCAGGAG 
B118 TTGCAAGAGTTGTCTAGAG 
B119 GACTGAAGTCTCTGAATCC 
B120 ACAGGCATATCACCTAAGG 
B121 GATCACAGCAGCAGGTGTT 
B122 GATTATCGACTGTCAAGCC 
B123 CCAAGAAGGAGAATCTTTGCTC 
B124 GATGTCCTCCAGCAGCTTGT 
B125 GAGCTTGAGGAGCTGTCACTTT 
B126 GGGTGCAACTCAAGATCAATTA 
B127 GGGCCAAAGACAAGTGAGATT 
B128 AGGATGCTATTATACAGACATTCA 
B129 TTCTTTATGTTAACCCACGAATC 
B130 GATCCTATATGATTACAC 
B131 GCTCAACGCTCTCTCGATAA 
B132 CCAGATATAATTATCGGATC 
B133 CCTCAGAATAACTATCAAT 
B134 TTCTCCTTCTGTGGTACC 
B135 GGTTAGAGGGAGAGCATG 
B136 TACTTCATTGTGTCCACAC 
B137 CACCTCCACTGGTCTGAA 
B138 AGCTCCACCACACTGATG 
B139 TTATGACATTAATACTTC 
B140 CTAGATCAGCTTGCAACTC 
B141 ATGAACACCTTGCTCGAA 
B142 GCAATACCTACAGATAGG 
B143 ATCATTGAGGAAGACCTC 
B144 TGCCTCAATGGTATCAGG 
B145 AGCACTGTGTTCAACTCC 
B146 CACAACTCCATTCAGAATG 
B147 GTTGTAAATGCTCATGTCC 
B148 TGCTGTTCGTACTTAATCC 
B149 CTCGCAGGATTGAATTTGG 
B150 CTCAGCTAACTACTATGAG 
B151 AATGTTATTGCTTTGGTTCC 
B152 GATGATTCACTCCTTCTCCG 
B153 GCCTCAATCTATTGAAGTACT 
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Appendix II: Queensland Rodent Sera 
VialNo Location Box Position Date Details 
16818 S2R4 6001 1 16/11/1998 Rat 1 R.Ratus Everton Park 25/5/98 Female 
16660 S2R4 6001 2 16/11/1998 Rat 2 R.Ratus Everton Park 25/5/98 Female 
16661 S2R4 6001 3 16/11/1998 Rat 3 R.Ratus  Everton Park 25/5/98 Female 
16662 S2R4 6001 4 16/11/1998 Rat 4 R.Ratus Everton Park 27/5/98 Female 
16663 S2R4 6001 5 16/11/1998 Rat 5 R.Ratus Everton Park 28/5/98 
16664 S2R4 6001 6 16/11/1998 Rat 6 R.Ratus Everton Park 3/6/98 Female 
16665 S2R4 6001 7 16/11/1998 Rat 7 R.Ratus Everton Park 4/6/98 Female 
16666 S2R4 6001 8 16/11/1998 Rat 8 R.Ratus Everton Park 9/6/98 Female 
16667 S2R4 6001 9 16/11/1998 Rat 9 R.Ratus Everton Park 9/6/98 Female 
16668 S2R4 6001 10 16/11/1998 Rat 10 R.Ratus Everton Park 12/6/98 
16669 S2R4 6001 11 16/11/1998 Rat 11 R.Ratus Wacol 23/6/98 Female 
16670 S2R4 6001 12 16/11/1998 Rat 12 R.RatusCoopers Plains Female 
16805 S2R4 6001 13 16/11/1998 Rat 13 R.Ratus Tennyson 24/6/98 Male 
16806 S2R4 6001 14 16/11/1998 Rat 14 R.Ratus Tennyson 24/6/98 Female 
16807 S2R4 6001 15 16/11/1998 Rat 15 R.Ratus Redland Bay 25/6/98 Male 
16808 S2R4 6001 16 16/11/1998 Rat 16 R.Ratus Redland Bay 26/6/98 Female 
16809 S2R4 6001 17 16/11/1998 Rat 17 R.Ratus Redland Bay 26/6/98 Male 
16810 S2R4 6001 18 16/11/1998 Rat 18 R.Ratus Redland Bay 26/6/98 Male 
16811 S2R4 6001 19 16/11/1998 Rat 19 R.Ratus Redland Bay 29/6/98 Male 
16812 S2R4 6001 20 16/11/1998 Rat 20 R.Ratus Pinkemba 29/6/98 Male 
16813 S2R4 6001 21 16/11/1998 Rat 21 Durack R.Norwegicus  1/7/98 Female 
16819 S2R4 6001 22 16/11/1998 Rat 22 Durack R.Norwegicus 1/7/98 Male 
16815 S2R4 6001 23 16/11/1998 Rat 23 R.Ratus Willawong 1/7/98 Female 
16816 S2R4 6001 24 16/11/1998 Rat 24 R.Ratus Willawong 1/7/98 Female 
16817 S2R4 6001 25 16/11/1998 Rat 25 R.Ratus Pinkenmba 1/7/98 Female 
16820 S2R4 6001 26 16/11/1998 Rat 26 Durack R.Norwegicus 2/7/98 Male 
16821 S2R4 6001 27 16/11/1998 Rat 27 Durack R.Lutreolus 2/7/98 Female 
16822 S2R4 6001 28 16/11/1998 Rat 28 R.Lutreolus Willawong 2/7/98 Male 
16823 S2R4 6001 29 16/11/1998 Rat 29 Durack R.Lutreolus 3/7/98 Male 
16824 S2R4 6001 30 16/11/1998 Rat 30 Durack R.Norwegicus 3/7/98 Female 
16825 S2R4 6001 31 16/11/1998 Rat 31 Durack R.Norwegicus 6/7/98 Female 
16826 S2R4 6001 32 16/11/1998 Rat 32 R.RatusDohleys Rocks Rd 8/7/98 Male 
16827 S2R4 6001 33 16/11/1998 Rat 33 R.RatusDohleys Rocks Rd 8/7/98 F 
16828 S2R4 6001 34 16/11/1998 Rat 34 R.Ratus Durack 8/7/98 F 
16829 S2R4 6001 35 16/11/1998 Rat 35 R.Lutreolus Dakabin 8/7/98 F 
16830 S2R4 6001 36 16/11/1998 Rat 36 R.RatusDakabin    9/7/98 M 
16831 S2R4 6001 37 16/11/1998 Rat 37 R.RatusDohleys Rocks Rd  9/7/98 F 
16832 S2R4 6001 38 16/11/1998 Rat 38 R.RatusDohleys Rocks Rd  9/7/98 M 
16833 S2R4 6001 39 16/11/1998 Rat 39 R.RatusDakabin    9/7/98 F 
16834 S2R4 6001 40 16/11/1998 Rat 40 R.RatusDohleys Rocks Rd    9/7/98 F 
16835 S2R4 6001 41 16/11/1998 Rat 41 R.RatusDohleys Rocks Rd    9/7/98 F 
16836 S2R4 6001 42 16/11/1998 Rat 42 R.Ratus Dakabin  10/7/98 F 
16837 S2R4 6001 43 16/11/1998 Rat 43 R.Ratus Dohleys Rocks Rd  10/7/98 M 
16838 S2R4 6001 44 16/11/1998 Rat 44 R.Ratus Dohleys Rocks Rd  10/7/98 M 
16839 S2R4 6001 45 16/11/1998 Rat 45 R.Ratus Dohleys Rocks Rd  10/7/98 M 
16840 S2R4 6001 46 16/11/1998 Rat 46 R.Ratus Dakabin  16/7/98 M 
16841 S2R4 6001 47 16/11/1998 Rat 47 R.Ratus Dakabin  16/7/98 F 
16842 S2R4 6001 48 16/11/1998 Rat 48 R.Ratus Dakabin  16/7/98 F 
16843 S2R4 6001 49 16/11/1998 Rat 49 R.Ratus Dakabin  16/7/98 M 
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16844 S2R4 6001 50 16/11/1998 Rat 50 R.Ratus Dakabin  16/7/98 M 
16845 S2R4 6001 51 16/11/1998 Rat 51 R.Ratus Dakabin  16/7/98 F 
16846 S2R4 6001 52 16/11/1998 Rat 52 R.Ratus Dakabin  16/7/98 F 
16847 S2R4 6001 53 16/11/1998 Rat 53 R.Ratus Dakabin  16/7/98 F 
16848 S2R4 6001 54 16/11/1998 Rat 54 R.Ratus Dakabin  16/7/98 F 
16849 S2R4 6001 55 16/11/1998 Rat 55 R.Ratus Dakabin  29/7/98 
16850 S2R4 6001 56 16/11/1998 Rat 56 R.Ratus Dakabin  29/7/98 
16851 S2R4 6001 57 16/11/1998 Rat 57 R.Ratus Dakabin  29/7/98 
16852 S2R4 6001 58 16/11/1998 Rat 58 R.Ratus Dakabin  29/7/98 
16853 S2R4 6001 59 16/11/1998 Rat 59 R.Ratus Dakabin  29/7/98 
16854 S2R4 6001 60 16/11/1998 Rat 60 R.Ratus Dakabin  29/7/98 
16855 S2R4 6001 61 16/11/1998 Rat 61 R.Ratus Dakabin  29/7/98 
16856 S2R4 6001 62 16/11/1998 Rat 62 R.Ratus Dakabin  29/7/98 
16857 S2R4 6001 63 16/11/1998 Rat 63 R.Ratus Dakabin  29/7/98 
16858 S2R4 6001 64 16/11/1998 Rat 64 R.Ratus Dakabin  29/7/98 
16859 S2R4 6001 65 16/11/1998 Rat 65 R.Ratus Dakabin  29/7/98 
16860 S2R4 6001 66 16/11/1998 Rat 66 R.Ratus Dakabin  29/7/98 
16861 S2R4 6001 67 16/11/1998 Rat 67 R.Ratus Dakabin  29/7/98 
16862 S2R4 6001 68 16/11/1998 Rat 68 R.Ratus Dakabin  29/7/98 
16863 S2R4 6001 69 16/11/1998 Rat 69 R.Ratus Dakabin  29/7/98 
16864 S2R4 6001 70 16/11/1998 Rat 70 R.Ratus Dakabin  29/7/98 
16865 S2R4 6001 71 16/11/1998 Rat 71 R.Ratus Dakabin  29/7/98 
16997 S2R4 6001 72 17/11/1998 RAT109 R.RATUS EVERTON PARK OCT 98 
17140 S2R4 6002 1 17/11/1998 MUS 1 COOPERS PLAINS 16/6/98 F 
17135 S2R4 6002 2 17/11/1998 MUS 2 WILLAWONG 23/6/98 F 
17136 S2R4 6002 3 17/11/1998 MUS 3 WILLAWONG 23/6/98 F 
17137 S2R4 6002 4 17/11/1998 MUS 4 WACOL     23/6/98 F 
17138 S2R4 6002 5 17/11/1998 MUS 5 COOPERS PLAINS 24/6/98 
17139 S2R4 6002 6 17/11/1998 MUS 6 REDLAND BAY  25/6/98 
17141 S2R4 6002 7 17/11/1998 MUS 7 CARBROOK    26/6/98 F 
17142 S2R4 6002 8 17/11/1998 MUS 8 ACACIA RIDGE  26/6/98 F 
17143 S2R4 6002 9 17/11/1998 MUS 9 ACACIA RIDGE  26/6/98 
17144 S2R4 6002 10 17/11/1998 MUS 10 CARBROOK  26/6/98 F 
17145 S2R4 6002 11 17/11/1998 MUS 11 CARBROOK  26/6/98 F 
17146 S2R4 6002 12 17/11/1998 MUS 12 CARBROOK  26/6/98 M 
17147 S2R4 6002 13 17/11/1998 MUS 13 COOPERS PLAINS  26/6/98 F 
17148 S2R4 6002 14 17/11/1998 MUS 14 CARBROOK  26/6/98 
17149 S2R4 6002 15 17/11/1998 MUS 15 CARBROOK  26/6/98 
17150 S2R4 6002 16 17/11/1998 MUS 16 CARBROOK  26/6/98 
17167 S2R4 6002 17 18/11/1998 MUS 17 BIRKDALE    26/6/98 
17168 S2R4 6002 18 18/11/1998 MUS 18 CARBROOK   26/6/98 
17169 S2R4 6002 19 18/11/1998 MUS 19 COOPERS PLAINS 26/6/98 M 
17170 S2R4 6002 20 18/11/1998 MUS 20 BEAUDESERT   29/6/98 
17171 S2R4 6002 21 18/11/1998 MUS 21 PINKEMBA  30/6/98 
17172 S2R4 6002 22 18/11/1998 MUS 22 PINKEMBA  30/6/98 
17173 S2R4 6002 23 18/11/1998 MUS 23 PINKEMBA  30/6/98 
17174 S2R4 6002 24 18/11/1998 MUS 24 HENDRA     30/6/98 
17175 S2R4 6002 25 18/11/1998 MUS 25 PINKEMBA     30/6/98 
17176 S2R4 6002 26 18/11/1998 MUS 26 PINKEMBA     30/6/98 M 
17177 S2R4 6002 27 18/11/1998 MUS 27 PINKEMBA     30/6/98 
17178 S2R4 6002 28 18/11/1998 MUS 28 PINKEMBA     1/7/98 
17179 S2R4 6002 29 18/11/1998 MUS 29 PINKEMBA   1/7/98 F 
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17180 S2R4 6002 30 18/11/1998 MUS 30 PINKEMBA    1/7/98 
17181 S2R4 6002 31 18/11/1998 MUS 31 PINKEMBA     1/7/98 
17185 S2R4 6002 32 18/11/1998 MUS 32 PINKEMBA   1/7/98 
17186 S2R4 6002 33 18/11/1998 MUS 33 WILLAWONG   1/7/98 
17184 S2R4 6002 34 18/11/1998 MUS 34 WILLAWONG   1/7/98 
17187 S2R4 6002 35 18/11/1998 MUS 35 WILLAWONG   1/7/98 
17188 S2R4 6002 36 18/11/1998 MUS 36 WILLAWONG   1/7/98 
17189 S2R4 6002 37 18/11/1998 MUS 37 WILLAWONG   1/7/98 
17190 S2R4 6002 38 18/11/1998 MUS 38 WILLAWONG   1/7/98 
17191 S2R4 6002 39 18/11/1998 MUS 39 WILLAWONG   2/7/98 
17192 S2R4 6002 40 18/11/1998 MUS 40 WILLAWONG   2/7/98 
17193 S2R4 6002 41 18/11/1998 MUS 41 ARCHERFIELD   2/7/98 
17194 S2R4 6002 42 18/11/1998 MUS 42 ARCHERFIELD   2/7/98 F 
17195 S2R4 6002 43 18/11/1998 MUS 43 WILLAWONG   2/7/98 F 
17196 S2R4 6002 44 18/11/1998 MUS 44 WILLAWONG   2/7/98 F 
17197 S2R4 6002 45 18/11/1998 MUS 45 ARCHERFIELD   2/7/98 F 
17198 S2R4 6002 46 18/11/1998 MUS 46 RESEARCH RD   2/7/98 F 
17199 S2R4 6002 47 18/11/1998 MUS 47 WILLAWONG   2/7/98 F 
17200 S2R4 6002 48 18/11/1998 MUS 48 WILLAWONG   2/7/98 
17201 S2R4 6002 49 18/11/1998 MUS 49 ACACIA RIDGE   2/7/98 
17202 S2R4 6002 50 18/11/1998 MUS 50 ACACIA RIDGE  2/7/98 
17203 S2R4 6002 51 18/11/1998 MUS 51 ACACIA RIDGE  2/7/98 
17204 S2R4 6002 52 18/11/1998 MUS 52 ACACIA RIDGE  2/7/98 M 
17205 S2R4 6002 53 18/11/1998 MUS 53 WILLAWONG  3/7/98 F 
17206 S2R4 6002 54 18/11/1998 MUS 54 WILLAWONG  3/7/98 F 
17207 S2R4 6002 55 18/11/1998 MUS 55 ARCHERFIELD  3/7/98 F 
17208 S2R4 6002 56 18/11/1998 MUS 56 ARCHERFIELD  3/7/98 F 
17209 S2R4 6002 57 18/11/1998 MUS 57 ARCHERFIELD  3/7/98 
17210 S2R4 6002 58 18/11/1998 MUS 58 WILLAWONG  3/7/98 
17211 S2R4 6002 59 18/11/1998 MUS 59 PINKEMBA  7/7/98 
17212 S2R4 6002 60 18/11/1998 MUS 60 HENDRA     7/7/98 
17213 S2R4 6002 61 18/11/1998 MUS 61 PINKEMBA     7/7/98 
17214 S2R4 6002 62 18/11/1998 MUS 62 DEAGON     7/7/98 
17215 S2R4 6002 63 18/11/1998 MUS 63 PINKEMBA   7/7/98 
17216 S2R4 6002 64 18/11/1998 MUS 64 DOHLEYS ROCKS RD 8/7/98 
17217 S2R4 6002 65 18/11/1998 MUS 65 DAKABIN    8/7/98 
17218 S2R4 6002 66 18/11/1998 MUS 66 DOHLEYS ROCKS RD   8/7/98 
17219 S2R4 6002 67 18/11/1998 MUS 67 CABOULTURE   8/7/98 
17220 S2R4 6002 68 18/11/1998 MUS 68 CABOULTURE   8/7/98 
17221 S2R4 6002 69 18/11/1998 MUS 69 DOHLEYS ROCKS RD  9/7/98 
17222 S2R4 6002 70 18/11/1998 MUS 70 DOHLEYS ROCKS RD  9/7/98 
17223 S2R4 6002 71 18/11/1998 MUS 71 DOHLEYS ROCKS RD  9/7/98 
17224 S2R4 6002 72 18/11/1998 MUS 72 DOHLEYS ROCKS RD  10/7/98 
17225 S2R4 6002 73 18/11/1998 MUS 73 DOHLEYS ROCKS RD 10/7/98 F 
17226 S2R4 6002 74 18/11/1998 MUS 74 DOHLEYS ROCKS RD 10/7/98 F 
17227 S2R4 6002 75 18/11/1998 MUS 75 DOHLEYS ROCKS RD 10/7/98 M 
17228 S2R4 6002 76 18/11/1998 MUS 76 DOHLEYS ROCKS RD 10/7/98 M 
17229 S2R4 6002 77 18/11/1998 MUS 77 DOHLEYS ROCKS RD 10/7/98 F 
17230 S2R4 6002 78 18/11/1998 MUS 78 DOHLEYS ROCKS RD 10/7/98 F 
17231 S2R4 6002 79 18/11/1998 MUS 79 WEST END   13/7/98 F 
17232 S2R4 6002 80 18/11/1998 MUS 80 ACACIA RIDGE  13/7/98 
11695 S2R4 6005 1 07/08/1998 Serum MOUSE 81 
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11696 S2R4 6005 2 07/08/1998 Serum MOUSE 82 
11697 S2R4 6005 3 07/08/1998 Serum MOUSE 83 
11698 S2R4 6005 4 07/08/1998 Serum MOUSE 84 
11699 S2R4 6005 5 07/08/1998 Serum MOUSE 85 
11700 S2R4 6005 6 07/08/1998 Serum MOUSE 86 
11701 S2R4 6005 7 07/08/1998 Serum MOUSE 87 
11702 S2R4 6005 8 07/08/1998 Serum MOUSE 88 
11703 S2R4 6005 9 07/08/1998 Serum MOUSE 89 
11704 S2R4 6005 10 07/08/1998 Serum MOUSE 90 
11705 S2R4 6005 11 07/08/1998 Serum MOUSE 91 
11706 S2R4 6005 12 07/08/1998 Serum MOUSE 92 
11707 S2R4 6005 13 07/08/1998 Serum MOUSE 93 
11708 S2R4 6005 14 07/08/1998 Serum MOUSE 94 
11709 S2R4 6005 15 07/08/1998 Serum MOUSE 95 
11710 S2R4 6005 16 07/08/1998 Serum MOUSE 96 
11711 S2R4 6005 17 07/08/1998 Serum MOUSE 97 
11712 S2R4 6005 18 07/08/1998 Serum MOUSE 98 
11713 S2R4 6005 19 07/08/1998 Serum MOUSE 99 
11714 S2R4 6005 20 07/08/1998 Serum MOUSE 100 
11715 S2R4 6005 21 07/08/1998 Serum MOUSE 101 
11716 S2R4 6005 22 07/08/1998 Serum MOUSE 102 
11717 S2R4 6005 23 07/08/1998 Serum MOUSE 103 
11718 S2R4 6005 24 07/08/1998 Serum MOUSE 104 
17233 S2R4 6024 1 18/11/1998 RAT 1 26/8/97 
17234 S2R4 6024 2 18/11/1998 RAT 1 ACT GUNGAHLIN  1998 
17235 S2R4 6024 3 18/11/1998 RAT 2 ACT GUNGAHLIN  1998 
17236 S2R4 6024 4 18/11/1998 RAT 3 ACT GUNGAHLIN  1998 
17237 S2R4 6024 5 18/11/1998 RAT 4 ACT GUNGAHLIN  1998 
17238 S2R4 6024 6 18/11/1998 RAT 5 ACT GUNGAHLIN  1998 
17239 S2R4 6024 7 18/11/1998 RAT 6 ACT GUNGAHLIN   1998 
17240 S2R4 6024 8 18/11/1998 RAT 7 ACT GUNGAHLIN   1998 
17241 S2R4 6024 9 18/11/1998 RAT 8 ACT GUNGAHLIN   1998 
17242 S2R4 6024 10 18/11/1998 RAT 9 ACT GUNGAHLIN   1998 
17243 S2R4 6024 11 18/11/1998 RAT 10  ACT GUNGAHLIN   1998 
17244 S2R4 6024 12 18/11/1998 RAT 11  ACT GUNGAHLIN   1998 
17245 S2R4 6024 13 18/11/1998 RAT 12  ACT GUNGAHLIN   1998 
17246 S2R4 6024 14 18/11/1998 RAT 13  ACT GUNGAHLIN   1998 
17247 S2R4 6024 15 18/11/1998 RAT 14  ACT GUNGAHLIN   1998 
17248 S2R4 6024 16 18/11/1998 RAT 15  ACT GUNGAHLIN   1998 
17249 S2R4 6024 17 18/11/1998 RAT 16  ACT GUNGAHLIN   1998 
17250 S2R4 6024 18 18/11/1998 RAT 17  ACT GUNGAHLIN   1998 
17251 S2R4 6024 19 18/11/1998 Rat 2 R.Ratus Everton Park 25/5/98 Female 
17252 S2R4 6024 20 18/11/1998 Rat 3 R.Ratus Everton Park 25/5/98 Female 
17253 S2R4 6024 21 18/11/1998 Rat 4 R.Ratus Everton Park 27/5/98 Female 
17254 S2R4 6024 22 18/11/1998 Rat 5 R.Ratus Everton Park 28/5/98 Female 
17255 S2R4 6024 23 18/11/1998 Rat 6 R.Ratus Everton Park 3/6/98 Female 
17256 S2R4 6024 24 18/11/1998 Rat 7 R.Ratus Everton Park 4/6/98 Female 
17257 S2R4 6024 25 18/11/1998 Rat 8 R.Ratus Everton Park 9/6/98 Female 
17258 S2R4 6024 26 18/11/1998 Rat 9 R.Ratus Everton Park 9/6/98 Female 
17259 S2R4 6024 27 18/11/1998 Rat 10 R.Ratus Everton Park 9/6/98 Female 
17260 S2R4 6024 28 18/11/1998 Rat 11 R.Ratus Wacol 23/6/98 Female 
21204 S2R4 6024 29 01/03/1999 R.norvegicus F Mature  DPI99/107330-1 
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21205 S2R4 6024 30 01/03/1999 R.norvegicus F Mature  DPI99/107330-2 
21206 S2R4 6024 31 01/03/1999 R.norvegicus M Pre Breeding DPI99/107330-3 
21207 S2R4 6024 32 01/03/1999 R.norvegicus F Mature DPI99/107330-4 
21208 S2R4 6024 33 01/03/1999 R.norvegicus F Mature DPI99/107330-5 
21209 S2R4 6024 34 01/03/1999 R.norvegicus M Pre-breeding DPI99/107330-6 
21210 S2R4 6024 35 01/03/1999 R.norvegicus F Pre-breeding DPI99/107330-7 
21211 S2R4 6024 36 01/03/1999 R.norvegicus M Pre-breeding DPI99/107330-8 
21212 S2R4 6024 37 01/03/1999 R.norvegicus F Mature DPI99/108511-1 
21213 S2R4 6024 38 01/03/1999 R.norvegicus M Mature DPI99/108511-2 
21214 S2R4 6024 39 01/03/1999 R.norvegicus M Mature DPI99/108511-3 
21215 S2R4 6024 40 01/03/1999 R.norvegicus M Pre-breeding DPI99/108511-4 
21216 S2R4 6024 41 01/03/1999 R.norvegicus F Mature DPI99/108511-5 
21217 S2R4 6024 42 01/03/1999 R.norvegicus M Pre-breeding DPI99/108511-6 
21218 S2R4 6024 43 01/03/1999 R.norvegicus F Mature DPI99/108511-7 
21219 S2R4 6024 44 01/03/1999 R.norvegicus F Mature DPI99/108511-8 
21220 S2R4 6024 45 01/03/1999 R.norvegicus F Mature DPI99/108511-9 
21221 S2R4 6024 46 01/03/1999 R.norvegicus F Mature DPI99/108511-10 
21222 S2R4 6024 47 01/03/1999 R.norvegicus F Pre-breeding DPI99/108511-11 
21223 S2R4 6024 48 01/03/1999 R.norvegicus M Pre-breeding DPI99/108511-12 
21224 S2R4 6024 49 01/03/1999 R.norvegicus M Mature DPI99/108511-13 
21225 S2R4 6024 50 01/03/1999 R.norvegicus M Mature DPI99/108511-14 
21226 S2R4 6024 51 02/03/1999 Rat DPI 99/103235-1 
21227 S2R4 6024 52 02/03/1999 Rat DPI 99/103235-2 
21228 S2R4 6024 53 02/03/1999 Rat DPI 99/103235-3 
21229 S2R4 6024 54 02/03/1999 Rat DPI 99/103235-4 
21230 S2R4 6024 55 02/03/1999 Rat DPI 99/103235-5 
21231 S2R4 6024 56 02/03/1999 Rat DPI 99/103235-6 
21232 S2R4 6024 57 02/03/1999 Rat DPI 99/103235-7 
21233 S2R4 6024 58 02/03/1999 Rat DPI 99/103951-1 
21234 S2R4 6024 59 02/03/1999 Rat DPI 99/103951-2 
21235 S2R4 6024 60 02/03/1999 Rat DPI 99/103951-3 
21236 S2R4 6024 61 02/03/1999 Rat DPI 99/103951-4 
21237 S2R4 6024 62 02/03/1999 Rat DPI 99/104304-1 
21238 S2R4 6024 63 02/03/1999 Rat DPI 99/104304-2 
21239 S2R4 6024 64 02/03/1999 Rat DPI 99/104304-3 
21240 S2R4 6024 65 02/03/1999 Rat DPI 99/104304-4 
21241 S2R4 6024 66 02/03/1999 Rat DPI 99/104304-5 
21242 S2R4 6024 67 02/03/1999 Rat DPI 99/104304-6 
21243 S2R4 6024 68 02/03/1999 Rat DPI 99/104304-7 
21244 S2R4 6024 69 02/03/1999 Rat DPI 99/104304-8 
21245 S2R4 6024 70 02/03/1999 Rat DPI 99/104304-9 
21246 S2R4 6024 71 02/03/1999 Rat DPI 99/104304-10 
21247 S2R4 6024 72 02/03/1999 Rat DPI 99/104304-11 
21248 S2R4 6024 73 02/03/1999 Rat DPI 99/104304-12 
21249 S2R4 6024 74 02/03/1999 Rat DPI 99/104304-13 
21250 S2R4 6024 75 02/03/1999 Rat DPI 99/104304-14 
21251 S2R4 6024 76 02/03/1999 Rat DPI 99/104602 
21252 S2R4 6024 77 02/03/1999 Rat DPI 99/104811-1 
21253 S2R4 6024 78 02/03/1999 Rat DPI 99/104811-2 
21254 S2R4 6024 79 02/03/1999 Rat DPI 99/104811-3 
21255 S2R4 6024 80 02/03/1999 Rat DPI 99/104811-4 
21256 S2R4 6024 81 02/03/1999 Rat DPI 99/104811-5 
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11529 S2R4 6025 1 07/08/1998 Serum RAT 97 
11530 S2R4 6025 2 07/08/1998 Serum RAT 98 
11531 S2R4 6025 3 07/08/1998 Serum RAT 99 
11532 S2R4 6025 4 07/08/1998 Serum RAT 100 
11533 S2R4 6025 5 07/08/1998 Serum RAT 101 
11534 S2R4 6025 6 07/08/1998 Serum RAT 102 
11535 S2R4 6025 7 07/08/1998 Serum RAT 103 
11536 S2R4 6025 8 07/08/1998 Serum RAT 104 
11537 S2R4 6025 9 07/08/1998 Serum RAT 105 
11538 S2R4 6025 10 07/08/1998 Serum RAT 106 
11539 S2R4 6025 11 07/08/1998 Serum RAT 107 
11540 S2R4 6025 12 07/08/1998 Serum RAT 108 
11504 S2R4 6026 1 07/08/1998 Serum RAT 72 
11505 S2R4 6026 2 07/08/1998 Serum RAT 73 
11506 S2R4 6026 3 07/08/1998 Serum RAT 74 
11507 S2R4 6026 4 07/08/1998 Serum RAT 75 
11508 S2R4 6026 5 07/08/1998 Serum RAT 76 
11509 S2R4 6026 6 07/08/1998 Serum RAT 77 
11510 S2R4 6026 7 07/08/1998 Serum RAT 78 
11511 S2R4 6026 8 07/08/1998 Serum RAT 79 
11512 S2R4 6026 9 07/08/1998 Serum RAT 80 
11513 S2R4 6026 10 07/08/1998 Serum RAT 81 
11514 S2R4 6026 11 07/08/1998 Serum RAT 82 
11515 S2R4 6026 12 07/08/1998 Serum RAT 83 
11516 S2R4 6026 13 07/08/1998 Serum RAT 84 
11517 S2R4 6026 14 07/08/1998 Serum RAT 85 
11518 S2R4 6026 15 07/08/1998 Serum RAT 86 
11519 S2R4 6026 16 07/08/1998 Serum RAT 87 
11520 S2R4 6026 17 07/08/1998 Serum RAT 88 
11521 S2R4 6026 18 07/08/1998 Serum RAT 89 
11522 S2R4 6026 19 07/08/1998 Serum RAT 90 
11523 S2R4 6026 20 07/08/1998 Serum RAT 91 
11524 S2R4 6026 21 07/08/1998 Serum RAT 92 
11525 S2R4 6026 22 07/08/1998 Serum RAT 93 
11526 S2R4 6026 23 07/08/1998 Serum RAT 94 
11527 S2R4 6026 24 07/08/1998 Serum RAT 95 
11528 S2R4 6026 25 07/08/1998 Serum RAT 96 
21257 S2R4 6035 1 02/03/1999 Rat DPI 99/104811-6 
21258 S2R4 6035 2 02/03/1999 Rat DPI 99/104811-7 
21259 S2R4 6035 3 02/03/1999 Rat DPI 99/104811-8 
21260 S2R4 6035 4 02/03/1999 Rat DPI 99/104811-9 
21261 S2R4 6035 5 02/03/1999 Rat DPI 99/104811-10 
21262 S2R4 6035 6 02/03/1999 Rat DPI 99/104811-11 
21263 S2R4 6035 7 02/03/1999 Rat DPI 99/180630-1 
21264 S2R4 6035 8 02/03/1999 Rat DPI 99/180982-1 
21265 S2R4 6035 9 02/03/1999 Rat DPI 99/189064-2 
21266 S2R4 6035 10 02/03/1999 Rat DPI 99/189064-3 
21267 S2R4 6035 11 02/03/1999 Rat DPI 99/189926-1 
21268 S2R4 6035 12 02/03/1999 Rat DPI 99/191925-1 
21269 S2R4 6035 13 02/03/1999 Rat DPI 99/104811-1 
22703 S2R4 6035 14 29/04/1999 Jervis Bay - Rattus Rattus, 1 (1999 2946) 
22704 S2R4 6035 15 29/04/1999 Jervis Bay - Rattus Rattus, 3 (1999 2947) 
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22705 S2R4 6035 16 29/04/1999 Jervis Bay - Rattus Rattus, 4 (1999 2948) 
22706 S2R4 6035 17 29/04/1999 Jervis Bay - Rattus Rattus, 5 (1999 2949) 
22707 S2R4 6035 18 29/04/1999 Jervis Bay - Rattus Rattus, 6 (1999 2950) 
22708 S2R4 6035 19 29/04/1999 Jervis Bay - Rattus Rattus, 7 (1999 2951) 
22709 S2R4 6035 20 29/04/1999 Jervis Bay - Rattus Rattus, 8 (1999 2952) 
22710 S2R4 6035 21 29/04/1999 Jervis Bay - Rattus Rattus, 9 (1999 2953) 
22711 S2R4 6035 22 29/04/1999 J B Beecroft - Rattus Rattus, 2(a) (1999 2954) 
22712 S2R4 6035 23 29/04/1999 J B Beecroft - Rattus Rattus, 2(b) (1999 2955) 
22713 S2R4 6035 24 29/04/1999 J B Beecroft - Rattus Rattus, 3 (1999 2956) 
22714 S2R4 6035 25 29/04/1999 J B Beecroft - Rattus Rattus, 4 (1999 2957) 
22715 S2R4 6035 26 29/04/1999 J B Beecroft - Rattus Rattus, 5 (1999 2958) 
22716 S2R4 6035 27 29/04/1999 J B Beecroft - Rattus Rattus, 6 (1999 2959) 
22717 S2R4 6035 28 29/04/1999 J B Beecroft - Rattus Rattus, 7 (1999 2960) 
22718 S2R4 6035 29 29/04/1999 J B Beecroft - Rattus Rattus, 8 (1999 2961) 
22719 S2R4 6035 30 29/04/1999 J B Beecroft - Rattus Rattus, 9 (1999 2962) 
22720 S2R4 6035 31 29/04/1999 J B Beecroft - Rattus Rattus, 10 (1999 2963) 
22721 S2R4 6035 32 29/04/1999 J B Beecroft - Rattus Rattus, 11 (1999 2964) 
22722 S2R4 6035 33 29/04/1999 J B Beecroft - Rattus Rattus, 12 (1999 2965) 
 
